Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 28, 2013

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 000-30684

 

 

 

LOGO

OCLARO, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   20-1303994

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

2560 Junction Avenue, San Jose, California 95134

(Address of principal executive offices, zip code)

(408) 383-1400

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:    Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No   ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨   (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes   ¨     No   x

106,558,998 shares of common stock outstanding as of February 3, 2014

 

 

 

 


Table of Contents

OCLARO, INC.

TABLE OF CONTENTS

 

         Page  
PART I. FINANCIAL INFORMATION   

Item 1.

  Financial Statements (Unaudited):   
  Condensed Consolidated Balance Sheets as of December 28, 2013 and June 29, 2013      3   
  Condensed Consolidated Statements of Operations for the three and six months ended December 28, 2013 and December 29, 2012      4   
  Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended December 28, 2013 and December 29, 2012      5   
  Condensed Consolidated Statements of Cash Flows for the six months ended December 28, 2013 and December 29, 2012      6   
  Notes to Condensed Consolidated Financial Statements      7   

Item 2.

  Management’s Discussion and Analysis of Financial Condition and Results of Operations      28   

Item 3.

  Quantitative and Qualitative Disclosures About Market Risk      39   

Item 4.

  Controls and Procedures      40   
PART II. OTHER INFORMATION   

Item 1.

  Legal Proceedings      40   

Item 1A.

  Risk Factors      43   

Item 6.

  Exhibits      63   

Signatures

     64   

 

2


Table of Contents

P ART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

OCLARO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

     December 28, 2013     June 29, 2013  
     (Thousands, except par value)  
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 141,560      $ 84,635   

Restricted cash

     2,285        2,719   

Short-term investments

     160        200   

Accounts receivable, net, including $2,873 and $2,975 due from related parties at December 28, 2013 and June 29, 2013, respectively

     77,740        100,774   

Inventories

     89,511        86,029   

Prepaid expenses and other current assets

     57,537        33,498   

Assets of discontinued operations held for sale

     —          55,333   
  

 

 

   

 

 

 

Total current assets

     368,793        363,188   
  

 

 

   

 

 

 

Property and equipment, net

     57,110        72,028   

Other intangible assets, net

     9,167        10,233   

Other non-current assets

     13,076        4,445   
  

 

 

   

 

 

 

Total assets

   $ 448,146      $ 449,894   
  

 

 

   

 

 

 
LIABILITIES AND STOCKHOLDERS’ EQUITY     

Current liabilities:

    

Accounts payable, including $2,326 and $2,246 due to related parties at December 28, 2013 and June 29, 2013, respectively

   $ 104,517      $ 94,157   

Accrued expenses and other liabilities

     54,594        52,010   

Capital lease obligations, current

     5,559        8,281   

Term loan payable

     —          24,647   

Credit line payable

     —          39,964   

Liabilities of discontinued operations held for sale

     —          17,470   
  

 

 

   

 

 

 

Total current liabilities

     164,670        236,529   
  

 

 

   

 

 

 

Deferred gain on sale-leasebacks

     10,841        10,477   

Convertible notes payable

     —          22,990   

Capital lease obligations, non-current

     6,121        9,914   

Other non-current liabilities

     16,879        15,852   
  

 

 

   

 

 

 

Total liabilities

     198,511        295,762   
  

 

 

   

 

 

 

Commitments and contingencies (Note 9)

    

Stockholders’ equity:

    

Preferred stock: 1,000 shares authorized; none issued and outstanding

     —          —     

Common stock: $0.01 par value per share; 175,000 shares authorized and 106,536 shares issued and outstanding at December 28, 2013; 175,000 shares authorized and 92,766 shares issued and outstanding at June 29, 2013

     1,065        928   

Additional paid-in capital

     1,453,999        1,429,155   

Accumulated other comprehensive income

     45,121        39,368   

Accumulated deficit

     (1,250,550     (1,315,319
  

 

 

   

 

 

 

Total stockholders’ equity

     249,635        154,132   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 448,146      $ 449,894   
  

 

 

   

 

 

 

The accompanying notes form an integral part of these condensed consolidated financial statements.

 

3


Table of Contents

OCLARO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

     Three Months Ended     Six Months Ended  
     December 28,
2013
    December 29,
2012
    December 28,
2013
    December 29,
2012
 
     (Thousands, except per share amounts)  

Revenues, including $3,390 and $4,701 from related parties for the three and six months ended December 28, 2013, respectively, and $4,358 and $7,340 from related parties for the three and six months ended December 29, 2012, respectively

   $ 102,914      $ 112,071      $ 199,562      $ 207,706   

Cost of revenues

     86,001        99,796        171,431        190,438   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     16,913        12,275        28,131        17,268   

Operating expenses:

        

Research and development

     16,424        20,714        34,511        41,227   

Selling, general and administrative

     18,557        19,927        39,507        41,350   

Amortization of other intangible assets

     417        1,372        841        2,604   

Restructuring, acquisition and related (income) expense, net

     6,721        (24,257     9,598        (12,663

Flood-related (income) expense, net

     (140     641        (140     905   

Impairment of other intangibles

     —          —          —          864   

Loss on sale of property and equipment

     205        231        657        213   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     42,184        18,628        84,974        74,500   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating loss

     (25,271     (6,353     (56,843     (57,232

Other income (expense):

        

Interest income (expense), net

     (8,532     (649     (9,085     (1,127

Gain (loss) on foreign currency transactions, net

     (2,848     (4,032     (1,071     (3,994

Other income (expense), net

     28        —          549        —     

Gain on bargain purchase

     —          —          —          24,866   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense)

     (11,352     (4,681     (9,607     19,745   
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from continuing operations before income taxes

     (36,623     (11,034     (66,450     (37,487

Income tax provision

     1,424        1,234        1,726        2,152   
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from continuing operations

     (38,047     (12,268     (68,176     (39,639

Income from discontinued operations, net of tax

     69,538        2,013        132,945        4,276   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

   $ 31,491      $ (10,255   $ 64,769      $ (35,363
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted net income (loss) per share:

        

Loss per share from continuing operations

   $ (0.41   $ (0.14   $ (0.74   $ (0.47

Income per share from discontinued operations

     0.75        0.03        1.44        0.05   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted net income (loss) per share

   $ 0.34      $ (0.11   $ 0.70      $ (0.42
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computing net income (loss) per share:

        

Basic

     93,204        89,827        92,085        85,023   

Diluted

     93,204        89,827        92,085        85,023   

The accompanying notes form an integral part of these condensed consolidated financial statements.

 

4


Table of Contents

OCLARO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

 

     Three Months Ended     Six Months Ended  
     December 28,
2013
    December 29,
2012
    December 28,
2013
    December 29,
2012
 
     (Thousands)  

Net income (loss)

   $ 31,491      $ (10,255   $ 64,769      $ (35,363

Other comprehensive income (loss):

        

Unrealized loss on hedging transactions

     —          —          —          (7

Unrealized gain (loss) on marketable securities

     (9     (8     (39     12   

Currency translation adjustments

     2,846        3,940        (41     4,816   

Pension adjustment, net of tax benefits

     16        96        5,833        189   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total comprehensive income (loss)

   $ 34,344      $ (6,227   $ 70,522      $ (30,353
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes form an integral part of these condensed consolidated financial statements.

 

5


Table of Contents

OCLARO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

     Six Months Ended  
     December 28,
2013
    December 29,
2012
 
     (Thousands)  

Cash flows from operating activities:

    

Net income (loss)

   $ 64,769      $ (35,363

Adjustments to reconcile net income (loss) to net cash used in operating activities:

    

Amortization of deferred gain on sale-leasebacks

     (1,060     (1,039

Amortization and write-off of issuance costs in connections with Term Loan

     4,293        —     

Gain on sale of Zurich Business

     (62,812     —     

Gain on sale of Amplifier Business

     (69,705     —     

Gain on sale of assets

     —          (25,014

Depreciation and amortization

     15,847        22,935   

Impairment of other intangibles

     —          864   

Flood-related non-cash losses

     2,011        —     

Gain on bargain purchase

     —          (24,866

Stock-based compensation expense

     2,030        3,654   

Other non-cash adjustments

     (288     4   

Changes in operating assets and liabilities:

    

Accounts receivable, net

     29,005        20,667   

Inventories

     (4,986     (10,553

Prepaid expenses and other current assets

     (26,432     (5,767

Other non-current assets

     1,427        (542

Accounts payable

     7,784        (2,799

Accrued expenses and other liabilities

     (8,698     (7,013
  

 

 

   

 

 

 

Net cash used in operating activities

     (46,815     (64,832
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property and equipment

     (3,685     (10,634

Proceeds from sale of Amplifier Business

     84,600        —     

Proceeds from sale of Zurich Business

     90,618        —     

Proceeds from sale of assets

     —          26,000   

Transfer from restricted cash

     454        2,857   

Cash acquired from business combinations

     —          36,123   
  

 

 

   

 

 

 

Net cash provided by investing activities

     171,987        54,346   
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     (175     709   

Proceeds from borrowings under credit line

     —          15,256   

Proceeds from the sale of convertible notes, net

     —          22,768   

Payments on capital lease obligations

     (4,855     (4,027

Repayments on borrowings under credit line and term loan

     (64,964     (386

Cash paid under earnout obligations

     —          (8,628
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     (69,994     25,692   
  

 

 

   

 

 

 

Effect of exchange rate on cash and cash equivalents

     1,747        1,110   

Net increase in cash and cash equivalents

     56,925        16,316   

Cash and cash equivalents at beginning of period

     84,635        61,760   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 141,560      $ 78,076   
  

 

 

   

 

 

 

Supplemental disclosures of non-cash transactions:

    

Issuance of common stock in connection with exercise of Convertible Notes

   $ 23,050      $ —     

Issuance of common stock, stock options and stock appreciation rights related to the acquisition of Opnext

     —          89,842   

Capital lease obligations incurred for purchases of property and equipment

     —          (658

The accompanying notes form an integral part of these condensed consolidated financial statements.

 

6


Table of Contents

OCLARO, INC.

NOTES TO COND ENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. BASIS OF PREPARATION

Basis of Presentation

Oclaro, Inc., a Delaware corporation, is sometimes referred to in this Quarterly Report on Form 10-Q as “Oclaro,” “we,” “us” or “our.”

On November 1, 2013, we sold our optical amplifier and micro-optics business (the “Amplifier Business”) to II-VI Incorporated (II-VI). The sale is more fully discussed in Note 5, Business Combinations and Dispositions .

On September 12, 2013, we sold our Oclaro Switzerland GmbH subsidiary and associated laser diodes and pump business (the “Zurich Business”) to II-VI. The sale is more fully discussed in Note 5, Business Combinations and Dispositions .

These sales are reported as discontinued operations, which require retrospective restatement of prior periods to classify the assets, liabilities and results of operations as discontinued operations. We have classified the assets and liabilities to be sold as “assets of discontinued operations held for sale” and “liabilities of discontinued operations held for sale” within current assets and current liabilities, respectively, on the condensed consolidated balance sheet as of June 29, 2013. The notes to our condensed consolidated financial statements relate to our continuing operations only, unless otherwise indicated.

On July 23, 2012, we completed a merger with Opnext, Inc. (Opnext). The acquisition is more fully discussed in Note 5, Business Combinations and Dispositions . The condensed consolidated balance sheets as of December 28, 2013 and June 29, 2013, include the assets and liabilities assumed in the Opnext acquisition. The condensed consolidated statements of operations, comprehensive loss and cash flows for the six months ended December 29, 2012 include the results of operations of the combined entities from July 23, 2012, the date of the acquisition.

The accompanying unaudited condensed consolidated financial statements of Oclaro as of December 28, 2013 and for the three and six months ended December 28, 2013 and December 29, 2012 have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Article 10 of Securities and Exchange Commission (SEC) Regulation S-X, and include the accounts of Oclaro and all of our subsidiaries. Accordingly, they do not include all of the information and footnotes required by such accounting principles for annual financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our consolidated financial position and results of operations have been included. The condensed consolidated results of operations for the three and six months ended December 28, 2013 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year ending June 28, 2014.

The condensed consolidated balance sheet as of June 29, 2013 has been derived from our audited financial statements as of such date, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended June 29, 2013 (2013 Form 10-K).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. These judgments can be subjective and complex, and consequently, actual results could differ materially from those estimates and assumptions. Descriptions of some of the key estimates and assumptions are included in our 2013 Form 10-K.

 

7


Table of Contents

Fiscal Years

We operate on a 52/53 week year ending on the Saturday closest to June 30. Our fiscal year ending June 28, 2014 will be a 52 week year, with the quarter ended December 28, 2013 being a 13 week quarterly period. Our fiscal year ended June 29, 2013 was a 52 week year, with the quarter ended December 29, 2012 being a 13 week quarterly period.

Reclassifications

For presentation purposes, we have reclassified certain prior period amounts to conform to the current period financial statement presentation. These reclassifications did not affect our consolidated revenues, net loss, cash flows, cash and cash equivalents or stockholders’ equity as previously reported.

Out of Period Adjustment

In the second quarter of fiscal 2014, the Company recorded an out-of-period adjustment of approximately $2.0 million in Flood Related (income) expense line of the accompanying condensed consolidated statements of operations. The adjustment, which decreased flood related (income) expense and decreased property and equipment, net, was made to account for the impairment of leased assets assumed pursuant to the Opnext merger that had been damaged in the 2011 Thailand flood (See Note 10, Flood-Related (Income) Expense, Net). The Company determined that this adjustment did not have a material impact to its current or prior period consolidated financial statements.

NOTE 2. RECENT ACCOUNTING STANDARDS

In March 2013, the Financial Accounting Standards Board (FASB) issued ASU No. 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. This guidance amends a parent company’s accounting for the cumulative translation adjustment recorded in accumulated other comprehensive income associated with a foreign entity. The amendment requires a parent to release into net income the cumulative translation adjustment related to its investment in a foreign entity when it either sells a part or all of its investment, or no longer holds a controlling financial interest in a subsidiary or group of assets within a foreign entity. We elected to early adopt this guidance during our first quarter of fiscal year 2014. Accordingly, we treated our sale of our Zurich Business in the first quarter of fiscal year 2014 in accordance with this guidance and recorded $3.1 million in income from discontinued operations related to the cumulative translation adjustment from deconsolidating our Swiss subsidiary during the six months ended December 28, 2013 within the condensed consolidated statement of operations. This guidance will continue to impact our financial position and results of operations prospectively in the instance of an event or transaction described above.

In July 2013, the FASB issued amended guidance that resolves the diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This new accounting guidance requires the netting of unrecognized tax benefits (UTBs) against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. Under the new standard, UTBs will be netted against all available same-jurisdiction loss or other tax carryforwards that would be utilized, rather than only against carryforwards that are created by the UTBs. The new standard requires prospective adoption but allows retrospective adoption for all periods presented. We have adopted this guidance during our second quarter of fiscal year 2014. The adoption of the guidance did not have a significant impact on our financial position, results of operations or cash flows.

NOTE 3. BALANCE SHEET DETAILS

The following table provides details regarding our cash and cash equivalents at the dates indicated:

 

     December 28, 2013      June 29, 2013  
     (Thousands)  

Cash and cash equivalents:

  

Cash-in-bank

   $ 140,346       $ 82,634   

Money market funds

     1,214         2,001   
  

 

 

    

 

 

 
   $ 141,560       $ 84,635   
  

 

 

    

 

 

 

 

8


Table of Contents

The following table provides details regarding our inventories at the dates indicated:

 

     December 28, 2013      June 29, 2013  
     (Thousands)  

Inventories:

  

Raw materials

   $ 30,454       $ 32,678   

Work-in-process

     22,008         26,760   

Finished goods

     37,049         26,591   
  

 

 

    

 

 

 
   $ 89,511       $ 86,029   
  

 

 

    

 

 

 

The following table provides details regarding our property and equipment, net at the dates indicated:

 

     December 28, 2013     June 29, 2013  
     (Thousands)  

Property and equipment, net:

  

Buildings and improvements

   $ 12,757      $ 10,271   

Plant and machinery

     56,027        72,144   

Fixtures, fittings and equipment

     3,035        4,295   

Computer equipment

     14,867        13,940   
  

 

 

   

 

 

 
     86,686        100,650   

Less: Accumulated depreciation

     (29,576     (28,622
  

 

 

   

 

 

 
   $ 57,110      $ 72,028   
  

 

 

   

 

 

 

Property and equipment includes assets under capital leases of $11.7 million at December 28, 2013 and $18.2 million at June 29, 2013, respectively. Amortization associated with assets under capital leases is recorded in depreciation expense.

The following table presents details regarding our accrued expenses and other liabilities at the dates indicated:

 

     December 28, 2013      June 29, 2013  
     (Thousands)  

Accrued expenses and other liabilities:

  

Trade payables

   $ 11,164       $ 10,391   

Compensation and benefits related accruals

     14,846         13,117   

Warranty accrual

     5,487         4,670   

Accrued restructuring charges, current

     5,406         5,363   

Other accruals

     17,691         18,469   
  

 

 

    

 

 

 
   $ 54,594       $ 52,010   
  

 

 

    

 

 

 

The following table summarizes the activity related to our accrued restructuring charges for the six months ended December 28, 2013:

 

     Lease Cancellations,
Commitments and
Other Charges
    Termination
Payments to
Employees and
Related Costs
    Total Accrued
Restructuring Charges
 
     (Thousands)  

Balance at June 29, 2013

   $ 230      $ 7,036      $ 7,266   

Charged to restructuring costs

     375        8,487        8,862   

Paid or written-off

     (343     (7,685     (8,028
  

 

 

   

 

 

   

 

 

 

Balance at December 28, 2013

   $ 262      $ 7,838      $ 8,100   
  

 

 

   

 

 

   

 

 

 

Current portion

     262        5,144        5,406   

Non-current portion

     —          2,694        2,694   

 

9


Table of Contents

During the first quarter of fiscal year 2014, we initiated a restructuring plan to simplify our operating footprint, reduce our cost structure and focus our research and development investment in the optical communications market where we can leverage our core competencies. During the three months ended December 28, 2013, we recorded restructuring charges of $5.7 million and paid $2.9 million to settle a portion of these restructuring liabilities. The restructuring charges for the three months ended December 28, 2013, included $5.4 million related to workforce reductions and $0.3 million related to revised estimates related to lease cancellations and commitments. During the six months ended December 28, 2013, we recorded restructuring charges of $5.8 million and paid $3.1 million to settle a portion of these restructuring liabilities. The restructuring charges for the six months ended December 28, 2013, included $5.6 million related to workforce reductions and $0.3 million related to revised estimates related to lease cancellations and commitments. As of December 28, 2013, we had $2.7 million in accrued restructuring liabilities related to this restructuring plan. We expect to incur an additional $13.0 million to $18.0 million in restructuring charges over the course of the next year in connection with the ongoing activities related to this restructuring plan.

As of June 29, 2013, we also had $1.9 million in accrued restructuring liabilities relating to the separation agreement with our former Chief Executive Officer. During the three months ended December 28, 2013, we paid $0.3 million to settle a portion of this liability. At December 28, 2013, we have $1.6 million in accrued restructuring liabilities, which we expect to settle over the next two quarters.

During the first quarter of fiscal year 2013, we initiated a restructuring plan to integrate our acquisition of Opnext. In connection with this restructuring plan, we recorded $0.1 million and $1.1 million in restructuring charges during the three and six months ended December 28, 2013, respectively. The restructuring charges recorded in fiscal year 2014 included $0.9 million in external consulting charges and professional fees associated with reorganizing the infrastructure and $0.1 million in revised estimates related to lease cancellations and commitments. During the three and six months ended December 28, 2013 we made scheduled payments of $0.2 million and $2.2 million to settle a portion of these restructuring liabilities. During the three and six months ended December 29, 2012, we recorded $0.8 million and $9.1 million in restructuring charges, respectively. The restructuring charges for the three months ended December 29, 2012, included $0.8 million related to workforce reductions. The restructuring charges for the six months ended December 29, 2012, included $7.8 million related to workforce reductions, $0.9 million related to the impairment of certain technology that is now considered redundant following the acquisition and $0.4 million related to the write-off of net book value inventory that supported this technology. As of December 28, 2013, we had no further accrued restructuring liabilities related to this restructuring plan.

During fiscal year 2012, we initiated a restructuring plan in connection with the transfer of our Shenzhen, China manufacturing operations to Venture Corporation Limited (Venture). In connection with this transition, during the three and six months ended December 28, 2013, we recorded restructuring charges related to employee separation charges of $0.9 million and $1.9 million, respectively. During the three and six months ended December 28, 2013, we made scheduled payments of $1.9 million and $2.3 million, respectively, to settle a portion of these restructuring liabilities. During the three and six months ended December 29, 2012, we recorded restructuring charges related to employee separation charges of $1.4 million and $2.9 million, respectively. During the three and six months ended December 29, 2012, we made scheduled payments of $0.8 million and $1.9 million, respectively, to settle a portion of these restructuring liabilities. As of December 28, 2013, we had $3.8 million in accrued restructuring liabilities related to this restructuring plan. We expect to incur between $3.0 million and $5.0 million in additional restructuring costs in connection with the transition of our Shenzhen manufacturing operations to Venture over the next year.

The current portion of accrued restructuring liabilities is included in the caption accrued expenses and other liabilities and the non-current portion is included in the caption other non-current liabilities in the condensed consolidated balance sheet.

 

10


Table of Contents

The following table presents the components of accumulated other comprehensive income at the dates indicated:

 

     December 28, 2013     June 29, 2013  
     (Thousands)  

Accumulated other comprehensive income:

  

Currency translation adjustments

   $ 45,678      $ 45,719   

Unrealized loss on marketable securities

     (144     (105

Switzerland and Japan defined benefit plans

     (413     (6,246
  

 

 

   

 

 

 
   $ 45,121      $ 39,368   
  

 

 

   

 

 

 

In connection with the sale of the Zurich Business in the first quarter of fiscal year 2014, II-VI assumed the pension plan covering employees of the Swiss subsidiary.

NOTE 4. FAIR VALUE

We define fair value as the estimated price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. We apply the following fair value hierarchy, which ranks the quality and reliability of the information used to determine fair values:

 

Level 1  –    Quoted prices in active markets for identical assets or liabilities.
Level 2    Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices of identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets), or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3    Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Our cash equivalents and marketable securities are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The types of instruments valued based on quoted market prices in active markets include most marketable securities and money market securities. Such instruments are generally classified within Level 1 of the fair value hierarchy.

The contingent obligation related to the make-whole premium on our convertible notes was valued using a valuation model which estimated the value based on the probability and timing of conversion. The contingent obligation was previously classified within Level 3 of the fair value hierarchy. During the second quarter of fiscal year 2014, the holders of the Convertible Notes exercised their rights to exchange the Convertible Notes for common stock, and settled the make-whole premium.

 

11


Table of Contents

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets and liabilities measured at fair value on a recurring basis are shown in the table below by their corresponding balance sheet caption and consisted of the following types of instruments at December 28, 2013:

 

     Fair Value Measurement at Reporting Date Using  
     Quoted Prices      Significant                
     in Active      Other      Significant         
     Markets for      Observable      Unobservable         
     Identical Assets      Inputs      Inputs         
     (Level 1)      (Level 2)      (Level 3)      Total  
     (Thousands)  

Assets:

           

Cash and cash equivalents: (1)

           

Money market funds

   $ 1,214       $ —         $ —         $ 1,214   

Short-term investments:

           

Marketable securities

     160         —           —           160   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total assets measured at fair value

   $ 1,374       $ —         $ —         $ 1,374   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Excludes $140.3 million in cash held in our bank accounts at December 28, 2013.

The following table provides details regarding the changes in assets and liabilities classified within Level 3 from June 29, 2013 to December 28, 2013:

 

    

Other

non-current

 
     liabilities  
     (Thousands)  

Balance at June 29, 2013

   $ 99   

Current year adjustments to the contingent obligation for make-whole premium

     600   

Settlement of make-whole premium upon conversion of the Convertible Notes

     (699
  

 

 

 

Balance at December 28, 2013

   $ —     
  

 

 

 

During the second quarter of fiscal year 2014, the holders of the Convertible Notes exercised their rights to exchange the Convertible Notes for our common stock. The conversion of the Notes is more fully discussed in Note 7, Credit Line and Notes .

NOTE 5. BUSINESS COMBINATIONS AND DISPOSITIONS

Sale of Amplifier Business

On October 10, 2013, Oclaro Technology Limited entered into an Asset Purchase Agreement with II-VI, whereby Oclaro Technology Limited agreed to sell to II-VI and certain of its affiliates its Amplifier Business for $88.6 million in cash. The transaction closed on November 1, 2013.

Consideration, valued at $88.6 million, consists of $79.6 million in cash, which was received on November 1, 2013, $4.0 million subject to hold-back by II-VI until December 31, 2014 to address any post-closing claims and $5.0 million related to the exclusive option, which was received on September 12, 2013 and was credited against the purchase price upon closing of the sale.

We entered into certain transition service and manufacturing service agreements to allow the Amplifier Business to continue operations during the ownership transition.

Both parties provided customary and reciprocal representations, warranties and covenants in the Asset Purchase Agreement.

 

12


Table of Contents

We classified the sale of our Amplifier Business as a discontinued operation as of September 12, 2013, the date management committed to sell the business. In connection with this transaction, we transferred $16.2 million in net assets to II-VI. We also incurred approximately $2.9 million in legal fees, commissions and other administrative costs related to this transaction. We recognized a gain of $69.7 million on the sale of the Amplifier Business, which is recorded within discontinued operations in the condensed consolidated statements of operations for the three and six months ended December 28, 2013. As of December 28, 2013, we recorded a $4.0 million receivable in other non-current assets from II-VI related to the holdback for potential post-closing adjustments or claims.

The assets of the discontinued operation are presented as current assets under the caption assets of discontinued operations held for sale in the accompanying condensed consolidated balance sheets at December 28, 2013 and June 29, 2013, and consist of the following:

 

     December 28, 2013      June 29, 2013  
     (Thousands)  

Assets of Discontinued Operations Held for Sale

     

Inventories

     —           8,308   

Prepaid expenses and other current assets

     —           303   

Property and equipment, net

     —           6,555   
  

 

 

    

 

 

 
   $ —         $ 15,166   
  

 

 

    

 

 

 

The following table presents the statements of operations for the discontinued operations of the Amplifier Business for the three and six months ended December 28, 2013 and December 29, 2012:

 

     Three Months Ended      Six Months Ended  
     December 28,
2013
     December 29,
2012
     December 28,
2013
     December 29,
2012
 
     (Thousands)  

Revenues

   $ 6,869       $ 25,844       $ 35,185       $ 53,737   

Cost of revenues

     5,528         19,556         26,243         41,535   
  

 

 

    

 

 

    

 

 

    

 

 

 

Gross profit

     1,341         6,288         8,942         12,202   

Operating expenses

     1,508         4,422         5,576         8,746   

Other income (expense), net

     69,705         —           69,705         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from discontinued operations before income taxes

     69,538         1,866         73,071         3,456   

Income tax provision

     —           —           —           —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from discontinued operations

   $ 69,538       $ 1,866       $ 73,071       $ 3,456   
  

 

 

    

 

 

    

 

 

    

 

 

 

Sale of Zurich Business

On September 12, 2013, we completed a share and asset purchase agreement with II-VI, pursuant to which we sold our Oclaro Switzerland GmbH subsidiary and associated laser diodes and pump business to II-VI. We received proceeds of $90.6 million in cash on September 12, 2013. We will also receive $6.0 million subject to hold-back by II-VI until December 31, 2014 to address any post-closing adjustments or claims, and $2.0 million subject to a potential post-closing working capital adjustment, which was calculated based on the level of working capital in the Oclaro Switzerland GmbH subsidiary at the September 12, 2013 close versus a target based on working capital at June 29, 2013. In addition, we retained approximately $14.7 million in accounts receivable related to the Zurich Business and approximately $9.6 million of supplier and employee related payables related to the Zurich Business which were not included in the Zurich subsidiary.

 

13


Table of Contents

As part of the agreement, II-VI purchased our Swiss subsidiary, which includes its GaAs fabrication facility, and also the corresponding high power laser diodes, VCSEL and 980 nm pump laser product lines, including intellectual property, inventory, equipment and a related research and development facility in Tucson, all of which are associated with the business.

We will continue the back-end manufacturing of the 980 nm pump and some high power laser diode products at our Shenzhen, China manufacturing facility and supply them to II-VI under a manufacturing services agreement. The employees of Shenzhen, China will continue to be employed by us. In addition, various supply and transition service agreements have been established between the companies to ensure a smooth transition.

We have classified the sale of our Zurich Business as a discontinued operation. In connection with this transaction, in the first quarter of fiscal year 2014, we transferred $32.5 million in net assets to II-VI and incurred approximately $4.9 million in legal fees, commissions and other administrative costs. We recognized a gain of $62.8 million on the sale of the Zurich Business, which is recorded within discontinued operations in the condensed consolidated statements of operations for the six months ended December 28, 2013. During the first quarter of fiscal year 2014, we also recorded $3.1 million in income from discontinued operations within the condensed consolidated statement of operations related to the cumulative translation adjustment from deconsolidating our Swiss subsidiary. As of December 28, 2013, we recorded a $2.0 million receivable in prepaid expenses and other current assets and a $6.0 million receivable in other non-current assets from II-VI related to the holdback for potential post-closing working capital adjustments and other adjustments or claims.

The assets and liabilities of the discontinued operation are presented as current assets and current liabilities, separately under the captions assets of discontinued operations held for sale and liabilities of discontinued operations held for sale in the accompanying condensed consolidated balance sheets at December 28, 2013 and June 29, 2013, and consist of the following:

 

     December 28,
2013
     June 29,
2013
 
     (Thousands)  

Assets of Discontinued Operations Held for Sale

     

Accounts receivable, net

     —           79   

Inventories

     —           23,762   

Prepaid expenses and other current assets

     —           1,294   

Property and equipment, net

     —           12,749   

Deferred tax asset, non-current

     —           2,283   
  

 

 

    

 

 

 
   $ —         $ 40,167   
  

 

 

    

 

 

 

 

     December 28,
2013
     June 29,
2013
 
     (Thousands)  

Liabilities of Discontinued Operations Held for Sale

     

Accounts payable

     —           2,315   

Accrued expenses and other liabilities

     —           6,788   

Other non-current liabilities

     —           8,367   
  

 

 

    

 

 

 
   $ —         $ 17,470   
  

 

 

    

 

 

 

 

14


Table of Contents

The following table presents the statements of operations for the discontinued operations of the Zurich Business for the three and six months ended December 28, 2013 and December 29, 2012:

 

     Three Months Ended      Six Months Ended  
     December 28,
2013
     December 29,
2012
     December 28,
2013
     December 29,
2012
 
     (Thousands)      (Thousands)  

Revenues

   $ —         $ 21,550       $ 13,896       $ 46,835   

Cost of revenues

     —           17,804         11,593         37,958   
  

 

 

    

 

 

    

 

 

    

 

 

 

Gross profit

     —           3,746         2,303         8,877   

Operating expenses

     —           4,018         3,416         8,369   

Other income (expense), net

     —           609         61,150         767   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from discontinued operations before income taxes

     —           337         60,037         1,275   

Income tax provision

     —           190         163         455   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from discontinued operations

   $ —         $ 147       $ 59,874       $ 820   
  

 

 

    

 

 

    

 

 

    

 

 

 

Sale of Thin Film Filter Business and Interleaver Product Line

On November 19, 2012, we entered into an asset purchase agreement with II-VI Incorporated, Photop Technologies, Inc. and Photop Koncent, Inc. (FuZhou), both wholly owned subsidiaries of II-VI Incorporated, pursuant to which we sold substantially all of the assets of our thin film filter business and our interleaver product line. The transactions closed on December 3, 2012.

The total purchase price under the asset purchase agreement is $27.0 million in cash. We received $26.0 million in cash proceeds during the second quarter of fiscal year 2013, while the remaining $1.0 million is being held in escrow until December 31, 2013.

In connection with this transaction, during the second quarter of fiscal year 2013, we recognized a gain of $25.0 million within restructuring, acquisition and related costs in the condensed consolidated statements of operations.

This asset disposition is more fully discussed in Note 3, Business Combinations and Asset Dispositions , to our consolidated financial statements included in our 2013 Form 10-K.

Acquisition of Opnext

On March 26, 2012, we entered into an Agreement and Plan of Merger and Reorganization, by and among Opnext, Tahoe Acquisition Sub, Inc., a newly formed wholly-owned subsidiary of Oclaro (“Merger Sub”), and Oclaro, pursuant to which we acquired Opnext through a merger of Merger Sub with and into Opnext. On July 23, 2012, we consummated the acquisition following approval by the stockholders of both companies.

Any excess of the fair value of assets acquired and liabilities assumed over the aggregate consideration given for such acquisition results in a gain on bargain purchase. In the first quarter of fiscal year 2013, we initially recorded a gain on bargain purchase of $39.5 million in connection with the acquisition of Opnext, which was subsequently adjusted to $24.9 million, upon completing our purchase price allocation and finalizing our fair value estimates of assets acquired and liabilities assumed in the fourth quarter of fiscal year 2013.

This acquisition is more fully discussed in Note 3, Business Combinations and Asset Dispositions , to our consolidated financial statements included in our 2013 Form 10-K.

 

15


Table of Contents

Acquisition of Mintera

In July 2010, we acquired Mintera Corporation (“Mintera”). Under the terms of this acquisition, we agreed to pay certain revenue-based consideration, whereby former security holders of Mintera were entitled to receive earnouts up to $20.0 million, determined based on revenue from Mintera products following the acquisition. In the first quarter of fiscal year 2013, we settled the remaining earnout obligations of $8.6 million in cash.

This acquisition is more fully discussed in Note 3, Business Combinations and Asset Dispositions , to our consolidated financial statements included in our 2013 Form 10-K.

NOTE 6. OTHER INTANGIBLE ASSETS

In connection with our sale of the Zurich Business, we transferred certain of our other intangible assets to II-VI. As of September 12, 2013, the date of the sale, and as of June 29, 2013, these other intangible assets had no carrying value. For the three and six months ended December 29, 2012, we recorded $0.1 million and $0.1 million, respectively, in amortization related to these intangible assets, which has been reclassified to discontinued operations in the condensed consolidated statements of operations.

In connection with our acquisition of Opnext on July 23, 2012, we recorded $16.4 million in other intangible assets as our estimate of the fair value of acquired intangible assets. The intangible assets acquired from Opnext consist of $8.7 million of developed technology with an estimated weighted average useful life of 6 years, $0.2 million of contract backlog with an estimated weighted average useful life of 1 year, $4.9 million of customer relationships with an estimated weighted average useful life of 11 years, and $2.7 million of trademarks and other with an estimated weighted average useful life of 6 years.

During the first quarter of fiscal year 2013, we determined that a portion of the technology we acquired in connection with our acquisition of Mintera in July 2010 was redundant, following the acquisition of Opnext and its product lines. We recorded $0.9 million for the impairment loss related to these intangibles in our condensed consolidated statements of operations for the six months ended December 29, 2012.

The following table summarizes the activity related to our other intangible assets for the six months ended December 28, 2013:

 

     Core and
Current
Technology
    Development
and Supply
Agreements
     Customer
Relationships
     Patent
Portfolio
     Other
Intangibles
     Amortization     Total  
     (Thousands)  

Balance at June 29, 2013

   $ 8,333      $ 4,556       $ 5,198       $ 915       $ 3,338       $ (12,107   $ 10,233   

Amortization

     —          —           —           —           —           (841     (841

Translations and adjustments

     (304     79         —           —           —           —          (225
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balance at December 28, 2013

   $ 8,029      $ 4,635       $ 5,198       $ 915       $ 3,338       $ (12,948   $ 9,167   
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

We expect the amortization of intangible assets to be $1.7 million for fiscal years 2014 through 2018, and $0.9 million for fiscal year 2019, based on the current level of our other intangible assets.

NOTE 7. CREDIT LINE AND NOTES

Credit Line and Term Loan

On August 2, 2006, Oclaro, Inc., as the (“Parent”), along with Oclaro Technology Limited (“Borrower”), Oclaro Photonics, Inc. and Oclaro Technology, Inc., each a wholly-owned subsidiary, entered into a Credit Agreement with Wells Fargo Capital Finance, Inc. (“Wells Fargo”) and certain other lenders (the “Credit Agreement”). From time to time, we amended and restated the Credit Agreement, which is more fully discussed in Note 7, Credit Line and Notes , to our consolidated financial statements included in our 2013 Form 10-K.

 

16


Table of Contents

On May 6, 2013, Wells Fargo and Silicon Valley Bank (collectively, the “Lenders”), Parent, Borrower, Wells Fargo (“Agent”) and PECM Strategic Funding LP and Providence TMT Debt Opportunity Fund II LP (the “Term Lenders”) entered into Amendment Number Two to the Credit Agreement and the associated guaranties and security agreements (the “Amendment”), which amended the Credit Agreement in pertinent part by: (i) adding a $25.0 million term loan (the “Term Loan”) to be provided by the Term Lenders; (ii) reducing the revolving credit facility from $80 million to $50 million (to be further reduced on a dollar-for-dollar basis by an amount equal to the net proceeds of certain asset sale transactions that the Parent may undertake in the future), eliminating the Borrower’s option to increase the revolving credit facility to $100.0 million and implementing an availability block under the revolving credit facility of at least $10.0 million; (iii) removing the financial covenants so that Borrower is not required to maintain a minimum of $15.0 million of availability under the revolving credit facility or $15.0 million in qualified cash balances; (iv) adding an affirmative covenant that Borrower shall have consummated one or more asset sales by July 15, 2013 and with a minimum threshold of net proceeds, and (v) providing for payments and proceeds of asset sales to be applied to repay the credit facility and the Term Loan (with the first $20.0 million of such proceeds being applied to repay Wells Fargo Capital Finance, Inc. and Silicon Valley Bank and the next $25.0 million being applied to repay Providence and the remaining proceeds being used to repay Wells Fargo Capital Finance, Inc. and Silicon Valley Bank all amounts outstanding under the credit facility). In connection with the Term Loan, we also issued certain warrants.

On August 21, 2013, Parent, Borrower, Agent, and the Lenders entered into Waiver and Amendment Number Three to the Credit Agreement, which amended the Credit Agreement in pertinent part by: (i) extending the date by which the Borrower shall have consummated one or more asset sales with a minimum threshold of net proceeds to September 2, 2013; (ii) eliminating the mandatory reduction of the revolving credit facility upon the consummation of the asset sales described in (i) above; and (iii) adding a covenant that the Borrower is required to maintain a minimum liquidity of at least $45.0 million at all times (liquidity being the sum of the Borrower’s excess availability under the revolving credit facility plus the lesser of $25.0 million and qualified cash balances). The Borrower paid the lenders an amendment fee of $650,000.

Under the Credit Agreement, as amended, we were required to complete certain asset sales on or by September 2, 2013. We completed the sale of the Zurich Business on September 12, 2013 and applied the net proceeds to repay the entire credit line and Term Loan. The event of default resulting from not completing the transaction on September 2, 2013, was waived on September 26, 2013. This waiver eliminated the requirement for the Agent and Lenders to make any advances, issue any letters of credit or provide any other extension of credit until the Agent and Lenders agree otherwise and prevents us from exercising any right or action set forth in the applicable loan documents that is conditioned on the absence of any event of default. As of December 28, 2013, no amounts were available to us under this Credit Agreement.

At December 28, 2013, there are no amounts outstanding under the credit line or the Term Loan. At June 29, 2013, we had $40.0 million outstanding under the credit line and $25.0 million outstanding related to the Term Loan. Upon repaying the credit line and the Term Loan during the first quarter of fiscal year 2014, we recorded the remaining unamortized debt discount and issuance costs of $4.3 million related to the Term Loan in discontinued operations within the condensed consolidated statement of operations for the six months ended December 28, 2013.

7.50 % Exchangeable Senior Secured Second Lien Notes (Convertible Notes)

On December 14, 2012, we and our indirect, wholly owned subsidiary, Oclaro Luxembourg S.A., closed the private placement of $25.0 million aggregate principal amount 7.50% Exchangeable Senior Secured Second Lien Notes due 2018 (“Convertible Notes”). The sale of the Convertible Notes resulted in net proceeds of approximately $22.8 million. The private placement was completed pursuant to a purchase agreement, dated December 14, 2012 entered into by us, certain of our domestic and foreign subsidiaries (the Guarantors) and Morgan Stanley & Co. LLC, which is more fully discussed in Note 7, Credit Line and Notes , to our consolidated financial statements included in our 2013 Annual Report on Form 10-K.

Under the terms of the Convertible Notes, on or after December 15, 2013, in the event that the last reported sale price of our common stock for 20 or more trading days (whether or not consecutive) in a period of 30 consecutive trading days ending within five trading days immediately prior to the date that we receive a notice of exchange exceeded the exchange price in effect on each such trading day, we were obliged, in addition to delivering shares upon exchange by the holder of Convertible Notes, together with cash in lieu of fractional shares, to make a “make-whole premium” payment in cash equal to the sum of the present value of the remaining scheduled payments of interest on the Convertible Notes to be exchanged through the maturity date computed using a discount rate equal to 0.50%. The initial exchange price was $1.846 per share of common stock. Any holder that exchanged its Convertible Notes after such holder’s Convertible Notes had been called for redemption by us would, in addition to receiving shares of common stock deliverable upon such exchange and cash in lieu of fractional shares, receive a payment (the “redemption exchange make-whole payment”) in cash equal to the sum of the remaining scheduled payments of interest that would have been made on the Convertible Notes to be exchanged had such Convertible Notes remained outstanding from the applicable exchange date to the maturity date. If the redemption exchange make-whole payment is payable upon exchange of a holder’s Convertible Notes, then such holder would not receive the “make-whole premium” payment described above.

 

17


Table of Contents

We considered the contingent obligation of having to make a make-whole payment in the event of an early conversion by the holders of the Convertible Notes as an embedded derivative. We estimated the fair value of the make-whole payment by using a valuation model to predict the probability and timing of a conversion. At June 29, 2013, the fair value of this contingent obligation was estimated at $0.1 million. On December 19, 2013, the holders exercised their rights to exchange the Convertible Notes for our common stock. The exchange rate for the exchanges was 541.7118 shares of common stock per $1,000 in principal amount of Convertible Notes. On December 17, 2013 through December 19, 2013, the Company issued 13,542,791 shares of common stock in connection with the exchange, with cash payable in lieu of fractional shares. In addition, pursuant to the terms of the indenture governing the Convertible Notes, we made a redemption exchange make-whole payment of $8.3 million, which we recorded in interest (income) expense, net, in the condensed consolidated statements of operations for the three and six months ended December 28, 2013.

In connection with the private placement of the Convertible Notes, we incurred approximately $1.3 million in debt discount and $0.9 million in issuance costs. Upon exchange of the Convertible Notes during the second quarter of fiscal year 2014, we recorded the remaining unamortized debt discount and issuance costs of $1.8 million in additional paid-in capital within the condensed consolidated balance sheets at December 28, 2013.

NOTE 8. POST-RETIREMENT BENEFITS

Switzerland Defined Benefit Plan

During the first quarter of fiscal year 2014, we sold our Zurich Business, and as part of the sale transferred our pension plan covering employees of our Swiss subsidiary (the “Swiss Plan”) to II-VI. At the end of our first quarter of fiscal year 2014, we had no remaining obligations under the Swiss Plan.

Net periodic pension costs associated with our Swiss Plan are recorded in discontinued operations for the six months ended December 28, 2013 and for the three and six months ended December 29, 2012, and included the following:

 

     Three Months Ended     Six Months Ended  
     December 28,
2013
     December 29,
2012
    December 28,
2013
    December 29,
2012
 
     (Thousands)  

Service cost

   $ —         $ 830      $ 703      $ 1,639   

Interest cost

     —           188        169        371   

Expected return on plan assets

     —           (314     (279     (620

Net amortization

     —           96        76        189   
  

 

 

    

 

 

   

 

 

   

 

 

 

Net periodic pension costs

   $ —         $ 800      $ 669      $ 1,579   
  

 

 

    

 

 

   

 

 

   

 

 

 

Prior to transferring our pension plan to II-VI, we contributed $0.5 million to our Swiss Plan during the six months ended December 28, 2013. During the three and six months ended December 29, 2012, we contributed $0.8 million and $1.2 million, respectively, to our Swiss Plan.

Japan Defined Contribution and Benefit Plan

In connection with our acquisition of Opnext, we assumed a defined contribution plan and a defined benefit plan that provides retirement benefits to our employees in Japan.

Under the defined contribution plan, contributions are provided based on grade level and totaled $0.2 million and $0.4 million for the three and six months ended December 28, 2013, respectively, and $0.3 million and $0.5 million for the three months ended December 29, 2012 and for the period from July 23, 2012, the acquisition date, to December 29, 2012, respectively. Employees can elect to receive the benefit as additional salary or contribute the benefit to the plan on a tax-deferred basis.

 

18


Table of Contents

Under the defined benefit plan in Japan (the “Japan Plan”), we calculate benefits based on an employee’s individual grade level and years of service. Employees are entitled to a lump sum benefit upon retirement or upon certain instances of termination. As of December 28, 2013, there were no plan assets. Net periodic pension costs for the Japan Plan for the three and six months ended December 28, 2013 and December 29, 2012 included the following:

 

     Three Months Ended      Six Months Ended  
     December 28,
2013
     December 29,
2012
     December 28,
2013
     December 29,
2012
 
     (Thousands)  

Service cost

   $ 233       $ 282       $ 481       $ 576   

Interest cost

     23         36         47         73   

Net amortization

     15         19         31         41   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net periodic pension costs

   $ 271       $ 337       $ 559       $ 690   
  

 

 

    

 

 

    

 

 

    

 

 

 

In connection with the Japan Plan, we have $0.2 million in accrued expenses and other liabilities and $7.9 million in other non-current liabilities in our condensed consolidated balance sheet as of December 28, 2013, to account for the projected benefit obligations.

We made benefit payments under the Japan plan of $0.1 million during the six months ended December 28, 2013, and $0.1 million during the six months ended December 29, 2012.

NOTE 9. COMMITMENTS AND CONTINGENCIES

Loss Contingencies

We are involved in various lawsuits, claims, and proceedings that arise in the ordinary course of business. We record a loss provision when we believe it is both probable that a liability has been incurred and the amount can be reasonably estimated.

Guarantees

We indemnify our directors and certain employees as permitted by law, and have entered into indemnification agreements with our directors and executive officers. We have not recorded a liability associated with these indemnification arrangements, as we historically have not incurred any material costs associated with such indemnification obligations. Costs associated with such indemnification obligations may be mitigated by insurance coverage that we maintain, however, such insurance may not cover any, or may cover only a portion of, the amounts we may be required to pay. In addition, we may not be able to maintain such insurance coverage in the future.

We also have indemnification clauses in various contracts that we enter into in the normal course of business, such as indemnifications in favor of customers in respect of liabilities they may incur as a result of purchasing our products should such products infringe the intellectual property rights of a third party. We have not historically paid out any material amounts related to these indemnifications; therefore, no accrual has been made for these indemnifications.

Warranty Accrual

We generally provide a warranty for our products for twelve to thirty-six months from the date of sale, although warranties for certain of our products may be longer. We accrue for the estimated costs to provide warranty services at the time revenue is recognized. Our estimate of costs to service our warranty obligations is based on historical experience and expectation of future conditions. To the extent we experience increased warranty claim activity or increased costs associated with servicing those claims, our warranty costs would increase, resulting in a decrease in gross profit.

 

19


Table of Contents

The following table summarizes movements in the warranty accrual for the periods indicated:

 

     Three Months Ended     Six Months Ended  
     December 28,
2013
    December 29,
2012
    December 28,
2013
    December 29,
2012
 
     (Thousands)  

Warranty provision—beginning of period

   $ 4,753      $ 7,270      $ 4,670      $ 2,599   

Warranties assumed in acquisitions

     —          —          —          4,867   

Warranties issued

     529        1,350        1,501        2,041   

Warranties utilized or expired

     (1,031     (2,492     (2,014     (3,464

Currency translation and other adjustments

     1,236        (208     1,330        (123
  

 

 

   

 

 

   

 

 

   

 

 

 

Warranty provision—end of period

   $ 5,487      $ 5,920      $ 5,487      $ 5,920   
  

 

 

   

 

 

   

 

 

   

 

 

 

Capital Leases

In connection with our acquisition of Opnext, we assumed certain capital leases with Hitachi Capital Corporation for certain equipment. The following table shows the future minimum lease payments due under non-cancelable capital leases with Hitachi Capital Corporation:

 

     Capital Leases  
     (Thousands)  

Fiscal Year Ending:

  

2014 (remaining)

   $ 3,157   

2015

     4,655   

2016

     2,821   

2017

     1,333   

2018

     47   

Thereafter

     115   
  

 

 

 

Total minimum lease payments

     12,128   

Less amount representing interest

     (448
  

 

 

 

Present value of capitalized payments

     11,680   

Less: current portion

     (5,559
  

 

 

 

Long-term portion

   $ 6,121   
  

 

 

 

Litigation

In the ordinary course of business, we are involved in various legal proceedings, and we anticipate that additional actions will be brought against us in the future. The most significant of these proceedings are described below. The following supplements and amends the discussion set forth in our Annual Report on Form 10-K for the year ended June 29, 2013. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims in various jurisdictions. Complex legal proceedings frequently extend for several years, and a number of the matters pending against us are at very early stages of the legal process. As a result, some pending matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to determine whether the proceeding is material to us or to estimate a range of possible loss, if any. Unless otherwise disclosed, we are unable to estimate the possible loss or range of loss for the legal proceedings described below. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our results of operations, financial position or cash flows.

On October 23, 2013, Xi’an Raysung Photonics Inc., or Xi’an Raysung, filed a civil suit against our wholly-owned subsidiary, Oclaro Technology (Shenzhen) Co., Ltd. (formerly known as Bookham Technology (Shenzhen) Co., Ltd.), or Oclaro Shenzhen, in the Xi’an Intermediate People’s Court in Shaanxi Province of the People’s Republic of China, or the Xi’an Court. The complaint filed by Xi’an Raysung alleges that Oclaro Shenzhen terminated its purchase order pursuant to which Xi’an Raysung had supplied certain products and was to supply certain products to Oclaro Shenzhen.

 

20


Table of Contents

Xi’an Raysung has requested the court award damages of approximately $0.8 million (equivalent to RMB 4,796,531), and requested that Oclaro Shenzhen take the finished products that are now stored in Xi’an Raysung’s warehouse (the value of the finished product is approximately, $2.2 million, (equivalent to RMB 13,505,162) and requested that Oclaro Shenzen pay its court fees in connection with this suit.

The Xi’an Court delivered an Asset Preservation Order which was served on Oclaro Shenzhen and the local Customs office. According to the Asset Preservation Order, Oclaro Shenzhen was ordered to maintain approximately $2.5 million (equivalent to RMB 15,000,000) or assets equivalent to the said amount during the litigation process, and the Customs office was ordered that before the Asset Preservation Order is lifted, Oclaro Shenzhen’s equipment is restricted from being exported. On November 11, 2013, Oclaro Shenzhen entered into a settlement agreement. Under the terms of this settlement agreement, Oclaro Shenzhen agreed to pay $500,000 in payment of invoices for certain materials to Xi’an Raysung and to work with Xi’an Raysung to requalify it as a vendor for certain Oclaro Shenzhen manufacturing requirements, in consideration of which Xi’an Raysung agreed to submit the settlement agreement to the Xi’an Court so it could issue a civil mediation agreement, apply for a discharge of the Asset Preservation Order and waive the right to bring any legal actions against Oclaro Shenzhen relating to these matters. Oclaro Shenzhen performed its obligations under the settlement agreement, however, on January 15, 2014, Xi’an Raysung applied to the Xi’an Court to terminate the settlement agreement and add Oclaro, Inc. as a co-defendant in the original civil suit. Oclaro, Inc. and Oclaro Shenzhen believe that they have meritorious defenses to the claims made by Xi’an Raysung and intend to defend this litigation vigorously.

On August 29, 2013, the Secured Lender Trustee of the Secured Lender Trust (“Trust”) established under the Second Amended Chapter 11 Plan of Liquidation of Dewey & LeBoeuf LLP (the “Trustee”) filed a complaint against Oclaro, Inc. in the United States Bankruptcy Court, Southern District of New York. The complaint alleges that we were formerly a client of Dewey & LeBoeuf LLP (“Dewey”) and engaged it to provide services for the period through June 5, 2012. The Trustee claimed that there were unpaid invoices outstanding totaling approximately $0.5 million. Oclaro, Inc. and the Trust, as a successor to Dewey, entered into a Stipulation of Settlement dated as of November 25, 2013, under which we agreed to pay the Trust the sum of $235,000 in full and final settlement of all outstanding claims by the Trust and in consideration of a full release of claims from the Trust. We also released the Trust from all claims. On December 6, 2013, the underlying adversary proceeding in the United States Bankruptcy Court for the Southern District of New York was dismissed with prejudice by stipulation of the parties.

On December 21, 2012, Labyrinth Optical Technologies LLC filed a complaint against us in United States District Court for the Central District of California alleging that certain coherent transponder modules, coherent receivers and DQPSK transceivers sold by us infringe Labyrinth Optical U.S. patent Nos. 7,599,627 and 8,103,173. The parties executed a settlement agreement on September 13, 2013 and on October 30, 2013 the litigation was dismissed with prejudice by stipulation of the parties.

On May 19, 2011, Curtis and Charlotte Westley filed a purported class action complaint in the United States District Court for the Northern District of California, against us and certain of our officers and directors. The Court subsequently appointed the Connecticut Laborers’ Pension Fund (“Pension Fund”) as lead plaintiff for the putative class. On April 26, 2012, the Pension Fund filed a second amended complaint, captioned as Westley v. Oclaro, Inc., No. 11 Civ. 2448 EMC, allegedly on behalf of persons who purchased our common stock between May 6 and October 28, 2010, alleging that we and certain of our officers and directors issued materially false and misleading statements during this time period regarding our current business and financial condition, including projections for demand for our products, as well as our revenues, earnings, and gross margins, for the first quarter of fiscal year 2011 as well as the full fiscal year. The complaint alleges violations of section 10(b) of the Securities Exchange Act and Securities and Exchange Commission Rule 10b-5, as well as section 20(a) of the Securities Exchange Act. The complaint seeks damages and costs of an unspecified amount. On September 21, 2012, the Court dismissed the second amended complaint with leave to amend. After the Pension Fund moved for reconsideration, on January 10, 2013, the Court allowed plaintiffs to take discovery regarding statements made in May and June 2010. On March 1, 2013 the Pension Fund filed a third amended complaint, attempting to cure pleading deficiencies with regard to statements allegedly made in July and August 2010. On April 1, 2013, defendants moved to dismiss the third amended complaint with respect to the statements made in July and August 2010. On May 30, 2013, the Court granted Defendants’ motion to dismiss the complaint’s claims based on statements made in July and August 2010. Discovery has commenced, and no trial has been scheduled in this action.

 

21


Table of Contents

On June 10, 2011, a purported shareholder, Stanley Moskal, filed a purported derivative action in the Superior Court for the State of California, County of Santa Clara, against us, as nominal defendant, and certain of our current and former officers and directors, as defendants. The case is styled Moskal v. Couder, No. 1:11 CV 202880 (Santa Clara County Super. Ct., filed June 10, 2011). Four other purported shareholders, Matteo Guindani, Jermaine Coney, Jefferson Braman and Toby Aguilar, separately filed substantially similar lawsuits in the United States District Court for the Northern District of California on June 27, June 28, July 7 and July 26, 2011, respectively. By Order dated September 14, 2011, the Guindani, Coney, and Braman actions were consolidated under In re Oclaro, Inc. Derivative Litigation, Lead Case No. 11 Civ. 3176 EMC. On October 5, 2011, the Aguilar action was voluntarily dismissed. Each remaining purported derivative complaint alleges that Oclaro has been, or will be, damaged by the actions alleged in the Westley complaint, and the litigation of the Westley action, and any damages or settlement paid in the Westley action. Each purported derivative complaint alleges counts for breaches of fiduciary duty, waste, and unjust enrichment. Each purported derivative complaint seeks damages and costs of an unspecified amount, as well as injunctive relief. By Order dated March 6, 2012, the parties in the Moskal action agreed that defendants shall not be required to respond to the original complaint. By Order dated February 27, 2013, the parties in the Moskal action agreed that plaintiff would serve an amended complaint no later than 30 days after the Court in the Westley action rules on defendants’ motion to dismiss the third amended complaint in the Westley action and the stay of discovery would remain in effect until further order of the Court or agreement by the parties, provided, however, that they obtain discovery produced in the Westley Action. By Order dated March 12, 2013, the parties to In re Oclaro, Inc. Derivative Litigation agreed to stay all proceedings until such time as (a) the defendants file an answer to any complaint in the Westley action; or (b) the Westley action is dismissed in its entirety with prejudice, provided, however, that they obtain discovery produced in the Westley Action. No trial has been scheduled in any of these actions.

On September 3, 2013, the parties agreed to settle the Westley, Moskal, and In re Oclaro Derivative matters for a total of $3.95 million, plus certain corporate governance changes. The money will be paid entirely by our directors and officers liability insurance carriers. Any fees awarded to the plaintiffs in these actions, or their respective counsel, will be included in this amount. The settlement is subject to final documentation and court approval.

On May 27, 2011, Opnext Japan filed a complaint against Furukawa in the Tokyo District Court alleging that certain laser diode modules sold by Furukawa infringe Opnext Japan’s Japanese patent No. 3,887,174. Opnext Japan is seeking an injunction as well as damages in the amount of 100.0 million Japanese yen.

On August 5, 2011, Opnext Japan filed a complaint against Furukawa in the Tokyo District Court alleging that certain integratable tunable laser assemblies sold by Furukawa infringe Opnext Japan’s Japanese patent No. 4,124,845. Opnext Japan is seeking an injunction as well as damages in the amount of 200.0 million Japanese yen.

NOTE 10. FLOOD-RELATED (INCOME) EXPENSE, NET

In October 2011, certain areas in Thailand suffered major flooding as a result of monsoons. This flooding had a material impact on our business and results of operations. Our primary contract manufacturer, Fabrinet, suspended operations at two factories located in Chokchai, Thailand and Pinehurst, Thailand. The Chokchai factory suffered extensive flood damage and became inaccessible due to high water levels inside and surrounding the manufacturing facility.

During the three and six months ended December 28, 2013, we recorded $0.1 million in flood-related income in our condensed consolidated statement of operations, consisting of $2.1 million in insurance settlement proceeds received in the second quarter of fiscal year 2014, partially offset by an out-of-period adjustment of $2.0 million related to the impairment of leased assets assumed pursuant to the Opnext merger that had been damaged by the flooding. During the three and six months ended December 29, 2012, we recorded flood-related expenses of $0.6 million and $0.9 million, respectively, related to professional fees and related expenses incurred in connection with our recovery efforts.

As of December 28, 2013, we have not recorded any estimated amounts relating to potential future insurance recoveries in the condensed consolidated statement of operations.

 

22


Table of Contents

NOTE 11. EMPLOYEE STOCK PLANS

Stock Incentive Plans

As of December 28, 2013, we maintain the Amended and Restated 2004 Stock Incentive Plan (“2004 Plan”). Under the 2004 Plan, there are a total of 7.8 million shares of common stock authorized for issuance, with full value awards being counted as 1.25 shares of common stock for purposes of the share limit. The 2004 Plan expires in October 2020.

In connection with our acquisition of Opnext, we assumed Opnext’s Third Amended and Restated 2001 Long-Term Stock Incentive Plan and the shares reserved for issuance thereunder. After giving effect to the exchange ratio, the unused and converted share reserve thereunder consisted of 6.3 million shares of common stock as of the acquisition date. Subject to compliance with applicable NASDAQ rules, we can only make grants to legacy Opnext employees and employees hired after the close of the merger unless stockholder approval was obtained to permit awards to all our employees. On July 23, 2013, our board of directors approved the Fourth Amended and Restated 2001 Long-Term Stock Incentive Plan and on January 14, 2014, our shareholders ratified this plan, establishing it as our primary equity incentive plan and revising the eligibility section to allow us to make grants to all our employees, among other changes. The Fourth Amended and Restated 2001 Long-Term Stock Incentive Plan is more fully discussed in Note 17, Subsequent Events.

As of December 28, 2013, there were 8.3 million shares of our common stock available for grant under both plans.

We generally grant stock options that vest over a four year service period, and restricted stock awards and units that vest over a one to four year service period, and in certain cases each may vest earlier based upon the achievement of specific performance-based objectives as set by our board of directors or the compensation committee of our board of directors.

In July 2011, our board of directors approved the grant of 0.2 million performance stock units (“PSUs”) to certain executive officers with an aggregate estimated grant date fair value of $0.9 million. These PSUs vest, up to 150 percent of the target PSUs, upon the achievement of certain revenue growth targets through June 30, 2013, relative to certain comparable companies. In October 2013, the board of directors determined that achievement of the performance conditions were reached at the 100 percent target level. Approximately 0.1 million of the grants outstanding, or 50 percent, vested on October 22, 2013, with the remaining 50 percent scheduled to vest upon a two-year service condition through August 2015. As of December 28, 2013, there were less than 0.1 million PSUs outstanding, after adjustments for forfeitures due to terminations, related to this grant, with an aggregate estimated grant date fair value of $0.1 million.

In July 2012, our board of directors approved an additional grant of 0.6 million PSUs to certain executive officers, subject to shareholder approval of an amendment to our current Plan. These PSUs are not included in the awards outstanding or granted disclosures or in stock-based compensation expense as they are not deemed granted for accounting purposes until the foregoing shareholder approval is obtained. Approximately 0.3 million of the PSUs were forfeited as a result of certain executive officer departures. We will record a cumulative adjustment for stock-based compensation expense based on the fair value of these awards at the date of approval. These PSUs vest upon the achievement of certain adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) targets through June 30, 2014. Vesting is also contingent upon service conditions being met through August 2016. If the performance conditions are not achieved, then the corresponding PSUs will be forfeited in the first quarter of fiscal year 2015.

 

23


Table of Contents

The following table summarizes the combined activity under all of our equity incentive plans for the six months ended December 28, 2013:

 

     Shares
Available
For Grant
    Stock
Options /
SARs

Outstanding
    Weighted-
Average
Exercise Price
     Restricted Stock
Awards / Units
Outstanding
    Weighted-
Average Grant
Date Fair Value
 
     (Thousands)     (Thousands)            (Thousands)        

Balances at June 29, 2013

     7,578        6,475      $ 9.36         2,850      $ 3.17   

Granted

     (730     65        2.15         556        1.42   

Exercised or released

     —          (103     0.81         (1,175     2.81   

Cancelled or forfeited

     1,459        (948     15.50         (520     3.29   
  

 

 

   

 

 

      

 

 

   

Balances at December 28, 2013

     8,307        5,489        8.44         1,711        2.74   
  

 

 

   

 

 

      

 

 

   

Supplemental disclosure information about our stock options and SARs outstanding as of December 28, 2013 is as follows:

 

     Shares      Weighted-
Average
Exercise Price
     Weighted-
Average
Remaining
Contractual Life
     Aggregate
Intrinsic
Value
 
     (Thousands)             (Years)      (Thousands)  

Options and SARs exercisable at December 28, 2013

     4,907       $ 8.84         4.0       $ 173   

Options and SARs outstanding at December 28, 2013

     5,489         8.44         4.4         207   

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the closing price of our common stock of $2.54 on December 27, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. There were approximately 0.1 million shares of common stock subject to in-the-money options which were exercisable as of December 28, 2013. We settle employee stock option exercises with newly issued shares of common stock.

NOTE 12. STOCK-BASED COMPENSATION

We recognize stock-based compensation expense in our statement of operations related to all share-based awards, including grants of stock options, based on the grant date fair value of such share-based awards. Estimating the grant date fair value of such share-based awards requires us to make judgments in the determination of inputs into the Black-Scholes stock option pricing model which we use to arrive at an estimate of the grant date fair value for such awards. The assumptions used in this model to value stock option grants for the three and six months ended December 28, 2013 and December 29, 2012 were as follows:

 

     Three Months Ended      Six Months Ended  
     December 28,
2013
    December 29,
2012
     December 28,
2013
    December 29,
2012
 

Stock options:

         

Expected life

     5.3 years        —           5.3 years        5.1 years   

Risk-free interest rate

     1.5     —           1.5     0.7

Volatility

     82.2     —           82.2     82.9

Dividend yield

     —          —           —          —     

 

24


Table of Contents

The amounts included in cost of revenues and operating expenses for stock-based compensation for the three and six months ended December 28, 2013 and December 29, 2012 were as follows:

 

    Three Months Ended     Six Months Ended  
    December 28,
2013
    December 29,
2012
    December 28,
2013
    December 29,
2012
 
    (Thousands)  

Stock-based compensation by category of expense:

 

Cost of revenues

  $ 250      $ 455      $ 502      $ 729   

Research and development

    206        469        452        788   

Selling, general and administrative

    390        885        855        1,665   
 

 

 

   

 

 

   

 

 

   

 

 

 
  $ 846      $ 1,809      $ 1,809      $ 3,182   
 

 

 

   

 

 

   

 

 

   

 

 

 

Stock-based compensation by type of award:

       

Stock options

  $ 262      $ 628      $ 593      $ 1,374   

Restricted stock awards

    566        1,019        1,224        1,536   

Purchase rights under ESPP

    —          233        —          413   

Inventory adjustment to cost of revenues

    18        (71     (8     (141
 

 

 

   

 

 

   

 

 

   

 

 

 
  $ 846      $ 1,809      $ 1,809      $ 3,182   
 

 

 

   

 

 

   

 

 

   

 

 

 

As of December 28, 2013 and June 29, 2013, we had capitalized approximately $0.2 million and $0.4 million, respectively, of stock-based compensation as inventory.

NOTE 13. INCOME TAXES

The income tax provision of $1.4 million and $1.7 million for the three and six months ended December 28, 2013, respectively, related primarily to our foreign operations, and includes approximately $1.1 million related to the completion of our tax audit in China.

The income tax provision of $1.2 million and $2.2 million for the three and six months ended December 29, 2012, respectively, related primarily to our foreign operations.

The total amounts of our unrecognized tax benefits as of December 28, 2013 and June 29, 2013 were approximately $8.8 million and $8.0 million, respectively. For the three and six months ended December 28, 2013, respectively, we had $4.1 million in unrecognized tax benefits that, if recognized, would affect our effective tax rate. While it is often difficult to predict the final outcome of any particular uncertain tax position, we believe that unrecognized tax benefits could decrease by approximately $1.0 million in the next twelve months.

NOTE 14. NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed using only the weighted-average number of shares of common stock outstanding for the applicable period, while diluted net income per share is computed assuming conversion of all potentially dilutive securities, such as stock options, unvested restricted stock awards, warrants and convertible notes during such period.

For the three and six months ended December 28, 2013, we excluded 22.0 million and 21.7 million, respectively, of outstanding stock options, stock appreciation rights, warrants, shares issuable in connection with convertible notes, and unvested restricted stock awards from the calculation of diluted net income per share because their effect would have been anti-dilutive.

For the three and six months ended December 29, 2012, we excluded 13.5 million and 11.2 million of outstanding stock options, stock appreciation rights, warrants, shares issuable in connection with convertible notes, and unvested restricted stock awards, respectively, from the calculation of diluted net loss per share because their effect would have been anti-dilutive.

 

25


Table of Contents

NOTE 15. GEOGRAPHIC INFORMATION, PRODUCT GROUPS AND CUSTOMER CONCENTRATION INFORMATION

Geographic Information

The following table shows revenues by geographic area based on the delivery locations of our products:

 

     Three Months Ended      Six Months Ended  
     December 28,
2013
     December 29,
2012
     December 28,
2013
     December 29,
2012
 
     (Thousands)  

Hong Kong

   $ 20,772       $ 25,390       $ 37,753       $ 40,395   

Germany

     20,619         17,937         35,014         28,068   

Malaysia

     13,917         12,988         23,428         23,159   

Japan

     8,953         13,996         21,441         26,936   

United States

     8,541         7,233         15,931         21,181   

Mexico

     8,411         4,407         21,265         8,699   

Italy

     5,113         6,023         11,500         11,893   

China, excluding Hong Kong

     4,867         8,724         10,703         19,257   

Thailand

     2,077         2,931         5,384         6,790   

Rest of world

     9,644         12,442         17,143         21,328   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 102,914       $ 112,071       $ 199,562       $ 207,706   
  

 

 

    

 

 

    

 

 

    

 

 

 

Product Groups

The following table sets forth revenues by product group:

 

     Three Months Ended      Six Months Ended  
     December 28,
2013
     December 29,
2012
     December 28,
2013
     December 29,
2012
 
     (Thousands)  

40 Gb/s and 100 Gb/s transmission

   $ 45,700       $ 40,026       $ 84,558       $ 71,471   

10 Gb/s and lower transmission

     49,828         64,836         100,402         123,366   

Industrial and consumer

     7,386         7,209         14,602         12,869   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 102,914       $ 112,071       $ 199,562       $ 207,706   
  

 

 

    

 

 

    

 

 

    

 

 

 

Significant Customers and Concentration of Credit Risk

For the three months ended December 28, 2013, Coriant accounted for 15 percent, Cisco Systems, Inc. (“Cisco”) accounted for 13 percent and Huawei Technologies Co., Ltd. (“Huawei”) accounted for 10 percent of our revenues. For the six months ended December 28, 2013, Cisco accounted for 14 percent, Coriant accounted for 13 percent and Huawei accounted for 10 percent of our revenues.

For the three months ended December 29, 2012, Fiberhome Technologies Group (“Fiberhome”) accounted for 12 percent, Cisco accounted for 12 percent and Coriant accounted for 11 percent of our revenues. For the six months ended December 29, 2012, Cisco accounted for 14 percent and Fiberhome accounted for 10 percent of our revenues.

As of December 28, 2013, Coriant accounted for 18 percent and Flextronics International Ltd. accounted for 10 percent of our accounts receivable. As of June 29, 2013, Huawei accounted for 15 percent of our accounts receivable.

 

26


Table of Contents

NOTE 16. RELATED PARTY TRANSACTIONS

As a result of our acquisition of Opnext on July 23, 2012, Hitachi, Ltd. (Hitachi) holds approximately 11 percent of our outstanding common stock as of December 28, 2013 based on Hitachi’s most recent Schedule 13G filed with the Securities and Exchange Commission on July 27, 2012.

We continue to enter into transactions with Hitachi in the normal course of business. Sales to Hitachi were $3.4 million and $4.7 million for the three and six months ended December 28, 2013, respectively, and $4.4 million and $7.3 million for the three and six months ended December 29, 2012, respectively. Purchases from Hitachi were $4.0 million and $6.7 million for the three and six months ended December 28, 2013, respectively, and $6.4 million and $11.2 million for the three and six months ended December 29, 2012, respectively. At December 28, 2013, we had $2.9 million accounts receivable due from Hitachi and $2.3 million accounts payable due to Hitachi. At June 29, 2013 we had $3.0 million accounts receivable due from Hitachi and $2.2 million accounts payable due to Hitachi. We also have certain capital equipment leases with Hitachi Capital Corporation as described in Note 9, Commitments and Contingencies .

We are now party to the following material agreements with Hitachi:

 

    Intellectual Property License Agreements

We are party to two intellectual property license agreements pursuant to which Hitachi licenses certain intellectual property rights to us on the terms and subject to the conditions stated therein on a fully paid, nonexclusive basis and we license certain intellectual property rights to Hitachi on a fully paid, nonexclusive basis. Hitachi has also agreed to sublicense certain intellectual property to us to the extent that Hitachi has the right to make available such rights to us in accordance with the terms and subject to the conditions stated therein.

We are also party to an intellectual property license agreement with Hitachi Communication Technologies, Ltd., a wholly owned subsidiary of Hitachi, whereby Hitachi Communication Technologies, Ltd. licenses certain intellectual property rights to us on a fully paid, nonexclusive basis, and we license certain intellectual property rights to Hitachi Communication Technologies, Ltd. on a fully paid, nonexclusive basis.

 

    Research and Development Agreement

We are party to a Research and Development Agreement pursuant to which Hitachi provides certain research and development support to us in accordance with the terms and conditions of the agreement. Intellectual property resulting from certain research and development projects is owned by us and licensed to Hitachi on a fully paid, nonexclusive basis. Intellectual property resulting from certain other research and development projects is owned by Hitachi and licensed to us on a fully paid, nonexclusive basis. Certain other intellectual property is jointly owned.

NOTE 17. SUBSEQUENT EVENTS

On July 23, 2013, our board of directors approved the Fourth Amended and Restated 2001 Long-Term Stock Incentive Plan (the Plan) and on January 14, 2014, our shareholders ratified the Plan, establishing it as our primary equity incentive plan. The Plan (i) revises the eligibility section to allow us to make grants to all our employees, non-employee directors and consultants, (ii) allows us to grant incentive stock options and awards which may be able to qualify as qualified performance-based compensation under Section 162(m) of the Internal Revenue Code, (iii) extends the term of the Plan to ten years from the effective date of the Plan, and (iv) conforms the share counting provisions of the Plan to provide that full value awards count as 1.25 shares for purposes of the Plan.

 

27


Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q and the documents incorporated herein by reference contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, about our future expectations, plans or prospects and our business. You can identify these statements by the fact that they do not relate strictly to historical or current events, and contain words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “will,” “plan,” “believe,” “should,” “outlook,” “could,” “target,” “model,” “may” and other words of similar meaning in connection with discussion of future operating or financial performance. We have based our forward looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including (i) the effect of receiving a “going concern” statement in our auditors report on our 2013 consolidated financial statements, (ii) the sale of businesses which may or may not arise in connection with executing our restructuring plans, (iii) the future performance of Oclaro and our ability to effectively integrate the operations of acquired companies following the closing of acquisitions and mergers, including our merger with Opnext, (iv) our ability to serve as a supplier to the buyers of our Zurich Business and the Amplifier Business during the transition of manufacturing activities and meet our related transition agreement obligations, (v) our ability to effectively restructure our operations and business following the sale of our Zurich Business and the Amplifier Business in accordance with our business plan, (vi) the potential inability to realize the expected and ongoing benefits and synergies of acquisitions and mergers and from the utilization of capital from our asset dispositions, (vii) the impact of continued uncertainty in world financial markets and any resulting reduction in demand for our products, (viii) our ability to meet or exceed our gross margin expectations, (ix) the effects of fluctuating product mix on our results, (x) our ability to timely develop and commercialize new products, (xi) our ability to reduce costs and operating expenses, (xii) our ability to respond to evolving technologies and customer requirements and demands, (xiii) our dependence on a limited number of customers for a significant percentage of our revenues, (xiv) our ability to maintain strong relationships with certain customers, (xv) our ability to effectively compete with companies that have greater name recognition, broader customer relationships and substantially greater financial, technical and marketing resources than we do, (xvi) our ability to effectively and efficiently transition to an outsourced back-end assembly and test model, (xvii) our ability to timely capitalize on any increase in market demand, (xviii) increased costs related to downsizing and compliance with regulatory and legal requirements in connection with such downsizing, (xix) competition and pricing pressure, (xx) the risks associated with our international operations, (xxi) our ability to service and repay our outstanding indebtedness pursuant to the terms of the applicable agreements, (xxii) the outcome of tax audits or similar proceedings, (xxiii) the outcome of pending or potential litigation against us, (xxiv) our ability to maintain or increase our cash reserves and obtain debt or equity-based financing on terms acceptable to us or at all, and (xxv) other factors described in other documents we periodically file with the SEC. We cannot guarantee any future results, levels of activity, performance or achievements. You should not place undue reliance on forward-looking statements. Moreover, we assume no obligation to update forward-looking statements or update the reasons actual results could differ materially from those anticipated in forward-looking statements. Several of the important factors that may cause our actual results to differ materially from the expectations we describe in forward-looking statements are identified in the sections captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in this Quarterly Report on Form 10-Q and the documents incorporated herein by reference.

As used herein, “Oclaro,” “we,” “our,” and similar terms include Oclaro, Inc. and its subsidiaries, unless the context indicates otherwise.

OVERVIEW

We are one of the largest providers of optical components, modules and subsystems for the optical communications market. We are a global leader dedicated to photonics innovation, with research and development (R&D) and chip fabrication facilities in the U.K., Italy, Korea and Japan. We have in-house and contract manufacturing sites in the U.S., China, Malaysia and Thailand, with design, sales and service organizations in most of the major regions around the world.

Our customers include ADVA Optical Networking; Alcatel-Lucent; Ciena; Cisco; Coriant; Ericsson; Fujitsu; Huawei; Juniper Networks; Tellabs, Inc. and ZTE.

 

28


Table of Contents

RECENT DEVELOPMENTS

On July 23, 2013, our board of directors approved the Fourth Amended and Restated 2001 Long-Term Stock Incentive Plan (the “Plan”) and on January 14, 2014, our shareholders ratified the Plan, establishing it as our primary equity incentive plan. The Plan (i) revises the eligibility section to allow us to make grants to all our employees, non-employee directors and consultants, (ii) allows us to grant incentive stock options and awards which may be able to qualify as qualified performance-based compensation under Section 162(m) of the Internal Revenue Code, (iii) extends the term of the Plan to ten years from the effective date of the Plan, and (iv) conforms the share counting provisions of the Plan to provide that full value awards count as 1.25 shares for purposes of the Plan.

On October 10, 2013, Oclaro Technology Limited entered into an Asset Purchase Agreement with II-VI Incorporated (“II-VI”), whereby Oclaro Technology Limited agreed to sell its optical amplifier and micro-optics business (the “Amplifier Business”) to II-VI and certain of its affiliates for $88.6 million in cash. The transaction closed on November 1, 2013.

Consideration, valued at $88.6 million, consisted of $79.6 million in cash, which was received on November 1, 2013, $4.0 million subject to hold-back by II-VI until December 31, 2014 to address any post-closing claim and $5.0 million related to the exclusive option, which was received by us on September 12, 2013, and was credited against the purchase price.

We entered into certain transition service and manufacturing service agreements to allow the Amplifier Business to continue operations during the ownership transition.

On September 12, 2013, we also sold our Oclaro Switzerland GmbH subsidiary and associated laser diodes and pump business (the “Zurich Business”) to II-VI. We received proceeds of $90.6 million in cash on September 12, 2013. We will also receive $6.0 million subject to hold-back by II-VI until December 31, 2014 to address any post-closing adjustments or claims, and $2.0 million subject to a potential post-closing working capital adjustment. This adjustment will be calculated based on the level of working capital in the Oclaro Switzerland GmbH subsidiary at the September 12, 2013 close versus a target based on working capital at June 29, 2013. In addition, we retained approximately $14.7 million in accounts receivable related to the Zurich Business and approximately $9.6 million of supplier and employee related payables related to the Zurich Business which were not included in the Oclaro Switzerland GmbH subsidiary.

As part of the agreement, II-VI has purchased our Swiss subsidiary, which includes its GaAs fabrication facility, and also the corresponding high power laser diodes, VCSEL and 980 nm pump laser product lines, including intellectual property, inventory, equipment and a related research and development facility in Tucson, Arizona, all of which are associated with this business.

We will continue the back-end manufacturing of the 980 nm pump and certain high power laser diode products at our Shenzhen, China manufacturing facility and supply them to II-VI under a manufacturing services agreement. The employees of Shenzhen, China will continue to be employed by us. In addition, various supply and transition service agreements have been established between the companies to ensure a smooth transition.

We have used a portion of the proceeds from the sale of the Zurich and Amplifier Businesses to repay our term loan and to repay our entire outstanding balance under our credit line. We are using a portion of the remaining proceeds to begin restructuring Oclaro for the future. We intend to further simplify our operating footprint, reduce our cost structure and focus our research and development investment in the optical communications market where we can leverage our core competencies.

RESULTS OF OPERATIONS

On September 12, 2013 we announced the sale of our Zurich Business to II-VI, along with an exclusive option to purchase our Amplifier Business. On October 10, 2013, we entered into an Asset Purchase Agreement with II-VI for the sale of our Amplifier Business, which subsequently closed on November 1, 2013. We have classified the financial results of the Zurich and Amplifier Businesses as discontinued operations for all periods presented. The following presentations relate to continuing operations only, unless otherwise indicated.

On July 23, 2012, we completed a merger with Opnext, Inc. (“Opnext”). The acquisition is more fully discussed in Note 5, Business Combinations and Dispositions to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. The condensed consolidated statements of operations for the six months ended December 29, 2012 include the results of operations of the combined entities from July 23, 2012, the date of the acquisition.

 

29


Table of Contents

The following tables set forth our condensed consolidated results of operations for the three month periods indicated, along with amounts expressed as a percentage of revenues, and comparative information regarding the absolute and percentage changes in these amounts:

 

     Three Months Ended           Increase  
     December 28, 2013     December 29, 2012     Change     (Decrease)  
     (Thousands)     %     (Thousands)     %     (Thousands)     %  

Revenues

   $ 102,914        100.0      $ 112,071        100.0      $ (9,157     (8.2

Cost of revenues

     86,001        83.6        99,796        89.0        (13,795     (13.8
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Gross profit

     16,913        16.4        12,275        11.0        4,638        37.8   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Operating expenses:

            

Research and development

     16,424        16.0        20,714        18.5        (4,290     (20.7

Selling, general and administrative

     18,557        18.0        19,927        17.8        (1,370     (6.9

Amortization of other intangible assets

     417        0.4        1,372        1.2        (955     (69.6

Restructuring, acquisition and related (income) expense, net

     6,721        6.5        (24,257     (21.6     30,978        n/m (1)  

Flood-related (income) expense, net

     (140     (0.1     641        0.5        (781     n/m (1)  

Loss on sale of property and equipment

     205        0.2        231        0.2        (26     (11.3
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Total operating expenses

     42,184        41.0        18,628        16.6        23,556        126.5   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Operating loss

     (25,271     (24.6     (6,353     (5.6     (18,918     297.8   

Other income (expense):

            

Interest income (expense), net

     (8,532     (8.3     (649     (0.6     (7,883     1,214.6   

Gain (loss) on foreign currency transactions, net

     (2,848     (2.7     (4,032     (3.6     1,184        (29.4

Other income (expense), net

     28        0.0        —          —          28        n/m (1)  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Total other income (expense)

     (11,352     (11.0     (4,681     (4.2     (6,671     142.5   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Loss from continuing operations before income taxes

     (36,623     (35.6     (11,034     (9.8     (25,589     231.9   

Income tax provision

     1,424        1.4        1,234        1.1        190        15.4   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Loss from continuing operations

     (38,047     (37.0     (12,268     (10.9     (25,779     210.1   

Income from discontinued operations, net of tax

     69,538        67.6        2,013        1.7        67,525        3,354.4   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Net income (loss)

   $ 31,491        30.6      $ (10,255     (9.2   $ 41,746        n/m (1)  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

(1) Not meaningful.

 

30


Table of Contents
     Six Months Ended           Increase  
     December 28, 2013     December 29, 2012     Change     (Decrease)  
     (Thousands)     %     (Thousands)     %     (Thousands)     %  

Revenues

   $ 199,562        100.0      $ 207,706        100.0      $ (8,144     (3.9

Cost of revenues

     171,431        85.9        190,438        91.7        (19,007     (10.0
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Gross profit

     28,131        14.1        17,268        8.3        10,863        62.9   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Operating expenses:

            

Research and development

     34,511        17.3        41,227        19.8        (6,716     (16.3

Selling, general and administrative

     39,507        19.8        41,350        19.9        (1,843     (4.5

Amortization of other intangible assets

     841        0.4        2,604        1.3        (1,763     (67.7

Restructuring, acquisition and related (income) expense, net

     9,598        4.8        (12,663     (6.1     22,261        n/m (1)  

Flood-related (income) expense, net

     (140     (0.1     905        0.5        (1,045     n/m (1)  

Impairment of other intangibles

     —          —          864        0.4        (864     (100.0

Loss on sale of property and equipment

     657        0.4        213        0.1        444        208.5   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Total operating expenses

     84,974        42.6        74,500        35.9        10,474        14.1   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Operating loss

     (56,843     (28.5     (57,232     (27.6     389        (0.7

Other income (expense):

            

Interest income (expense), net

     (9,085     (4.6     (1,127     (0.6     (7,958     706.1   

Gain (loss) on foreign currency transactions, net

     (1,071     (0.5     (3,994     (1.9     2,923        (73.2

Other income (expense), net

     549        0.3        —          —          549        n/m (1)  

Gain on bargain purchase

     —          —          24,866        12.0        (24,866     (100.0
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Total other income (expense)

     (9,607     (4.8     19,745        9.5        (29,352     n/m (1)  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Loss from continuing operations before income taxes

     (66,450     (33.3     (37,487     (18.1     (28,963     77.3   

Income tax provision

     1,726        0.8        2,152        1.0        (426     (19.8
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Loss from continuing operations

     (68,176     (34.1     (39,639     (19.1     (28,537     72.0   

Income from discontinued operations, net of tax

     132,945        66.6        4,276        2.1        128,669        3,009.1   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

Net income (loss)

   $ 64,769        32.5      $ (35,363     (17.0   $ 100,132        n/m (1)  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

(1) Not meaningful.

Revenues

Revenues for the three months ended December 28, 2013 decreased by $9.2 million, or 8 percent, compared to the three months ended December 29, 2012. Compared to the three months ended December 29, 2012, revenues from sales of our 40 Gb/s and 100 Gb/s transmission modules increased by $5.7 million, or 14 percent; revenues from sales of our 10 Gb/s transmission modules decreased by $15.0 million, or 23 percent; and revenues from sales of our industrial and consumer products increased by $0.2 million, or 2 percent.

For the three months ended December 28, 2013, Coriant GmbH (“Coriant”) accounted for 15 percent, Cisco Systems, Inc. (“Cisco”) accounted for 13 percent and Huawei Technologies Co., Ltd. (“Huawei”) accounted for 10 percent of our revenues. For the three months ended December 29, 2012, Fiberhome Technologies Group (“Fiberhome”) accounted for 12 percent, Cisco accounted for 12 percent and Coriant accounted for 11 percent of our revenues.

Revenues for the six months ended December 28, 2013 decreased by $8.1 million, or 4 percent, compared to the six months ended December 29, 2012. Compared to the six months ended December 29, 2012, revenues from sales of our 40 Gb/s and 100 Gb/s transmission modules increased by $13.1 million, or 18 percent; revenues from sales of our 10 Gb/s transmission modules decreased by $23.0 million, or 19 percent; and revenues from sales of our industrial and consumer products increased by $1.7 million, or 13 percent.

 

31


Table of Contents

For the six months ended December 28, 2013, Cisco accounted for 14 percent, Coriant accounted for 13 percent and Huawei accounted for 10 percent of our revenues. For the six months ended December 29, 2012, Cisco accounted for 14 percent and Fiberhome accounted for 10 percent of our revenues.

Cost of Revenues

Our cost of revenues consists of the costs associated with manufacturing our products, and includes the purchase of raw materials, labor costs and related overhead, including stock-based compensation charges and the costs charged by our contract manufacturers for the products they manufacture for us. Charges for excess and obsolete inventory are also included in cost of revenues. Costs and expenses related to our manufacturing resources incurred in connection with the development of new products are included in research and development expenses.

Our cost of revenues for the three months ended December 28, 2013 decreased by $13.8 million, or 14 percent, from the three months ended December 29, 2012. The decrease was primarily related to the lower volume of revenue, merger related synergies and realizing the benefits of previous cost reduction efforts.

Our cost of revenues for the six months ended December 28, 2013 decreased by $19.0 million, or 10 percent, from the six months ended December 29, 2012. The decrease was primarily related to the lower volume of revenue, merger related synergies and realizing the benefits of previous cost reduction efforts.

Gross Profit

Gross profit is calculated as revenues less cost of revenues. Gross margin rate is gross profit reflected as a percentage of revenues.

Our gross margin rate increased to 16 percent for the three months ended December 28, 2013, compared to 11 percent for the three months ended December 29, 2012. The 5 percentage point improvement in gross margin rate primarily related to a richer mix of 100 Gb/s products, improved margins in our 40 Gb/s products as result of lower costs related to subassemblies manufactured in-house, and less provisions for excess or obsolete inventory.

Our gross margin rate increased to 14 percent for the six months ended December 28, 2013, compared to 8 percent for the six months ended December 29, 2012. The 6 percentage point improvement in gross margin rate primarily related to a richer mix of 100 Gb/s products, improved margins in our 40 Gb/s products as result of lower costs related to subassemblies manufactured in-house, less provisions for excess or obsolete inventory, and the sale of our Santa Rosa facility.

Research and Development Expenses

Research and development expenses consist primarily of salaries and related costs of employees engaged in research and design activities, including stock-based compensation charges related to those employees, costs of design tools and computer hardware, costs related to prototyping and facilities costs for certain research and development focused sites.

Research and development expenses decreased to $16.4 million for the three months ended December 28, 2013 from $20.7 million for the three months ended December 29, 2012. The decrease was primarily related to a decrease of $2.4 million as a result of aligning and reducing combined research and development resources of Oclaro and Opnext in association with the merger, and a decrease of $1.2 million in Japan-related research and development expenses which includes the impact of the depreciation of the Japanese Yen.

Research and development expenses decreased to $34.5 million for the six months ended December 28, 2013 from $41.2 million for the six months ended December 29, 2012. The decrease was primarily related to a decrease of $4.4 million as a result of aligning and reducing combined research and development resources of Oclaro and Opnext in association with the merger, and a decrease of $1.1 million in Japan-related research and development expenses which includes the impact of the depreciation of the Japanese Yen.

 

32


Table of Contents

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of personnel-related expenses, including stock-based compensation charges related to employees engaged in sales, general and administrative functions, legal and professional fees, facilities expenses, insurance expenses and certain information technology costs.

Selling, general and administrative expenses decreased to $18.6 million for the three months ended December 28, 2013, from $19.9 million for the three months ended December 29, 2012. The decrease was primarily related to a decrease of $3.8 million as a result of aligning and reducing combined selling, general and administrative resources of Oclaro and Opnext in association with the merger, partially offset by an increase in legal fees of $1.9 million.

Selling, general and administrative expenses decreased to $39.5 million for the six months ended December 28, 2013, from $41.4 million for the six months ended December 29, 2012. The decrease was primarily related to a decrease of $6.8 million as a result of aligning and reducing combined selling, general and administrative resources of Oclaro and Opnext in association with the merger, partially offset by an increase in legal fees of $1.9 million, an increase in banking fees of $1.6 million, and an increase in audit fees of $1.4 million.

Amortization of Other Intangible Assets

Amortization of other intangible assets decreased to $0.4 million for the three months ended December 28, 2013 from $1.4 million for the three months ended December 29, 2012, and decreased to $0.8 million for the six months ended December 28, 2013 from $2.6 million for the six months ended December 29, 2012. The decrease in our amortization is a result of recording $14.2 million in impairment losses during the fourth quarter of fiscal year 2013, including $6.4 million related to intangibles acquired in connection with our acquisition of Mintera, $2.6 million related to intangibles acquired in connection with our acquisition of Opnext, and $5.2 million related to intangibles acquired in connection with other earlier acquisitions. As a result of these impairments, we expect the amortization of intangible assets to decrease from $5.3 million in fiscal year 2013 to $1.7 million for fiscal years 2014 through 2018 based on the current level of our other intangible assets.

Restructuring, Acquisition and Related Costs

During the first quarter of fiscal year 2014, we initiated a restructuring plan to simplify our operating footprint, reduce our cost structure and focus our research and development investment in the optical communications market where we can leverage our core competencies. During the three months ended December 28, 2013, we recorded restructuring charges of $5.7 million related to this restructuring plan, which included $5.4 million related to workforce reductions and $0.3 million related to revised estimates related to lease cancellations and commitments. During the six months ended December 28, 2013, we recorded restructuring charges of $5.8 million related to this restructuring plan, which included $5.6 million related to workforce reductions and $0.3 million related to revised estimates related to lease cancellations and commitments. We expect to incur an additional $13.0 million to $18.0 million in restructuring charges over the course of the next twelve months in connection with the ongoing activities related to this restructuring plan.

During the first quarter of fiscal year 2013, we initiated a restructuring plan to integrate our acquisition of Opnext. In connection with this restructuring plan, we recorded $0.1 million and $1.1 million in restructuring charges during the three and six months ended December 28, 2013, respectively. The restructuring charges recorded in fiscal year 2014 included $0.9 million in external consulting charges and professional fees associated with reorganizing the infrastructure and $0.1 million in revised estimates related to lease cancellations and commitments. During the three and six months ended December 29, 2012, we recorded $0.8 million and $9.1 million in restructuring charges, respectively. The restructuring charges for the three months ended December 29, 2012, included $0.8 million related to workforce reductions. The restructuring charges for the six months ended December 29, 2012, included $7.8 million related to workforce reductions, $0.9 million related to the impairment of certain technology that is now considered redundant following the acquisition and $0.4 million related to the write-off of net book value inventory that supported this technology. As of December 28, 2013, we had no further accrued restructuring liabilities related to this restructuring plan.

 

33


Table of Contents

During fiscal year 2012, we initiated a restructuring plan in connection with the transfer of our Shenzhen, China manufacturing operations to Venture Corporation Limited (“Venture”). In connection with this transition, during the three and six months ended December 28, 2013, we recorded restructuring charges related to employee separation charges of $0.9 million and $1.9 million, respectively. During the three and six months ended December 29, 2012, we recorded restructuring charges related to employee separation charges of $1.4 million and $2.9 million, respectively. We expect to incur between $3.0 million and $5.0 million in additional restructuring costs in connection with the transition of certain of our Shenzhen manufacturing operations to Venture over the next year.

Flood-related (Income) Expense, Net

In October 2011, certain areas in Thailand suffered major flooding as a result of monsoons. This flooding had a material and adverse impact on our business and results of operations. Our primary contract manufacturer, Fabrinet, suspended operations at two factories located in Chokchai, Thailand and Pinehurst, Thailand. The Chokchai factory suffered extensive flood damage and became inaccessible due to high water levels inside and surrounding the manufacturing facility.

During the three and six months ended December 28, 2013, we recorded $0.1 million in flood-related income in our condensed consolidated statement of operations, consisting of $2.1 million in insurance settlement proceeds received in the second quarter of fiscal year 2014, partially offset by an out-of-period adjustment of $2.0 million related to the impairment of leased assets assumed pursuant to the Opnext merger that had been damaged by the flooding. During the three and six months ended December 29, 2012, we recorded flood-related expenses of $0.6 million and $0.9 million, respectively, related to professional fees and related expenses incurred in connection with our recovery efforts.

During the three and six months ended December 29, 2012, we recorded flood-related charges of $0.6 million and $0.9 million, respectively, related to professional fees and related expenses incurred in connection with our recovery efforts.

Impairment of Other Intangible Assets

During the first quarter of fiscal year 2013, we determined that a portion of the technology we acquired in connection with our acquisition of Mintera in July 2010 was considered redundant, following the acquisition of Opnext and its product lines. We recorded $0.9 million for the impairment loss related to these intangibles in our condensed consolidated statement of operations for the six months ended December 29, 2012.

Other Income (Expense)

Other income (expense) decreased to $11.4 million in expense for the three months ended December 28, 2013 from $4.7 million in expense for the three months ended December 29, 2012. This decrease was primarily due to a $7.9 million increase in interest payments primarily related to the make-whole payment from the conversion of the 7.50% Exchangeable Senior Secured Second Lien Notes due 2018 (“Convertible Notes”) into common stock in the second quarter of fiscal year 2014, partially offset by smaller losses of $1.2 million on foreign currency transactions during the three months ended December 28, 2013, as compared to the three months ended December 29, 2012.

Other income (expense) decreased to $9.6 million in expense for the six months ended December 28, 2013 from $19.7 million in income for the six months ended December 29, 2012. This decrease was primarily due to a $24.9 million gain on bargain purchase in connection with our acquisition of Opnext in the first quarter of fiscal year 2013, an $8.0 million increase in interest payments primarily related to the make-whole payment from the conversion of the Convertible Notes into common stock in the second quarter of fiscal year 2014, partially offset by smaller losses of $2.9 million on foreign currency transactions during the six months ended December 28, 2013, as compared to the six months ended December 29, 2012.

Income Tax Provision

For the three and six months ended December 28, 2013, our income tax provisions of $1.4 million and $1.7 million, respectively, primarily related to our foreign operations, and includes approximately $1.1 million related to the completion of our tax audit in China.

For the three and six months ended December 29, 2012, our income tax provisions of $1.2 million and $2.2 million, respectively, primarily related to our foreign operations.

 

34


Table of Contents

Income from Discontinued Operations, Net of Tax

During the three and six months ended December 28, 2013, we recorded a gain on the sale of the Amplifier Business of $69.7 million. During the six months ended December 28, 2013, we recorded a gain on the sale of the Zurich Business of $62.8 million. During the three and six months ended December 28, 2013, we recorded income from discontinued operations of the Zurich and Amplifier Businesses of $69.5 million and $132.9 million, respectively. For the three and six months ended December 29, 2012, we recorded income from discontinued operations of the Zurich and Amplifier Businesses of $2.0 million and $4.3 million, respectively.

The following table sets forth the results of the discontinued operations of our Zurich and Amplifier Businesses for the three and six months ended December 28, 2013 and December 29, 2012 and the year-over-year increases (decreases) in our results:

 

    Three Months Ended     Six Months Ended  
    December 28,
2013
    December 29,
2012
    Change     December 28,
2013
    December 29,
2012
    Change  
    (Thousands)     (Thousands)  

Revenues

  $ 6,869      $ 47,394      $ (40,525   $ 49,081      $ 100,572      $ (51,491

Cost of revenues

    5,528        37,360        (31,832     37,836        79,493        (41,657
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

    1,341        10,034        (8,693     11,245        21,079        (9,834

Operating expenses

    1,508        8,440        (6,932     8,992        17,115        (8,123

Other income (expense), net

    69,705        609        69,096        130,855        767        130,088   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from discontinued operations before income taxes

    69,538        2,203        67,335        133,108        4,731        128,377   

Income tax provision

    —          190        (190     163        455        (292
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from discontinued operations

  $ 69,538      $ 2,013      $ 67,525      $ 132,945      $ 4,276      $ 128,669   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Revenues

Revenues of the Zurich and Amplifier Businesses decreased $40.5 million, or 86 percent, during the three months ended December 28, 2013 compared to the three months ended December 29, 2012, primarily as a result of decreased sales to our customers due to completing the sale of the Zurich Business during the quarter ended September 28, 2013 and completing the sale of the Amplifier Business during the quarter ended December 28, 2013.

Revenues of the Zurich and Amplifier Businesses decreased $51.5 million, or 51 percent, during the six months ended December 28, 2013 compared to the six months ended December 29, 2012, primarily as a result of decreased sales to our customers due to completing the sale of the Zurich Business during the quarter ended September 28, 2013 and completing the sale of the Amplifier Business during the quarter ended December 28, 2013.

Gross Profit and Gross Margin Rate

The gross profit decreased $8.7 million, or 87 percent, during the three months ended December 28, 2013 compared to the three months ended December 29, 2012, primarily as a result of decreased sales to our customers due to completing the sale of the Zurich Business during the quarter ended September 28, 2013 and completing the sale of the Amplifier Business during the quarter ended December 28, 2013. The gross margin rate of the Zurich and Amplifier Businesses decreased to 20 percent for the three months ended December 28, 2013 compared to 21 percent for the three months ended December 29, 2012, as a result of the absence of gross profit from the Zurich business in the three months ended December 28, 2013.

The gross profit decreased $9.8 million, or 47 percent, during the six months ended December 28, 2013 compared to the six months ended December 29, 2012, primarily as a result of decreased sales to our customers due to completing the sale of the Zurich Business during the quarter ended September 28, 2013 and completing the sale of the Amplifier Business during the quarter ended December 28, 2013. The gross margin rate of the Zurich and Amplifier Businesses increased to 23 percent for the six months ended December 28, 2013 compared to 21 percent for the six months ended December 29, 2012, as a result of lower inventory reserves in the six months ended December 28, 2013.

 

35


Table of Contents

Operating Expenses

Operating expenses of the Zurich and Amplifier Businesses decreased $6.9 million, or 82 percent, during the three months ended December 28, 2013 compared to the three months ended December 29, 2012, and decreased $8.1 million, or 47 percent, during the six months ended December 28, 2013 compared to the six months ended December 29, 2012, primarily as a result of completing the sales of the Zurich and Amplifier Businesses during the first half of fiscal year 2014.

Other Income (Expense)

Other income (expense) for the Zurich and Amplifier Businesses increased $69.1 million during the three months ended December 28, 2013 compared to the three months ended December 29, 2012, primarily as a result of a $69.7 million gain on the sale of the Amplifier Business.

Other income (expense) for the Zurich and Amplifier Businesses increased $130.1 million during the six months ended December 28, 2013 compared to the six months ended December 29, 2012, primarily as a result of a $69.7 million gain on the sale of the Amplifier Business and a $62.8 million gain on the sale of the Zurich business.

Income Tax Provision

Our income tax provision related to discontinued operations is negligible in each period presented.

RECENT ACCOUNTING STANDARDS

See Note 2, Recent Accounting Standards , to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information regarding the effect of new accounting pronouncements on our condensed consolidated financial statements.

APPLICATION OF CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements contained elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of our financial statements requires us to make estimates and judgments that affect our reported assets and liabilities, revenues and expenses and other financial information. Actual results may differ significantly from those based on our estimates and judgments or could be materially different if we used different assumptions, estimates or conditions. In addition, our financial condition and results of operations could vary due to a change in the application of a particular accounting policy.

We identified our critical accounting policies in our Annual Report on Form 10-K for the year ended June 29, 2013 (2013 Form 10-K) related to revenue recognition and sales returns, inventory valuation, business combinations, impairment of goodwill and other intangible assets, accounting for stock-based compensation and income taxes. It is important that the discussion of our operating results be read in conjunction with the critical accounting policies discussed in our 2013 Form 10-K.

LIQUIDITY AND CAPITAL RESOURCES

The condensed consolidated statement of cash flows and the discussion below on cash flows from operating, investing and financing activities have not been adjusted for the effects of the discontinued operations.

Cash Flows from Operating Activities

Net cash used in operating activities for the six months ended December 28, 2013 was $46.8 million, primarily resulting from non-cash adjustments of $109.7 million and a $1.9 million decrease in cash due to changes in operating assets and liabilities, partially offset by net income of $64.8 million. The $109.7 million decrease in cash resulting from non-cash adjustments primarily consisted of a $69.7 million gain on the sale of the Amplifier Business, a $62.8 million gain on the sale of the Zurich Business, $1.1 million from the amortization of deferred gain from sales-leaseback transactions, partially offset by $15.8 million in depreciation and amortization, $4.3 million related to the amortization and write-off of the issuance costs of the term loan, $2.0 million of expense related to stock-based compensation, and $2.0 million related to non-cash flood-related impairments. The $1.9 million decrease in cash due to changes in operating assets and liabilities was comprised of a $29.0 million decrease in accounts receivable, $7.8 million increase in accounts payable, and a $1.4 million decrease in other non-current assets, offset by a $26.4 million increase in prepaid expenses and other current assets, $8.7 million decrease in accrued expenses and other liabilities, and $5.0 million increase in inventories.

 

36


Table of Contents

Net cash used by operating activities for the six months ended December 29, 2012 was $64.8 million, primarily resulting from a net loss of $35.4 million, non-cash adjustments of $23.5 million and a $6.0 million decrease in cash due to changes in operating assets and liabilities. The $23.5 million decrease in cash resulting from non-cash adjustments primarily consisted of a decrease of $25.0 million related to the gain on the sale of the thin film filter business and interleaver product line, a decrease of $24.9 million for the bargain purchase gain related to the acquisition of Opnext, and $1.0 million from the amortization of deferred gain from sales-leaseback transactions, partially offset by $22.9 million in depreciation and amortization, $3.7 million of expense related to stock-based compensation and $0.9 million related to the impairment of certain intangibles. The $6.0 million decrease in cash due to changes in operating assets and liabilities was comprised of a $10.6 million increase in inventories, a $7.0 million decrease in accrued expenses and other liabilities, a $5.8 million increase in prepaid expenses and other current assets, a $2.8 million decrease in accounts payable and a $0.5 million increase in other non-current assets, partially offset by a $20.7 million decrease in accounts receivable.

Cash Flows from Investing Activities

Net cash provided by investing activities for the six months ended December 28, 2013 was $172.0 million, primarily consisting of $90.6 million proceeds from the sale of Zurich Business, $84.6 million from the sale of the Amplifier Business and a $0.5 million reduction in restricted cash, which were partially offset by $3.7 million used in capital expenditures.

Net cash provided by investing activities for the six months ended December 29, 2012 was $54.3 million, primarily consisting of $36.1 million cash acquired in the acquisition of Opnext, $26.0 million in proceeds from the sale of the thin film filter business and interleaver product line, and $2.9 million reduction in restricted cash, partially offset by $10.6 million used in capital expenditures.

Cash Flows from Financing Activities

Net cash used in financing activities for the six months ended December 28, 2013 was $70.0 million, primarily consisting of $65.0 million in repayments on a term loan and our revolving credit facility, and $4.9 million in payments on capital lease obligations.

Net cash provided by financing activities for the six months ended December 29, 2012 was $25.7 million, primarily consisting of $22.8 million in proceeds from the sale of convertible notes, $15.3 million in borrowings under our revolving credit facility and $0.7 million received from the issuance of common stock through stock option exercises and our employee stock purchase plan, partially offset by $8.6 million in payments in connection with the remaining earnout obligations related to our acquisition of Mintera, $4.0 million in payments on capital lease obligations and $0.4 million repayments on a note payable.

Credit Line and Notes

As of December 28, 2013, no amounts were available to us under our senior secured revolving credit facility with Wells Fargo Capital Finance, Inc. and other lenders (the “Credit Agreement”). As of December 28, 2013, there were no amounts outstanding under the credit facility and no amounts owed in connection with the Term Loan.

As of June 29, 2013, there was $40.0 million outstanding under the credit facility and $25.0 million owed in connection with the Term Loan. As of June 29, 2013, the net carrying value of the liability component of our Convertible Notes was $22.8 million and the estimated fair value of the contingent obligation for the make-whole payment was valued at $0.1 million. During the first quarter of fiscal year 2014, we used part of the proceeds from the sale of the Zurich Business to fully repay our outstanding balance under the credit facility and the Term Loan. During the second quarter of fiscal year 2014, the holders of the Convertible Notes exercised their rights to exchange the Convertible Notes for our common stock, plus a make-whole payment. See Note 7, Credit Line and Notes for additional information regarding the credit facility, Term Loan and Convertible Notes.

 

37


Table of Contents

At December 28, 2013 and June 29, 2013, there was $30,000 and $30,000, respectively, in outstanding standby letters of credit secured under the Credit Agreement. These letters of credit expire in June 2015.

Future Cash Requirements

As of December 28, 2013, we held $144.0 million in cash and short-term investments, comprised of $141.6 million in cash and cash equivalents, $2.3 million in restricted cash and $0.2 million of short-term investments; and we had working capital of $204.1 million. On September 12, 2013, we completed the sale of our Zurich Business under which we expect to receive $6.0 million in additional proceeds which are subject to hold-back by II-VI until December 31, 2014 to address any post-closing adjustments or claims, and $2.0 million subject to a potential post-closing working capital adjustment. On September 12, 2013, we granted II-VI an exclusive option to purchase the Amplifier Business. On October 10, 2013, we entered into an Asset Purchase Agreement to sell the Amplifier Business, and on November 1, 2013, we completed the sale for $88.6 million. The $5.0 million previously received for the option was applied against the sale. We received $79.6 million in proceeds on November 1, 2013 and expect to receive the remaining $4.0 million subject to hold-back by II-VI until December 31, 2014 to address any post-closing claim. We currently expect that we will expend approximately an additional $25.0 million to $30.0 million in cash during the next twelve months to reduce our accounts payable. With our current cash and cash equivalent balances, we believe that we have sufficient funds to support our operations through fiscal year 2014, including costs associated with the implementation of our restructuring activities.

In the event we need additional liquidity beyond our current expectations, such as to fund future growth or strengthen our balance sheet or to fund the cost of restructuring activities, we may find it necessary to lower our operating income break-even level and undertake additional cost cutting measures. We will continue to explore other sources of additional liquidity. These additional sources of liquidity could include one, or a combination, of the following: (i) issuing equity securities, (ii) incurring indebtedness secured by our assets, (iii) issuing debt and/or convertible debt securities, or (iv) selling product lines, other assets and/or portions of our business. There can be no guarantee that we will be able to raise additional funds on terms acceptable to us, or at all. As of December 28, 2013, no amounts were available to us under the Credit Agreement.

We have incurred significant operating losses and generated negative cash flows for fiscal year 2013, the first half of fiscal year 2014 and anticipate that our net loss for the remaining fiscal year 2014 could be substantial. The continued operation of our business is dependent upon our achieving cash flows expected to be generated from the execution of our current operating plan, including anticipated restructuring plans.

For additional information on the risks we face related to future cash requirements, see Item 1A. Risk Factors under “— Risks Related to Our Business — We have a history of large operating losses and we may not be able to achieve profitability in the future and maintain sufficient levels of liquidity,” Note 1, Business and Summary of Significant Accounting Policies , and the Report of Independent Registered Public Accounting Firm included in our 2013 Annual Report on Form 10-K.

As of December 28, 2013, $116.4 million of the $141.6 million of our cash and cash equivalents was held by our foreign subsidiaries. If these funds are needed for our operations in the United States, we could be required to accrue and pay U.S. taxes to repatriate these funds. However, our intent is to permanently reinvest these funds outside of the U.S. and our current plans do not include repatriation of these funds.

Off-Balance Sheet Arrangements

We indemnify our directors and certain employees as permitted by law, and have entered into indemnification agreements with our directors and executive officers. We have not recorded a liability associated with these indemnification arrangements, as we historically have not incurred any material costs associated with such indemnification obligations. Costs associated with such indemnification obligations may be mitigated by insurance coverage that we maintain, however, such insurance may not cover any, or may cover only a portion of, the amounts we may be required to pay. In addition, we may not be able to maintain such insurance coverage in the future.

 

38


Table of Contents

We also have indemnification clauses in various contracts that we enter into in the normal course of business, such as indemnification in favor of customers in respect of liabilities they may incur as a result of purchasing our products should such products infringe the intellectual property rights of a third party. We have not historically paid out any material amounts related to these indemnifications; therefore, no accrual has been made for these indemnifications.

Other than as set forth above, we are not currently party to any material off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For quantitative and qualitative disclosures about market risk affecting us, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 7A of Part II of our Annual Report on Form 10-K for the fiscal year ended June 29, 2013, which is incorporated herein by reference. Our exposure to market risk has not changed materially since June 29, 2013.

INTEREST RATES

We finance our operations through a mixture of issuances of equity securities, finance leases, working capital and by drawing on our Credit Agreement. We have exposure to interest rate fluctuations on our cash deposits and for amounts borrowed under our Credit Agreement and through our capital leases. At December 28, 2013, we had $11.7 million under capital leases. An increase in our average interest rate by 1.0 percent would increase our annual interest expense by $0.1 million.

We monitor our interest rate risk on cash balances primarily through cash flow forecasting. Cash that is surplus to immediate requirements is invested in short-term deposits with banks accessible with one day’s notice and invested in overnight money market accounts. We believe our current interest rate risk is immaterial.

FOREIGN CURRENCY

As our business is multinational in scope, we are subject to fluctuations based upon changes in the exchange rates between the currencies in which we collect revenues and pay expenses. In the future, we expect that a majority of our revenues will continue to be denominated in U.S. dollars, while a significant portion of our expenses will continue to be denominated in U.K. pounds sterling and Japanese yen. Our expenses denominated in the Swiss franc have decreased significantly as a result of our sale of the Zurich Business in the first quarter of fiscal year 2014. Fluctuations in the exchange rate between the U.S. dollar, the U.K. pound sterling, and the Japanese yen and, to a lesser extent, other currencies in which we collect revenues and pay expenses, could affect our operating results. This includes the Chinese yuan, the Korean won and the Euro in which we pay expenses in connection with operating our facilities in Shenzhen and Shanghai, China; Daejeon, South Korea and San Donato, Italy. To the extent the exchange rate between the U.S. dollar and these currencies were to fluctuate more significantly than experienced to date, our exposure would increase.

As of December 28, 2013, our U.K. subsidiary had $33.4 million, net, in U.S. dollar denominated operating intercompany payables, $56.8 million in U.S. dollar denominated accounts receivable and payable, net, related to sales to external customers and purchases from suppliers, and $98.2 million in U.S. dollar denominated cash accounts. It is estimated that a 10 percent fluctuation in the U.S. dollar relative to the U.K. pound sterling would lead to a profit of $12.2 million (U.S. dollar strengthening), or loss of $12.2 million (U.S. dollar weakening) on the translation of these receivables and other cash balances, which would be recorded as gain (loss) on foreign currency transactions, net, in our condensed consolidated statement of operations.

As of December 28, 2013, our Japan subsidiary had $41.3 million, net, in U.S. dollar denominated operating intercompany payables, $13.3 million in U.S. dollar denominated accounts payable, net of accounts receivable, related to sales to external customers and purchases from suppliers, and $3.5 million in U.S. dollar denominated cash and restricted cash accounts. It is estimated that a 10 percent fluctuation in the U.S. dollar relative to the Japanese yen would lead to a profit of $5.1 million (U.S. dollar weakening), or loss of $5.1 million (U.S. dollar strengthening) on the translation of these balances, which would be recorded as gain (loss) on foreign currency transactions, net, in our condensed consolidated statement of operations.

 

39


Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 28, 2013. The term “disclosure controls and procedures,” as defined in Rules13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 28, 2013, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level.

As disclosed in our Annual Report on Form 10-K for the year ended June 29, 2013, we identified a material weakness in our internal control over financial reporting such that our disclosure controls and procedures related to accounting for the purchase of the Opnext acquisition were not effective. Over the next several quarters, we will be implementing enhancements to our internal controls over financial reporting, including hiring finance personnel and adding controls over the preparation and oversight of accounting for acquisitions and dispositions. Our remediation efforts, including the testing of these controls, will continue throughout our fiscal year 2014. We expect that the material weakness will be remediated during fiscal year 2014 once these controls have been operational for a sufficient period of time to allow management to conclude that these controls are operating effectively.

Notwithstanding the ineffectiveness of our disclosure controls and procedures as of December 28, 2013 and the material weakness in our internal control over financial reporting that existed as of that date as described above, management believes that (i) this Form 10-Q does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading with respect to the periods covered by this Report and (ii) the condensed consolidated financial statements, and other financial information, included in this Report fairly present in all material respects in accordance with U.S. GAAP our financial condition, results of operations and cash flows as of, and for, the dates and periods presented.

Except as noted in the preceding paragraph, there was no change in our internal control over financial reporting during the three months ended December 28, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Overview

In the ordinary course of business, we are involved in various legal proceedings, and we anticipate that additional actions will be brought against us in the future. The most significant of these proceedings are described below. The following supplements and amends the discussion set forth in our Annual Report on Form 10-K for the year ended June 29, 2013. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims in various jurisdictions. Complex legal proceedings frequently extend for several years, and a number of the matters pending against us are at very early stages of the legal process. As a result, some pending matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to determine whether the proceeding is material to us or to estimate a range of possible loss, if any. Unless otherwise disclosed, we are unable to estimate the possible loss or range of loss for the legal proceedings described below. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our results of operations, financial position or cash flows.

 

40


Table of Contents

Specific Matters

On October 23, 2013, Xi’an Raysung Photonics Inc. or Xi’an Raysung, filed a civil suit against our wholly-owned subsidiary, Oclaro Technology (Shenzhen) Co., Ltd. (formerly known as Bookham Technology (Shenzhen) Co., Ltd.), or Oclaro Shenzhen, in the Xi’an Intermediate People’s Court in Shaanxi Province of the People’s Republic of China, or the Xi’an Court. The complaint filed by Xi’an Raysung alleges that Oclaro Shenzhen terminated its purchase order pursuant to which Xi’an Raysung had supplied certain products and was to supply certain products to Oclaro Shenzhen.

Xi’an Raysung has requested the court award damages of approximately $0.8 million (equivalent to RMB 4,796,531.81), and requested that Oclaro Shenzhen take the finished products that are now stored in Xi’an Raysung’s warehouse (the value of the finished product is approximately, $2.2 million, (equivalent to RMB 13,505,162.34) and requested that Oclaro Shenzen pay its court fees in connection with this suit.

The Xi’an Court delivered an Asset Preservation Order which was served on Oclaro Shenzhen and the local Customs office. According to the Asset Preservation Order, Oclaro Shenzhen was ordered to maintain approximately $2.5 million (equivalent to RMB 15,000,000.00) or assets equivalent to the said amount during the litigation process, and the Customs office was ordered that before the Asset Preservation Order is lifted, Oclaro Shenzhen’s equipment is restricted from being exported. On November 11, 2013, Oclaro Shenzhen and Xi’an Raysung entered into a settlement agreement. Under the terms of this settlement agreement, Oclaro Shenzhen agreed to pay $500,000 in payment of invoices for certain materials to Xi’an Raysung and to work with Xi’an Raysung to requalify it as a vendor for certain Oclaro Shenzhen manufacturing requirements, in consideration of which Xi’an Raysung agreed to submit the settlement agreement to the Xi’an Court so it could issue a civil mediation agreement, apply for a discharge of the Asset Preservation Order and waive the right to bring any legal actions against Oclaro Shenzhen relating to these matters. Oclaro Shenzhen performed its obligations under the settlement agreement, however, on January 15, 2014, Xi’an Raysung applied to the Xi’an Court to terminate the settlement agreement and add Oclaro, Inc. as a co-defendant in the original civil suit. Oclaro, Inc. and Oclaro Shenzhen believe that they have meritorious defenses to the claims made by Xi’an Raysung and intend to defend this litigation vigorously.

On August 29, 2013, the Secured Lender Trustee of the Secured Lender Trust (“Trust”) established under the Second Amended Chapter 11 Plan of Liquidation of Dewey & LeBoeuf LLP (the “Trustee”) filed a complaint against Oclaro, Inc. in the United States Bankruptcy Court, Southern District of New York. The complaint alleges that we were formerly a client of Dewey & LeBoeuf LLP (“Dewey”) and engaged it to provide services for the period through June 5, 2012. The Trustee claimed that there were unpaid invoices outstanding totaling approximately $0.5 million. Oclaro, Inc. and the Trust, as a successor to Dewey, entered into a Stipulation of Settlement dated as of November 25, 2013, under which we agreed to pay the Trust the sum of $235,000 in full and final settlement of all outstanding claims by the Trust and in consideration of a full release of claims from the Trust. We also released the Trust from all claims. On December 6, 2013, the underlying adversary proceeding in the United States Bankruptcy Court for the Southern District of New York was dismissed with prejudice by stipulation of the parties.

On December 21, 2012, Labyrinth Optical Technologies LLC filed a complaint against us in United States District Court for the Central District of California alleging that certain coherent transponder modules, coherent receivers and DQPSK transceivers sold by us infringe Labyrinth Optical U.S. patent Nos. 7,599,627 and 8,103,173. The parties executed a settlement agreement on September 13, 2013 and on October 30, 2013 the litigation was dismissed with prejudice by stipulation of the parties.

 

41


Table of Contents

On May 19, 2011, Curtis and Charlotte Westley filed a purported class action complaint in the United States District Court for the Northern District of California, against us and certain of our officers and directors. The Court subsequently appointed the Connecticut Laborers’ Pension Fund (“Pension Fund”) as lead plaintiff for the putative class. On April 26, 2012, the Pension Fund filed a second amended complaint, captioned as Westley v. Oclaro, Inc., No. 11 Civ. 2448 EMC, allegedly on behalf of persons who purchased our common stock between May 6 and October 28, 2010, alleging that we and certain of our officers and directors issued materially false and misleading statements during this time period regarding our current business and financial condition, including projections for demand for our products, as well as our revenues, earnings, and gross margins, for the first quarter of fiscal year 2011 as well as the full fiscal year. The complaint alleges violations of section 10(b) of the Securities Exchange Act and Securities and Exchange Commission Rule 10b-5, as well as section 20(a) of the Securities Exchange Act. The complaint seeks damages and costs of an unspecified amount. On September 21, 2012, the Court dismissed the second amended complaint with leave to amend. After the Pension Fund moved for reconsideration, on January 10, 2013, the Court allowed plaintiffs to take discovery regarding statements made in May and June 2010. On March 1, 2013 the Pension Fund filed a third amended complaint, attempting to cure pleading deficiencies with regard to statements allegedly made in July and August 2010. On April 1, 2013, defendants moved to dismiss the third amended complaint with respect to the statements made in July and August 2010. On May 30, 2013, the Court granted Defendants’ motion to dismiss the complaint’s claims based on statements made in July and August 2010. Discovery has commenced, and no trial has been scheduled in this action.

On June 10, 2011, a purported shareholder, Stanley Moskal, filed a purported derivative action in the Superior Court for the State of California, County of Santa Clara, against us, as nominal defendant, and certain of our current and former officers and directors, as defendants. The case is styled Moskal v. Couder, No. 1:11 CV 202880 (Santa Clara County Super. Ct., filed June 10, 2011). Four other purported shareholders, Matteo Guindani, Jermaine Coney, Jefferson Braman and Toby Aguilar, separately filed substantially similar lawsuits in the United States District Court for the Northern District of California on June 27, June 28, July 7 and July 26, 2011, respectively. By Order dated September 14, 2011, the Guindani, Coney, and Braman actions were consolidated under In re Oclaro, Inc. Derivative Litigation, Lead Case No. 11 Civ. 3176 EMC. On October 5, 2011, the Aguilar action was voluntarily dismissed. Each remaining purported derivative complaint alleges that Oclaro has been, or will be, damaged by the actions alleged in the Westley complaint, and the litigation of the Westley action, and any damages or settlement paid in the Westley action. Each purported derivative complaint alleges counts for breaches of fiduciary duty, waste, and unjust enrichment. Each purported derivative complaint seeks damages and costs of an unspecified amount, as well as injunctive relief. By Order dated March 6, 2012, the parties in the Moskal action agreed that defendants shall not be required to respond to the original complaint. By Order dated February 27, 2013, the parties in the Moskal action agreed that plaintiff would serve an amended complaint no later than 30 days after the Court in the Westley action rules on defendants’ motion to dismiss the third amended complaint in the Westley action and the stay of discovery would remain in effect until further order of the Court or agreement by the parties, provided, however, that they obtain discovery produced in the Westley Action. By Order dated March 12, 2013, the parties to In re Oclaro, Inc. Derivative Litigation agreed to stay all proceedings until such time as (a) the defendants file an answer to any complaint in the Westley action; or (b) the Westley action is dismissed in its entirety with prejudice, provided, however, that they obtain discovery produced in the Westley Action. No trial has been scheduled in any of these actions.

On September 3, 2013, the parties agreed to settle the Westley, Moskal, and In re Oclaro Derivative matters for a total of $3.95 million, plus certain corporate governance changes. The money will be paid entirely by our directors and officers liability insurance carriers. Any fees awarded to the plaintiffs in these actions, or their respective counsel, will be included in this amount. The settlement is subject to final documentation and court approval.

On May 27, 2011, Opnext Japan filed a complaint against Furukawa in the Tokyo District Court alleging that certain laser diode modules sold by Furukawa infringe Opnext Japan’s Japanese patent No. 3,887,174. Opnext Japan is seeking an injunction as well as damages in the amount of 100.0 million Japanese yen.

On August 5, 2011, Opnext Japan filed a complaint against Furukawa in the Tokyo District Court alleging that certain integratable tunable laser assemblies sold by Furukawa infringe Opnext Japan’s Japanese patent No. 4,124,845. Opnext Japan is seeking an injunction as well as damages in the amount of 200.0 million Japanese yen.

 

42


Table of Contents

ITEM 1A. RISK FACTORS

Investing in our securities involves a high degree of risk. The risks described below are not the only ones facing us. Additional risks not currently known to us or that we currently believe are immaterial also may impair our business, operations, liquidity and stock price materially and adversely. You should carefully consider the risks and uncertainties described below in addition to the other information included or incorporated by reference in this Quarterly Report on Form 10-Q. If any of the following risks actually occur, our business, financial condition or results of operations would likely suffer. In that case, the trading price of our common stock could fall and you could lose all or part of your investment.

We have recently announced significant changes at Oclaro relating to our operations, strategic plan and management team. The operation of our business could be adversely affected by the transition of key personnel as we rebuild our executive leadership team and make additional organizational changes.

Beginning in June 2013, we have announced a series of events, transactions and restructuring plans, which have had a significant impact on our business. Among other things, we sold our Zurich and Amplifier Businesses and announced a restructuring plan to focus our business on our core competencies. While we believe these events, transactions and plans will have a positive impact on our financial condition and results of operations, these changes will result in at least a significant near-term reduction in our revenues, could lead to a disruption in our operations and employee morale, could lead to unplanned attrition of employees, and adversely affect our ability to attract highly skilled employees. In addition, many of our senior management are relatively new. Since June 2013, we have appointed a new Chief Executive Officer and Chief Financial Officer, and have hired a new head of Worldwide Sales, a new General Counsel and a new Principal Accounting Officer. We have also decreased the size of our Board of Directors from nine to seven. It is important to our success that our Chief Executive Officer continues building an effective management team and global organization. It may take some time for each of the new members of our management team to become fully integrated into our business. Our failure to manage these transitions, or to find and retain experienced management personnel, could adversely affect our ability to compete effectively and could adversely affect our operating results. If we experience these or other adverse consequences, fail to manage these transitions, do not find and retain experienced management personnel, or are otherwise unable to realize the expected benefits of our restructuring plan, our business, results of operations and financial condition would be materially and adversely affected and we may not be able to continue as a going concern over the long term.

The markets in which we operate are highly competitive, which could result in lost sales and lower revenues.

The market for optical components and modules is highly competitive and this competition could result in our existing customers moving their orders to our competitors. We are aware of a number of companies that have developed or are developing optical component products, including tunable lasers, pluggables, wavelength selective switches and thin film filter products, among others, that compete directly with our current and proposed product offerings.

Certain of our competitors may be able to more quickly and effectively:

 

    develop or respond to new technologies or technical standards;

 

    react to changing customer requirements and expectations;

 

    devote needed resources to the development, production, promotion and sale of products; and

 

    deliver competitive products at lower prices.

Some of our current competitors, as well as some of our potential competitors, have longer operating histories, greater name recognition, broader customer relationships and industry alliances and substantially greater financial, technical and marketing resources than we do. In addition, market leaders in industries such as semiconductor and data communications, who may also have significantly more resources than we do, may in the future enter our market with competing products. Our competitors and new Chinese companies are establishing manufacturing operations in China to take advantage of comparatively low manufacturing costs. All of these risks may be increased if the market were to further consolidate through mergers or other business combinations between competitors.

 

43


Table of Contents

We may not be able to compete successfully with our competitors and aggressive competition in the market may result in lower prices for our products and/or decreased gross margins. Any such development could have a material adverse effect on our business, financial condition and results of operations.

We relocated our operations formerly located in Totsuka, Japan. Our business may experience disruption due to this relocation.

We relocated our manufacturing and research and development facilities, as well as our administrative offices from Totsuka, Japan to a facility we leased from Yokogawa Electric Corporation in Sagamihara-shi, Kanagawa Prefecture, Japan. Although we have completed this transition, there can be no assurance that the relocation of these operations will not adversely impact our production capacity or manufacturing yields or divert management’s attention from the day-to-day operation of our business, any of which could adversely affect our business, results of operations and cash flows.

We depend on a limited number of customers for a significant percentage of our revenues and the loss of a major customer could have a materially adverse impact on our financial condition.

Historically, we have generated most of our revenues from a limited number of customers. Our dependence on a limited number of customers is due to the fact that the optical telecommunications systems industry is dominated by a small number of large companies. These companies in turn depend primarily on a limited number of major telecommunications carrier customers to purchase their products that incorporate our optical components. For example, during the fiscal years ended June 29, 2013, June 30, 2012 and July 2, 2011, our three largest customers accounted for 31 percent, 29 percent and 36 percent of our revenues, respectively, including our discontinued operations. Because we rely on a limited number of customers for significant percentages of our revenues, a decrease in demand for our products from any of our major customers for any reason (including due to market conditions, catastrophic events or otherwise) could have a materially adverse impact on our financial conditions and results of operations. For example, during the second half of fiscal 2012, our revenues were adversely impacted by a significant change in demand expectations from a particular major customer. Further, the industry in which our customers operate is subject to a trend of consolidation. To the extent this trend continues, we may become dependent on even fewer customers to maintain and grow our revenues.

Sales of older legacy products continue to represent a significant percentage of our total revenues and, if we do not increase the percentage of sales associated with new products, our revenues may not grow in the future.

The markets for our products are characterized by changing technology and continuing process development. The future of our business will depend in large part upon the continuing relevance of our technological capabilities, and our ability to introduce new products that address our customers’ requirements for more cost-effective bandwidth solutions. Our inability to successfully launch or sustain new or next generation programs or product features that anticipate future market trends could materially adversely affect our financial results. We may also encounter competition from new or revised technologies that render our products less profitable or obsolete in our chosen markets, and our operating results may suffer. Furthermore, we cannot assure you that we will introduce new or next generation products in a timely manner, or that these products will gain market acceptance, and failure to do so could materially affect our operating results.

Our products are complex and may take longer to develop than anticipated and we may not recognize revenues from new products until after long field testing and customer acceptance periods.

Many of our new products must be tailored to customer specifications. As a result, we are developing new products and using new technologies in those products. For example, while we currently manufacture and sell discrete “gold box” technology, we expect that many of our sales of “gold box” technology will soon be replaced by pluggable modules. New products or modifications to existing products often take many quarters or even years to develop because of their complexity and because customer specifications sometimes change during the development cycle. We often incur substantial costs associated with the research and development, design, sales and marketing activities in connection with products that may be purchased long after we have incurred such costs. In addition, due to the rapid technological changes in our market, a customer may cancel or modify a design project before we begin large-scale manufacture of the product and receive revenues from the customer. It is unlikely that we would be able to recover the expenses for cancelled or unutilized design projects. It is difficult to predict with any certainty, particularly in the present economic climate, the frequency with which customers will cancel or modify their projects, or the effect that any cancellation or modification would have on our results of operations. In some cases, the adoption of our new product offerings can also become a function of the pace of adoption of new technologies or new data rates at the telecom network level.

 

44


Table of Contents

If our customers do not qualify our manufacturing lines or the manufacturing lines of our subcontractors for volume shipments, our operating results could suffer.

Most of our customers do not purchase products, other than limited numbers of evaluation units, prior to qualification of the manufacturing line for volume production. Our existing manufacturing lines, as well as each new manufacturing line, must pass through varying levels of qualification with our customers. Our manufacturing lines have passed our qualification standards, as well as our technical standards. However, our customers also require that our manufacturing lines pass their specific qualification standards and that we, and any subcontractors that we may use, be registered under international quality standards. In addition, we have in the past, and may in the future, encounter quality control issues as a result of relocating our manufacturing lines or introducing new products to fill production. We may be unable to obtain customer qualification of our manufacturing lines or we may experience delays in obtaining customer qualification of our manufacturing lines. Such delays or failure to obtain qualifications would harm our operating results and customer relationships. To the extent we introduce new contract manufacturing partners and move any production lines from existing internal or external facilities the new production lines will likely need to be re-qualified with customers. Exposures to these risks could increase materially during the transition of our Shenzhen product lines to Venture Malaysia, and as a result of our acquisition and integration of Opnext, including the relocation of certain operations from Totsuka, Japan to a different leased facility in Sagamihara, Japan.

We have a history of large operating losses. We may not be able to achieve profitability in the future and as a result we may not be able to maintain sufficient levels of liquidity.

We have historically incurred losses and negative cash flows from operations since our inception. As of December 28, 2013, we had an accumulated deficit of $1,250.6 million. We incurred a loss from continuing operations of $68.2 million and negative cash flows from operations of $46.8 million during the six months ended December 28, 2013, and we incurred net losses for the years ended June 29, 2013, June 30, 2012 and July 2, 2011 of $122.7 million, $66.5 million and $46.4 million, respectively.

As of December 28, 2013, we held $144.0 million in cash and short-term investments, comprised of $141.6 million in cash and cash equivalents, $2.3 million in restricted cash and $0.2 million of short-term investments; and we had working capital of $204.1 million. At December 28, 2013, we had debt of $11.7 million, consisting of capital leases. During fiscal year 2013 and 2014, we executed a number of financing transactions in order to generate funds to help sustain our operations: we sold our interleaver and thin film filter business, we expanded our line of credit, we executed a convertible debt transaction and in the third quarter of fiscal year 2013, we began to evaluate and execute sales of product lines in order to generate additional capital. On May 6, 2013, we secured a short term loan from Providence Equity of $25.0 million (with net proceeds to us of $20.5 million after discounts and expenses) as a bridge to the conclusion of certain asset sales. In order to obtain the short term loan, we amended our Credit Agreement to add Providence as a term lender. In connection with this amendment, we agreed to complete certain asset sales and use the proceeds to repay amounts we have borrowed under the Credit Agreement by July 15, 2013. On August 21, 2013, we amended our Credit Agreement to extend the time frame within which we must complete such asset sales to make such repayments to September 2, 2013. The corresponding sale of our Zurich Business to II-VI was closed on September 12, 2013. We received proceeds of $90.6 million in cash on September 12, 2013. We will also receive $6.0 million subject to hold-back by II-VI until December 31, 2014 to address any post-closing adjustments or claims, and $2.0 million subject to a potential post-closing working capital adjustment, which will be calculated based on the level of working capital in the Oclaro Switzerland GmbH subsidiary at the September 12, 2013 close versus a target based on working capital at June 29, 2013. We also received $5.0 million for a 30 day option to sell our Amplifier Business for $88.0 million inclusive of the option amount. On November 1, 2013, we sold our Amplifier Business to II-VI and certain of its affiliates for $88.6 million in cash, consisting of $79.6 million in cash, subject to inventory valuation adjustments after closing, and $4.0 million, subject to hold-back by II-VI until December 31, 2014 to address any post-closing claims. In accordance with the option agreement we entered into with II-VI, the $5.0 million paid by II-VI was credited against the $88.6 million purchase price for the Amplifier Business.

Following the sale of the Zurich Business, we repaid all amounts outstanding under the Credit Agreement as required. The event of default resulting from not completing the sale of the Zurich Business on September 2, 2013 was waived on September 26, 2013. This waiver eliminated the requirement for the Agent and Lenders to make any advances, issue any letters of credit or provide any other extension of credit until the Agent and Lenders agree otherwise and prevents us from exercising any right or action set forth in the applicable loan documents that is conditioned on the absence of any event of default. If the Agent and Lenders do not agree to make amounts under the Credit Agreement available to us within 30 days of the waiver (or such later time as the Agent agrees), then the Agent and Lenders will have the option to immediately terminate the Credit Agreement.

 

45


Table of Contents

The optical communications industry is subject to significant operational fluctuations. In order to remain competitive we incur substantial costs associated with research and development, qualification, production capacity and sales and marketing activities in connection with products that may be purchased, if at all, long after we have incurred such costs. In addition, the rapidly changing industry in which we operate, the length of time between developing and introducing a product to market, frequent changing customer specifications for products, customer cancellations of products and general down cycles in the industry, among other things, make our prospects difficult to evaluate. We are not generating positive cash flow from operations, and it is possible that we may not (i) generate sufficient positive cash flow from operations; (ii) raise funds through the completion of a short term revolving credit facility, or the issuance of equity, equity-linked or convertible debt securities; (iii) repay any amounts we may draw down assuming we establish a revolving credit facility in the future; (iv) conclude additional strategic dispositions or similar transactions; or (v) otherwise have sufficient capital resources to meet our future capital or liquidity needs. We believe it is prudent to undertake additional restructuring activities to reduce our cost base and lower our operating income break-even level, which activities will also be financed from our existing financial resources. There are no guarantees we will be able to generate additional financial resources beyond our existing balances.

Our success will depend on our ability to anticipate and respond to evolving technologies and customer requirements.

The market for telecommunications equipment is characterized by substantial capital investment, rapid and unpredictable changes in customer demand and diverse and evolving technologies. For example, the market for optical components is currently characterized by a trend toward the adoption of pluggable components and tunable transmitters that do not require the customized interconnections of traditional fixed wavelength “gold box” devices and the increased integration of components on subsystems. Our ability to anticipate and respond to these and other changes in technology, industry standards, customer requirements and product offerings and to develop and introduce new and enhanced products will be significant factors in our ability to succeed. We expect that new technologies will continue to emerge as competition in the telecommunications industry increases and the need for higher and more cost efficient bandwidth expands. The introduction of new products embodying new technologies or the emergence of new industry standards could render our existing products or products in development uncompetitive from a pricing standpoint, obsolete or unmarketable, which would negatively affect our financial condition and results of operations.

We may not be able to maintain or improve gross margin levels.

We may not be able to maintain or improve our gross margins, due to slow introductions of new products, failure to effectively cost reduce existing products, the potential for future macroeconomic or market volatility reducing sales volumes, changes in customer demand (including a change in product mix between different areas of our business) and pricing pressure from increased competition or other factors. We are attempting to reduce our product costs and improve our product mix to offset price competition and erosion expected in most product categories, but there is no assurance that we will be successful. Our gross margins can also be adversely impacted for reasons including, but not limited to, fixed manufacturing costs that would not be expected to decrease in proportion to any decrease in revenues, as occurred due to the flooding in Thailand; unfavorable production yields or variances; increases in costs of input parts and materials; the timing of movements in our inventory balances; warranty costs and related returns; changes in foreign currency exchange rates; possible exposure to inventory valuation reserves; the sale of the Zurich and Amplifier Businesses, including procuring certain parts that were previously internally sourced; and failure to realize benefits of the transfer of certain manufacturing functions to Venture Corporation Limited (Venture). Any failure to maintain, or improve, our gross margins will adversely affect our financial results, including our goal to achieve sustainable cash flow positive operations.

We will incur significant additional restructuring charges that will adversely affect our results of operations.

We expect to incur significant restructuring expenses for incremental actions going forward, including restructuring actions we announced in the first half of fiscal year 2014 to reduce our complexity and to simplify our operating footprint subsequent to the sale of the Zurich and Amplifier Businesses.

 

46


Table of Contents

We have previously enacted a series of restructuring plans and cost reduction plans designed to reduce our manufacturing overhead and our operating expenses that have resulted in significant restructuring charges. Such charges have adversely affected, and will continue to adversely affect, our results of operations for the periods in which such charges have been, or will be, incurred. Additionally, actual costs have in the past, and may in the future, exceed the amounts estimated and provided for in our financial statements. Significant additional charges could materially and adversely affect our results of operations in the periods that they are incurred and recognized. In addition, any restructuring activities will require significant cash commitments and will adversely affect our cash balances.

For instance, during fiscal year 2012 and 2013, we incurred $6.0 million and $5.1 million in restructuring charges, respectively, in connection with the transition of our Shenzhen, China assembly and test operations to Venture, and expect to incur an additional $3.0 million to $5.0 million in restructuring charges over the remaining transition period. During the year ended June 29, 2013, we incurred $12.1 million in restructuring charges in connection with the acquisition and integration of Opnext, and expect to incur additional restructuring charges related to this plan over the next few quarters.

There is risk in executing the transition of our Shenzhen assembly and test operations, and in executing to the corresponding long term supply agreement, with Venture, and we may not realize the anticipated benefits from either.

In March 2012, we entered into a definitive agreement with Venture to transfer our Shenzhen final assembly and test operations to Venture’s Malaysia facility in a phased and gradual transfer of products over a period of three years. In conjunction with this agreement, we entered into a five-year supply agreement with Venture to manufacture and supply us with certain products that were previously manufactured at our Shenzhen facility. There can be no assurance that the transition of our Shenzhen assembly and test operations and the corresponding long term supply agreement with Venture will result in the benefits that we expect, or that revenues will not be adversely impacted during the transition period.

In addition, there is significant risk in our ability to execute stages of this transfer without negative impacts on production output, delivery to customer requests, quality and customer service in general. Revenues could be adversely impacted if production output falls short of expectations during the transfer or if customer service is perceived to be inadequate.

On March 28, 2012, shortly after announcing this agreement, certain of our employees in Shenzhen initiated a work stoppage up to and including April 4, 2012. Although we negotiated a resolution to this work stoppage, there can be no assurance that work stoppages will not arise in the future having a material adverse impact on our production output and/or the levels and gross margins of the corresponding product revenues supported by the production output, and/or increasing the net costs of executing the transfer to Venture. Any such work stoppage may adversely impact our revenues and our ability to deliver products to our customers. In addition, our recent sale of the Zurich and Amplifier Businesses, and our commitment to provide manufacturing services for the buyer using our Shenzhen facility and personnel, could potentially have an impact on corresponding employee relations in Shenzhen and impact our ability to deliver products to our customers.

The majority of our long-term customer contracts do not commit customers to specified buying levels, and our customers may decrease, cancel or delay their buying levels at any time with little or no advance notice to us.

The majority of our customers typically purchase our products pursuant to individual purchase orders or contracts that do not contain purchase commitments. Some customers provide us with their expected forecasts for our products several months in advance, but many of these customers may decrease, cancel or delay purchase orders already in place, and the impact of any such actions may be intensified given our dependence on a small number of large customers. If any of our major customers decrease, stop or delay purchasing our products for any reason, our business and results of operations would be harmed. Cancellation or delays of such orders may cause us to fail to achieve our short-term and long-term financial and operating goals and result in excess and obsolete inventory. For example, in fiscal year 2011, we did experience certain deferrals and cancellations of orders which adversely impacted our quarterly financial results. In addition, during the second half of fiscal year 2012, our revenues were adversely impacted by a significant change in demand expectations from a major customer.

Delays, disruptions or quality control problems in manufacturing could result in delays in product shipments to customers and could adversely affect our business.

We may experience delays, disruptions or quality control problems in our manufacturing operations or the manufacturing operations of our subcontractors. As a result, we could incur additional costs that would adversely affect our gross margins, and our product shipments to our customers could be delayed beyond the shipment schedules requested by our customers, which would negatively affect our revenues, competitive position and reputation. Furthermore, even if we are able to deliver products to our customers on a timely basis, we may be unable to recognize revenues at the time of delivery based on our revenue recognition policies. Exposures to these risks could increase during the transition of our Shenzhen product lines to Venture Malaysia over what is anticipated to be a two to three year period, and with regards to any product line manufacturing transitions associated with our integration of Opnext.

 

47


Table of Contents

Our results of operations may suffer if we do not effectively manage our inventory, and we may continue to incur inventory-related charges.

We need to manage our inventory of component parts and finished goods effectively to meet changing customer requirements. Accurately forecasting customers’ product needs is difficult. Some of our products and supplies have in the past, and may in the future, become obsolete or deemed excess while in inventory due to rapidly changing customer specifications or a decrease in customer demand. We also have exposure to contractual liabilities to our contract manufacturers for inventories purchased by them on our behalf, based on our forecasted requirements, which may become excess or obsolete. Our inventory balances also represent an investment of cash. To the extent our inventory turns are slower than we anticipate based on historical practice, our cash conversion cycle extends and more of our cash remains invested in working capital. If we are not able to manage our inventory effectively, we may need to write down the value of some of our existing inventory or write off non-saleable or obsolete inventory. We have from time to time incurred significant inventory-related charges. Any such charges we incur in future periods could materially and adversely affect our results of operations. As part of the transition of our Shenzhen manufacturing facility to Venture, we may need to invest in additional inventories during the corresponding transition period, and in the future may be exposed to contractual liabilities to Venture for inventories purchased by them on our behalf.

As a result of our global operations, our business is subject to currency fluctuations that have adversely affected our results of operations in recent quarters and may continue to do so in the future.

Our financial results have been and will continue to be materially impacted by foreign currency fluctuations. At certain times in our history, declines in the value of the U.S. dollar versus the U.K. pound sterling have had a major negative effect on our margins and our cash flow. A significant portion of our expenses are denominated in U.K. pounds sterling and Japanese yen and substantially all of our revenues are denominated in U.S. dollars.

Fluctuations in the exchange rate between these currencies and, to a lesser extent, other currencies in which we collect revenues and/or pay expenses could have a material effect on our future operating results. For example during fiscal year 2013, the Swiss franc appreciated approximately 1 percent relative to the U.S. dollar, the U.K. pound sterling depreciated approximately 2 percent relative to the U.S. dollar, and the Japanese yen depreciated approximately 20 percent relative to the U.S. dollar, impacting our manufacturing overhead and operating expenses. If the U.S. dollar stays the same or depreciates relative to the U.K. pound sterling and/or Japanese yen in the future, our future operating results may be materially impacted. Additional exposure could also result should the exchange rate between the U.S. dollar and the Chinese yuan, the South Korean won, or the Euro vary more significantly than they have to date.

We periodically engage in currency hedging transactions in an effort to cover some of our exposure to U.S. dollar to U.K. pound sterling currency fluctuations, and we may be required to convert currencies to meet our obligations. We may, in the future, enter into similar hedging transactions in an effort to cover some of our exposure to U.S. dollar to Japanese yen currency fluctuations. These transactions may not operate to fully hedge our exposure to currency fluctuations, and under certain circumstances, these transactions could have an adverse effect on our financial condition.

We may undertake divestitures of portions of our business, such as the divestiture of our Zurich Business and our Amplifier Business, that require us to continue providing substantial post-divestiture transition services and support, which may cause us to incur unanticipated costs and liabilities and adversely affect our financial condition and results of operations.

From time to time we consider divestitures of product lines or portions of our assets in order to streamline our business, focus on our core operations and raise cash. For example, on September 12, 2013, we sold our Zurich Business to II-VI and on November 1, 2013, we sold our Amplifier Business to II-VI (See Note 5, Business Combinations and Dispositions , elsewhere in this Quarterly Report on Form 10-Q for further details). In connection with these divestitures, we entered into transition service, manufacturing service and supply agreements with II-VI to facilitate the ownership transition, collectively referred to as “transition agreements.” Pursuant to these transition agreements, we continue to manufacture certain products for II-IV, we host certain IT infrastructure for II-IV and we perform certain administrative functions for II-VI. From time to time, substantial amounts of executive resources have been diverted from our core ongoing business to manage these transitions. For each of these divestitures, a material portion of the purchase price was held back by II-VI to address post-closing claims, including claims related to our performance of the transition agreements. Significant amounts of these holdbacks could be affected by our ability to properly discharge our transition agreement obligations. In order to perform under these transition agreements, on an interim basis, we have been required to retain certain employees and contractors, continue operating certain facilities, dedicate certain manufacturing capacity and maintain certain supplier agreements that have added additional costs and delayed our ability to fully restructure our operations to efficiently focus on our core ongoing business. If we fail to perform under these transition agreements, or if we do not successfully execute the restructuring of our operations after our transition agreement obligations have been fulfilled, our financial condition and results of operations could be harmed.

Despite our existing debt levels, we may have to incur substantially more debt in the future, which may subject us to restrictive covenants that could limit our ability to operate our business.

In the future, we may incur additional indebtedness through arrangements such as credit agreements or term loans that may impose restrictions and covenants that limit our ability to respond appropriately to market conditions, make capital investments or take advantage of business opportunities. In addition, any debt arrangements we may enter into would likely require us to make regular interest payments, which would adversely affect our results of operations.

 

48


Table of Contents

We may undertake mergers or acquisitions, such as our acquisition of Opnext, Inc. (Opnext), that do not prove successful, which would materially and adversely affect our business, prospects, financial condition and results of operations.

From time to time we consider mergers or acquisitions, collectively referred to as “acquisitions,” of other businesses, assets or companies that would complement our current product offerings, enhance our intellectual property rights or offer other competitive opportunities. For example, on March 26, 2012, we entered into an Agreement and Plan of Merger and Reorganization with Opnext, which was completed on July 23, 2012. However, in the future, we may not be able to identify suitable acquisition candidates at prices we consider appropriate. In addition, we are in an industry that is actively consolidating and, as a result, there is no guarantee that we will successfully and satisfactorily bid against third parties, including competitors, when we identify a critical target we want to acquire.

We cannot readily predict the timing or size of our future acquisitions, or the success of our recent or future acquisitions. Failure to successfully implement our acquisition plans could have a material adverse effect on our business, prospects, financial condition and results of operations. Even successful acquisitions could have the effect of reducing our cash balances, diluting the ownership interests of existing stockholders or increasing our indebtedness. For example, in our acquisition of Opnext we issued approximately 38.4 million newly issued shares of our common stock to the former stockholders of Opnext.

In addition, during the first quarter of fiscal year 2012, we issued 0.9 million shares of our common stock related to the settlement of our Xtellus escrow liability. In October 2011, we paid $0.5 million in cash and issued 0.8 million shares of our common stock to pay earnout obligations related to our acquisition of Mintera. In the fourth quarter of fiscal year 2012, we paid $2.2 million to settle a portion of our Mintera earnout obligations, and settled the remaining $8.6 million obligation in cash in the first quarter of fiscal year 2013.

Our acquisition of Opnext and other acquisitions involve a number of other potential risks to our business, including the following, any of which could harm our business:

 

    failure to realize the potential financial or strategic benefits of the acquisition;

 

    increased costs associated with merged or acquired operations;

 

    increased indebtedness obligations;

 

    economic dilution to gross and operating profit (loss) and earnings (loss) per share;

 

    failure to successfully further develop the combined, acquired or remaining technology, which could, among other things, result in the impairment of amounts recorded as goodwill or other intangible assets;

 

    unanticipated costs and liabilities and unforeseen accounting charges;

 

    difficulty in integrating product offerings;

 

    difficulty in coordinating and rationalizing research and development activities to enhance introduction of new products and technologies with reduced cost;

 

    difficulty in coordinating and integrating the manufacturing activities of our acquired businesses, including with respect to third-party manufacturers, including coordination, integration or transfers of any manufacturing activities associated with our acquisition of Opnext;

 

    delays and difficulties in delivery of products and services;

 

    failure to effectively integrate or separate management information systems, personnel, research and development, marketing, sales and support operations;

 

    difficulty in maintaining internal control procedures and disclosure controls that comply with the requirements of the Sarbanes-Oxley Act of 2002, or poor integration of a target’s procedures and controls;

 

    difficulty in preserving important relationships of our acquired businesses and resolving potential conflicts between business cultures;

 

49


Table of Contents
    uncertainty on the part of our existing customers, or the customers of an acquired company, about our ability to operate effectively after a transaction, and the potential loss of such customers;

 

    loss of key employees;

 

    difficulty in coordinating the international activities of our acquired businesses, including Opnext, which has substantial operations in Japan as well as the United States, and which uses contract manufacturing suppliers in Southeast Asia;

 

    the effect of tax laws and other legal and regulatory regimes due to increasing complexities of our global operating structure;

 

    greater exposure to the impact of foreign currency changes on our business;

 

    the effect of employment law or regulations or other limitations in foreign jurisdictions that could have an impact on timing, amounts or costs of achieving expected synergies; and

 

    substantial demands on our management as a result of these transactions that may limit their time to attend to other operational, financial, business and strategic issues.

Our integration with acquired businesses has been and will continue to be a complex, time-consuming and expensive process. We cannot assure you that we will be able to successfully integrate these businesses in a timely manner, or at all, or that any of the anticipated benefits from our acquisition of Opnext or previous acquisitions will be realized. There are inherent challenges in integrating the operations of geographically diverse companies. We may have difficulty, and may incur unanticipated expenses related to, integrating management and personnel from our acquisition of Opnext and previously acquired entities with our management and personnel. Our failure to achieve the strategic objectives of our acquisition of Opnext or previous acquisitions could have a material adverse effect on our revenues, expenses and our other operating results and cash resources, and could result in us not achieving the anticipated potential benefits of these transactions. In addition, we cannot assure you that the growth rate of the combined company will equal the historical growth rate experienced by any of the companies that we have acquired including Opnext. Comparable risks would accompany any divestiture of businesses or assets we might undertake.

In addition, even if we successfully integrate the operations of Opnext and other companies that we acquire in the future, we cannot predict with certainty which strategic, financial or operating synergies or other benefits, if any, will actually be achieved from our acquisition, the timing of any such benefits, or whether those benefits which have been achieved will be sustainable on a long-term basis. Our failure to successfully integrate the operations of Opnext would likely have a material and adverse impact on our business, prospects, financial condition and results of operations.

We recently exchanged convertible debt for common stock which diluted our shareholder base and in the future we may need to access the capital markets to raise additional equity.

We may need additional liquidity beyond our current expectations, such as to fund future growth or strengthen our balance sheet or to fund the cost of restructuring activities, and will continue to explore other sources of additional liquidity. These additional sources of liquidity could include one, or a combination, of the following: (i) issuing equity securities, (ii) incurring indebtedness secured by our assets, (iii) issuing debt and/or convertible debt securities, or (iv) selling product lines, other assets and/or portions of our business. There can be no guarantee that we will be able to raise additional funds on terms acceptable to us, or at all.

 

50


Table of Contents

If we raise funds through the issuance of equity, equity-linked or convertible debt securities, our stockholders may be significantly diluted, and these newly-issued securities may have rights, preferences or privileges senior to those of securities held by existing stockholders. If we raise funds through the issuance of debt instruments, the agreements governing such debt instruments may contain covenant restrictions that limit our ability to, among other things: (i) incur additional debt, assume obligations in connection with letters of credit, or issue guarantees; (ii) create liens; (iii) make certain investments or acquisitions; (iv) enter into transactions with our affiliates; (v) sell certain assets; (vi) redeem capital stock or make other restricted payments; (vii) declare or pay dividends or make other distributions to stockholders; and (viii) merge or consolidate with any entity. We cannot assure you that additional financing will be available on terms favorable to us, or at all. If adequate funds are not available or are not available on acceptable terms, if and when needed, our ability to fund our operations, develop or enhance our products, or otherwise respond to competitive pressures and operate effectively could be significantly limited.

We have a complex multinational tax structure, and changes in effective tax rates or adverse outcomes resulting from examination of our income tax returns could adversely affect our results.

We have a complex multinational tax structure with multiple types of intercompany transactions, and our allocation of profits and losses among us and our subsidiaries through our intercompany transfer pricing agreements is subject to review by the Internal Revenue Service and other tax authorities. Our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower statutory rates and higher than anticipated in countries where we have higher statutory rates, by changes in the valuation of our deferred tax assets and liabilities, or by changes in tax laws, regulations, accounting principles or interpretations thereof. In addition, we are also subject to the continuous examination of our income tax returns and related transfer pricing documentation by the Internal Revenue Service and other tax authorities. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There can be no assurance that the outcomes from these continuous examinations will not have an adverse effect on our operating results and financial condition.

Our intellectual property rights may not be adequately protected.

Our future success will depend, in large part, upon our intellectual property rights, including patents, copyrights, design rights, trade secrets, trademarks and know-how. We maintain an active program of identifying technology appropriate for patent protection. Our practice is to require employees and consultants to execute non-disclosure and proprietary rights agreements upon commencement of employment or consulting arrangements. These agreements acknowledge our exclusive ownership of all intellectual property developed by the individuals during their work for us and require that all proprietary information disclosed will remain confidential. Although such agreements may be binding, they may not be enforceable in full or in part in all jurisdictions and any breach of a confidentiality obligation could have a negative effect on our business and our remedy for such breach may be limited.

Our intellectual property portfolio is an important corporate asset. The steps we have taken and may take in the future to protect our intellectual property may not adequately prevent misappropriation or ensure that others will not develop competitive technologies or products. We cannot assure you that our competitors will not successfully challenge the validity of our patents or design products that avoid infringement of our proprietary rights with respect to our technology. There can be no assurance that other companies are not investigating or developing other similar technologies, that any patents will be issued from any application pending or filed by us, or that, if patents are issued, that the claims allowed will be sufficiently broad to deter or prohibit others from marketing similar products. In addition, we cannot assure you that any patents issued to us will not be challenged, invalidated or circumvented, or that the rights under those patents will provide a competitive advantage to us or that our products and technology will be adequately covered by our patents and other intellectual property. Further, the laws of certain regions in which our products are or may be developed, manufactured or sold, including Asia-Pacific, Southeast Asia and Latin America, may not be enforceable to protect our products and intellectual property rights to the same extent as the laws of the United States, the U.K. and continental European countries. This is especially relevant since we have transferred our assembly and test operations and chip-on-carrier operations, including certain engineering-related functions, to Shenzhen, China, and have recently signed an agreement to transition these assembly and test operations to Malaysia.

Opnext has historically relied on Hitachi, one of our major shareholders, for assistance with the research and development efforts related to Opnext’s product portfolio. Any failure of Hitachi to continue to provide these services could have a material adverse effect on our business. Opnext’s product expertise is based on the research ability developed within their Hitachi heritage and through joint research and development in lasers and optical technologies. A key factor to Opnext’s business success and strategy is fundamental laser research. Opnext relied on access to Hitachi’s research laboratories pursuant to a research and development agreement with Hitachi, which includes access to Hitachi’s research facilities and engineers, to conduct research and development activities that are important to the establishment of new technologies and products vital to their current and future business. Should access to Hitachi’s research laboratories become unavailable or available at less attractive terms in the future, this may impede development of new technologies and products, and our financial condition and operating results could be materially adversely affected.

 

51


Table of Contents

We have significant manufacturing and research and development operations in China, which exposes us to risks inherent in doing business in China.

A significant portion of our assembly and test operations, chip-on-carrier operations and manufacturing and supply chain management operations are concentrated in our facility in Shenzhen, China. In addition, we have substantial research and development related activities in Shenzhen, China. To be successful in China we will need to:

 

    qualify our manufacturing lines and the products we produce in Shenzhen, as required by our customers;

 

    attract and retain qualified personnel to operate our Shenzhen facility, even during the transition period to Venture; and

 

    attract and retain research and development employees at our Shenzhen facility.

We cannot assure you that we will be able to do any of these.

Employee turnover in China is high due to the intensely competitive and fluid market for skilled labor. To operate our Shenzhen facility under these conditions, we need to continue to hire direct manufacturing personnel, administrative personnel and technical personnel; obtain and retain required legal authorization to hire such personnel; and incur the time and expense to hire and train such personnel. On March 28, 2012, shortly after announcing the agreement with Venture, certain of our employees in Shenzhen initiated a work stoppage. The work stoppage impacted our Shenzhen manufacturing capabilities temporarily up to and including April 4, 2012. Revenues for the three months ended March 31, 2012 were adversely impacted by approximately $4.0 million due to the work stoppage.

Inflation rates in China are higher than in most jurisdictions in which we operate. We believe that salary inflation rates for the skilled personnel we hire and seek to retain in Shenzhen are likely to be higher than overall inflation rates.

Operations in China are subject to greater political, legal and economic risks than our operations in other countries. In particular, the political, legal and economic climate in China, both nationally and regionally, is fluid and unpredictable. Our ability to operate in China may be adversely affected by changes in Chinese laws and regulations such as those related to, among other things, taxation, import and export tariffs, environmental regulations, land use rights, intellectual property, currency controls, employee benefits and other matters. In addition, we may not obtain or retain the requisite legal permits to continue to operate in China, and costs or operational limitations may be imposed in connection with obtaining and complying with such permits.

We intend to continue to export the products manufactured at our Shenzhen facility. Under current regulations, upon application and approval by the relevant governmental authorities, we will not be subject to certain Chinese taxes and will be exempt from certain duties on imported materials that are used in the manufacturing process and subsequently exported from China as finished products. However, Chinese trade regulations are in a state of flux, and we may become subject to other forms of taxation and duties in China or may be required to pay export fees in the future. In the event that we become subject to new forms of taxation or export fees in China, our business and results of operations could be materially adversely affected. We may also be required to expend greater amounts than we currently anticipate in connection with increasing production at our Shenzhen facility. Any one of the factors cited above, or a combination of them, could result in unanticipated costs or interruptions in production, which could materially and adversely affect our business.

Our products may infringe the intellectual property rights of others, which could result in expensive litigation or require us to obtain a license to use the technology from third parties, or we may be prohibited from selling certain products in the future.

Companies in the industry in which we operate frequently are sued or receive informal claims of patent infringement or infringement of other intellectual property rights. We have, from time to time, received such claims, including from competitors and from companies that have substantially more resources than us.

 

52


Table of Contents

Third parties may in the future assert claims against us concerning our existing products or with respect to future products under development, or with respect to products that we may acquire through acquisitions. We have entered into and may in the future enter into indemnification obligations in favor of some customers that could be triggered upon an allegation or finding that we are infringing other parties’ proprietary rights. If we do infringe a third party’s rights, we may need to negotiate with holders of those rights in order to obtain a license to those rights or otherwise settle any infringement claim. We have from time to time received notices from third parties alleging infringement of their intellectual property and where appropriate have entered into license agreements with those third parties with respect to that intellectual property. Any license agreements that we wish to enter into the future with respect to intellectual property rights may not be available to us on commercially reasonable terms, or at all. We may not in all cases be able to resolve allegations of infringement through licensing arrangements, settlement, alternative designs or otherwise. We may take legal action to determine the validity and scope of the third-party rights or to defend against any allegations of infringement. Holders of intellectual property rights could become more aggressive in alleging infringement of their intellectual property rights and we may be the subject of such claims asserted by a third party. In the course of pursuing any of these means or defending against any lawsuits filed against us, we could incur significant costs and diversion of our resources and our management’s attention. Due to the competitive nature of our industry, it is unlikely that we could increase our prices to cover such costs. In addition, such claims could result in significant penalties or injunctions that could prevent us from selling some of our products in certain markets or result in settlements or judgments that require payment of significant royalties or damages.

We depend on a limited number of suppliers and key contract manufacturers who could disrupt our business if they stopped, decreased, delayed or were unable to meet our demand for shipments of their products or manufacturing of our products.

We depend on a limited number of suppliers of raw materials and equipment used to manufacture our products. We currently also depend on a limited number of contract manufacturers, principally Fabrinet in Thailand, to manufacture certain of our products. We will also increasingly depend on Venture as we transfer our Shenzhen assembly and test operations in a phased and gradual transfer of products to Venture. Some of these suppliers are sole sources. We typically have not entered into long-term agreements with our suppliers other than Fabrinet and Venture, therefore, these suppliers generally may stop supplying us materials and equipment at any time. Our reliance on a sole supplier or limited number of suppliers could result in delivery problems, reduced control over product pricing and quality, and an inability to identify and qualify another supplier in a timely manner. Some of our suppliers that may be small or undercapitalized may experience financial difficulties that could prevent them from supplying us materials and equipment. In addition, our suppliers, including our sole source suppliers, may experience manufacturing delays or shut downs due to circumstances beyond their control such as earthquakes, floods, fires, political unrest or other natural disasters.

Fabrinet’s manufacturing operations are located in Thailand. In October 2011, due to flooding in Thailand, Fabrinet suspended operations at both of their factories that supply us with finished goods. Thailand has also been subject to political unrest in the recent past, including the temporary interruption of service at one of its international airports, and may again experience such political unrest in the future. If Fabrinet is unable to supply us with materials or equipment, or if they are unable to ship our materials or equipment out of Thailand due to future flooding or political unrest, this could materially adversely affect our ability to fulfill customer orders and our results of operations.

Any supply deficiencies relating to the quality or quantities of materials or equipment we use to manufacture our products could materially adversely affect our ability to fulfill customer orders and our results of operations. Lead times for the purchase of certain materials and equipment from suppliers have increased and in some cases have limited our ability to rapidly respond to increased demand, and may continue to do so in the future. To the extent we introduce additional contract manufacturing partners, introduce new products with new partners and/or move existing internal or external production lines to new partners, we could experience supply disruptions during the transition process. In addition, due to our customers’ requirements relating to the qualification of our suppliers and contract manufacturing facilities and operations, we cannot quickly enter into alternative supplier relationships, which prevents us from being able to respond immediately to adverse events affecting our suppliers.

 

53


Table of Contents

Our business and results of operations may continue to be negatively impacted by general economic, financial market conditions and market conditions in the industries in which we operate, and such conditions may increase the other risks that affect our business.

Over the past few years, the world’s financial markets have experienced significant turmoil, resulting in reductions in available credit, increased costs of credit, extreme volatility in security prices, potential changes to existing credit terms, and rating downgrades of investments. In light of these economic conditions, many of our customers reduced their spending plans, leading them to draw down their existing inventory and reduce orders for our products. It is possible that economic conditions could result in further setbacks, and that these customers, or others, could as a result significantly reduce their capital expenditures, draw down their inventories, reduce production levels of existing products, defer introduction of new products or place orders and accept delivery for products for which they do not pay us due to their economic difficulties or other reasons. These conditions have contributed materially and adversely affected the market conditions in the industries in which we operate, and have had a material adverse impact on our revenues. In addition, the financial downturn affected the financial strength of certain of our customers, including their ability to obtain credit to finance purchases of our products, and could adversely affect additional customers in the future. Our suppliers may also be adversely affected by economic conditions that may impact their ability to provide important components used in our manufacturing processes on a timely basis, or at all. To a large degree, orders from our customers are dependent on demand from telecom carrier capital expenditures around the world. The capital expenditure plans and execution by telecom carriers can also be adversely impacted, both in terms of total spend and in determination of areas of investment within network infrastructures, by global and regional macroeconomic conditions.

These conditions could also result in reduced capital resources because of the potential lack of credit availability, higher costs of credit and the stretching of payables by creditors seeking to preserve their own cash resources. We are unable to predict the likely duration, severity and potential continuation of any disruption in financial markets and adverse economic conditions in the U.S. and other countries, but the longer the duration the greater the risks we face in operating our business.

Fluctuations in our operating results could adversely affect the market price of our common stock.

Our revenues and other operating results are likely to fluctuate significantly in the future. The timing of order placement, size of orders and satisfaction of contractual customer acceptance criteria, changes in the pricing of our products due to competitive pressures as well as order or shipment delays or deferrals, with respect to our products, acquisitions and asset sales may cause material fluctuations in revenues. Our lengthy sales cycle, which may extend to more than one year, may cause our revenues and operating results to vary from period to period and it may be difficult to predict the timing and amount of any variation. Delays or deferrals in purchasing decisions by our customers may increase as we develop new or enhanced products for new markets, including data communications, industrial, research, consumer and biotechnology markets. Purchase decisions by our customers are also impacted by the capital expenditure plans of the global telecom carriers, which tend to be the primary customers of our customers. Our current and anticipated future dependence on a small number of customers increases the revenue impact of each such customer’s decision to delay or defer purchases from us, or decision not to purchase products from us. Our expense levels in the future will be based, in large part, on our expectations regarding future revenue sources and, as a result, operating results for any quarterly period in which material orders fail to occur, or are delayed or deferred, could vary significantly.

Because of these and other factors, quarter-to-quarter comparisons of our results of operations may not be indicative of our future performance. In future periods, our results of operations may differ, in some cases materially, from the estimates of public market analysts and investors. Such a discrepancy, or our failure to meet published financial projections, could cause the market price of our common stock to decline.

We may experience low manufacturing yields.

Manufacturing yields depend on a number of factors, including the volume of production due to customer demand and the nature and extent of changes in specifications required by customers for which we perform design-in work. Higher volumes due to demand for a fixed, rather than continually changing, design generally results in higher manufacturing yields, whereas lower volume production generally results in lower yields. In addition, lower yields may result, and have in the past resulted, from commercial shipments of products prior to full manufacturing qualification to the applicable specifications. Changes in manufacturing processes required as a result of changes in product specifications, changing customer needs and the introduction of new product lines have historically caused, and may in the future cause, significantly reduced manufacturing yields, resulting in low or negative margins on those products. Moreover, an increase in the rejection rate of products during the quality control process, before, during or after manufacture, results in lower yields and margins. Finally, manufacturing yields and margins can also be lower if we receive or inadvertently use defective or contaminated materials from our suppliers. Any reduction in our manufacturing yields will adversely affect our gross margins and could have a material impact on our operating results.

 

54


Table of Contents

Sales of our products could decline if customer and/or supplier relationships are disrupted by our recent acquisition or divestiture activities.

Our existing customers, customers of acquired businesses, and/or of predecessor companies, may not continue their historical buying patterns. Customers may defer purchasing decisions as they evaluate our financial strength, the likelihood of successful integration or divestiture of our products and our future product strategy, or consider purchasing products of our competitors.

Customers may also seek to modify or terminate existing agreements, or prospective customers may delay entering into new agreements or purchasing our products or may decide not to purchase any products from us.

Competitive positions in the market, including relative to suppliers who are also competitors, could change as a result of an acquisition or divestiture, and this could impact supplier relationships, including the terms under which we do business with such suppliers.

We sold the Zurich and Amplifier Businesses and may pursue other strategic dispositions or a further reduction in the number of our locations which could be difficult to implement, disrupt our business or further change our business profile significantly.

The sale of the Zurich and Amplifier Businesses, and any future strategic disposition of assets or businesses or reduction in the number of our locations involve numerous risks, including: (i) potential disruption of our ongoing business and distraction of management; (ii) difficulty segregating assets or businesses to be disposed of or consolidated; (iii) exposure to unknown, contingent or other liabilities, including litigation arising in connection with the disposition; (iv) changing our business profile in ways that could have unintended negative consequences; (v) the failure to achieve anticipated benefits, (vi) accounting charges that may affect our financial condition and results of operations; (vii) significant fluctuations in our revenues and operating results; (viii) our ability to support manufacturing services and transition services and the risk to the rest of our business resulting from resources focusing on those services; and (ix) with respect to the sale of the Zurich Business, (A) our ability to support the buyer’s transition from Shenzhen; and (B) the ability of the buyer to supply us with 980 nm pumps. We expect the completion of these asset sales to cause a decrease in our total revenues during fiscal year 2014, which will adversely impact our operating results for this period. Additional asset sales that we may consider in the future could cause us to face similar risks, which could weaken our financial condition and adversely impact our operating results.

Our revenues and operating results are likely to fluctuate significantly as a result of factors that are outside our control.

Our revenues and operating results are likely to fluctuate significantly in the future as a result of factors that are outside our control. The timing of order placement, size of orders and satisfaction of contractual customer acceptance criteria, changes in the pricing of our products due to competitive pressures as well as order or shipment delays or deferrals, with respect to our products, may cause material fluctuations in revenues. Our lengthy sales cycle, which may extend to more than one year, may cause our revenues and operating results to vary from period to period and it may be difficult to predict the timing and amount of any variation. Delays or deferrals in purchasing decisions by our customers may increase as we develop new or enhanced products for new markets, including data communications, industrial, research, consumer and biotechnology markets. Purchase decisions by our customers are also impacted by the capital expenditure plans of the global telecom carriers, which tend to be the primary customers of our customers. Our current and anticipated future dependence on a small number of customers increases the revenue impact of each such customer’s decision to delay or defer purchases from us, or decision not to purchase products from us. For example, during the second half of fiscal 2012, our revenues were adversely impacted by a significant change in demand expectations from a particular major customer. Our expense levels in the future will be based, in large part, on our expectations regarding future revenue sources and, as a result, operating results for any quarterly period in which material orders fail to occur, or are delayed or deferred, could vary significantly. Because our business is capital intensive, significant fluctuations in our revenues, without a corresponding decrease in expenses, can have a significant adverse impact on our operating results.

 

55


Table of Contents

If we fail to attract and retain key personnel, our business could suffer.

Our future success depends, in part, on our ability to attract and retain key personnel. Competition for highly skilled technical personnel is extremely intense and we continue to face difficulty identifying and hiring qualified engineers in many areas of our business. We may not be able to hire and retain such personnel at compensation levels consistent with our existing compensation and salary structure. Our future success also depends on the continued contributions of our executive management team and other key management and technical personnel, each of whom would be difficult to replace. The loss of services of these or other executive officers or key personnel or the inability to continue to attract qualified personnel could have a material adverse effect on our business.

In addition, certain employees of companies we have acquired, including Opnext, that are now employed by us may decide to no longer work for us with little or no notice for a number of reasons, including dissatisfaction with our corporate culture, compensation, and new roles or responsibilities, among others.

If we fail to obtain the right to use the intellectual property rights of others necessary to operate our business, our business and results of operations will be materially and adversely affected.

Certain companies in the telecommunications and optical components markets in which we sell our products have experienced frequent litigation regarding patent and other intellectual property rights. Numerous patents in these industries are held by others, including academic institutions and our competitors. Optical component suppliers may seek to gain a competitive advantage or other third parties, inside or outside our market, may seek an economic return on their intellectual property portfolios by making infringement claims against us. We currently in-license certain intellectual property of third parties, and in the future, we may need to obtain license rights to patents or other intellectual property held by others to the extent necessary for our business. Unless we are able to obtain such licenses on commercially reasonable terms, patents or other intellectual property held by others could be used to inhibit or prohibit our production and sale of existing products and our development of new products for our markets. Licenses granting us the right to use third-party technology may not be available on commercially reasonable terms, or at all. Generally, a license, if granted, would include payments of up-front fees, ongoing royalties or both. These payments or other terms could have a significant adverse impact on our operating results. In addition, in the event we are granted such a license, it is likely such license would be non-exclusive and other parties, including competitors, may be able to utilize such technology. Our larger competitors may be able to obtain licenses or cross-license their technology on better terms than we can, which could put us at a competitive disadvantage. In addition, our larger competitors may be able to buy such technology and preclude us from licensing or using such technology.

We generate a significant portion of our revenues internationally and therefore are subject to additional risks associated with the extent of our international operations.

For fiscal years ended June 29, 2013, June 30, 2012 and July 2, 2011, 13 percent, 18 percent and 17 percent of our revenues, respectively, were derived from sales to customers located in the United States and 87 percent, 82 percent and 83 percent of our revenues, respectively, were derived from sales to customers located outside the United States, including our discontinued operations. We are subject to additional risks related to operating in foreign countries, including:

 

    currency fluctuations, which could result in increased operating expenses and reduced revenues;

 

    greater difficulty in accounts receivable collection and longer collection periods;

 

    difficulty in enforcing or adequately protecting our intellectual property;

 

    ability to hire qualified candidates;

 

    foreign taxes;

 

    political, legal and economic instability in foreign markets;

 

    foreign regulations;

 

    changes in, or impositions of, legislative or regulatory requirements;

 

56


Table of Contents
    trade restrictions, including restrictions imposed by the United States government on trading with parties in foreign countries;

 

    transportation delays;

 

    epidemics and illnesses;

 

    terrorism and threats of terrorism;

 

    work stoppages and infrastructure problems due to adverse weather conditions or natural disasters;

 

    work stoppages related to employee dissatisfaction;

 

    changes in import/export regulations, tariffs, and freight rates; and

 

    the effective protections of, and the ability to enforce, contractual arrangements.

Any of these risks, or any other risks related to our foreign operations, could materially adversely affect our business, financial condition and results of operations.

We have been named as a party to derivative action lawsuits, and we may be named in additional litigation, all of which will require significant management time and attention and result in significant legal expenses and may result in an unfavorable outcome which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

When the market price of a stock experiences a sharp decline, as our stock price recently has, holders of that stock have often brought securities class action litigation against the company that issued the stock. Several securities class action lawsuits have been filed against us and certain of our current and former officers and directors. Other class action lawsuits have been initiated against Opnext, us and certain of our respective current and former officers and directors as purported derivative actions. The securities class action complaints allege violations of section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the Securities and Exchange Commission. Each purported derivative complaint alleges, among other things, counts for breaches of fiduciary duty, waste, and unjust enrichment. For a description of these lawsuits, see Part II, Item 1 – Legal Proceedings of this Quarterly Report on Form 10-Q. These lawsuits will likely divert the time and attention of our management and cause us to incur significant expense in defending against the litigation. In addition, if these suits are resolved in a manner adverse to us, the damages we could be required to pay may be substantial and could have an adverse impact on our results of operations and our ability to operate our business.

We may face product liability claims.

Despite quality assurance measures, defects may occur in our products. The occurrence of any defects in our products could give rise to liability for damages caused by such defects, including consequential damages. Such defects could, moreover, impair market acceptance of our products. Both could have a material adverse effect on our business and financial condition. In addition, we may assume product warranty liabilities related to companies we acquire, which could have a material adverse effect on our business and financial condition. In order to mitigate the risk of liability for damages, we carry product liability insurance with a $25.0 million aggregate annual limit and errors and omissions insurance with a $5.0 million annual limit. We cannot assure you that this insurance would adequately cover our costs arising from any defects in our products or otherwise.

At times, the market price of our common stock has fluctuated significantly.

The market price of our common stock has been, and is likely to continue to be, highly volatile. For example, between July 1, 2012 and June 29, 2013, the market price of our common stock ranged from a low of $0.99 per share to a high of $3.19 per share. Many factors could cause the market price of our common stock to rise and fall.

 

57


Table of Contents

In addition to the matters discussed in other risk factors included in our public filings, some of the events that could impact our stock price are:

 

    fluctuations in our results of operations, including our gross margins;

 

    changes in our business, operations or prospects;

 

    hiring or departure of key personnel;

 

    new contractual relationships with key suppliers or customers by us or our competitors;

 

    proposed acquisitions and dispositions by us or our competitors;

 

    financial results or projections that fail to meet public market analysts’ expectations and changes in stock market analysts’ recommendations regarding us, other optical technology companies or the telecommunication industry in general;

 

    future sales of common stock, or securities convertible into, exchangeable or exercisable for common stock;

 

    adverse judgments or settlements obligating us to pay damages;

 

    future issuances of common stock in connection with acquisitions or other transactions;

 

    acts of war, terrorism, or natural disasters;

 

    industry, domestic and international market and economic conditions, including the global macroeconomic downturn over the last three years and related sovereign debt issues in certain parts of the world;

 

    low trading volume in our stock;

 

    developments relating to patents or property rights; and

 

    government regulatory changes.

In connection with our acquisition of Xtellus, during the first quarter of fiscal year 2012 we issued 0.9 million shares of our common stock to settle our escrow liability. In connection with our acquisition of Mintera, during the second quarter of fiscal year 2012, we issued 0.8 million shares of our common stock to pay portions of the 12 month earnout obligations. In connection with our acquisition of Opnext, during the first quarter of fiscal year 2013, we issued 38.4 million shares of our common stock. In addition, during the second quarter of fiscal year 2014, we issued 13.5 million shares of our common stock in connection with the exercise of the Convertible Notes. In May 2013, we also issued 1.8 million warrants to purchase our common stock at an exercise price of $1.50 per share in connection with the Term Loan we received in May 2013 (See Note 7, Credit Line and Notes elsewhere in this Quarterly Report on Form 10-Q for further details). These issuances and the subsequent sale of these shares will dilute our existing stockholders and could potentially have a negative impact on our stock price.

Our shares of common stock have experienced substantial price and volume fluctuations, in many cases without any direct relationship to our operating performance. An outgrowth of this market volatility is the significant vulnerability of our stock price to any actual or perceived fluctuation in the strength of the markets we serve, regardless of the actual consequence of such fluctuations. As a result, the market price for our stock is highly volatile. These broad market and industry factors have caused the market price of our common stock to fluctuate, and may in the future cause the market price of our common stock to fluctuate, regardless of our actual operating performance.

We are not restricted from issuing additional shares of our common stock, including securities that are convertible into or exchangeable for, or that represent the right to receive, shares of our common stock. Issuances of shares of our common stock or convertible securities, including outstanding options and warrants, will dilute the ownership interest of our stockholders.

 

58


Table of Contents

Because we do not intend to pay dividends, stockholders will benefit from an investment in our common stock only if it appreciates in value.

We have never declared or paid any dividends on our common stock. We anticipate that we will retain any future earnings to support operations and to finance the development of our business and do not expect to pay cash dividends in the foreseeable future. As a result, the success of an investment in our common stock will depend entirely upon any future appreciation in its value. There is no guarantee that our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

We are subject to anti-corruption laws in the jurisdictions in which we operate, including the U.S. Foreign Corrupt Practices Act, or the FCPA. Our failure to comply with these laws could result in penalties which could harm our reputation and have a material adverse effect on our business, results of operations and financial condition.

We are subject to the FCPA, which generally prohibits companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or keeping business and/or other benefits, along with various other anticorruption laws. Although we have implemented policies and procedures designed to ensure that we, our employees and other intermediaries comply with the FCPA and other anticorruption laws to which we are subject, there is no assurance that such policies or procedures will work effectively all of the time or protect us against liability under the FCPA or other laws for actions taken by our employees and other intermediaries with respect to our business or any businesses that we may acquire. We have manufacturing operations in China and other jurisdictions, many of which pose elevated risks of anti-corruption violations, and we export our products for sale internationally. This puts us in frequent contact with persons who may be considered “foreign officials” under the FCPA, resulting in an elevated risk of potential FCPA violations. If we are not in compliance with the FCPA and other laws governing the conduct of business with government entities (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Any investigation of any potential violations of the FCPA or other anticorruption laws by U.S. or foreign authorities could harm our reputation and have an adverse impact on our business, financial condition and results of operations.

Litigation may substantially increase our costs and harm our business.

We are a party to numerous lawsuits and will continue to incur legal fees and other costs related thereto, including potentially expenses for the reimbursement of legal fees of officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. In addition, there can be no assurance that we will be successful in any defense. Further, the amount of time that will be required to resolve these lawsuits is unpredictable and these actions may divert management’s attention from the day-to-day operations of our business, which could adversely affect our business, results of operations and cash flows. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters that may arise from time to time could have a material adverse effect on our business, results of operations and financial condition.

For a description of our current material litigation, see Part II, Item 1 – Legal Proceedings of this Quarterly Report on Form 10-Q.

In addition, from time to time, we have been a party to certain intellectual property infringement litigation as more fully described above under “Risks Related to Our Business — Our products may infringe the intellectual property rights of others, which could result in expensive litigation or require us to obtain a license to use the technology from third parties, or we may be prohibited from selling certain products in the future .”

The inability to obtain government licenses and approvals for desired international trading activities or technology transfers may prevent the profitable operation of our business.

Many of our present and future business activities are subject to licensing by the United States government under the Export Administration Act, the Export Administration Regulations and other laws, regulations and requirements governing international trade and technology transfer. We presently manufacture products in China and Thailand that require such licenses. The profitable operations of our business may require the continuity of these licenses and may require further licenses and approvals for future products in these and other countries. However, there is no certainty to the continuity of these licenses, nor that further desired licenses and approvals may be obtained.

 

59


Table of Contents

Prior to our acquisition of Opnext, Opnext licensed its intellectual property to Hitachi and its wholly owned subsidiaries without restriction. In addition, Hitachi is free to license certain of Hitachi’s intellectual property that Opnext used in its business to any third party, including competitors, which could harm our business and operating results.

Opnext was initially created as a stand-alone entity by acquiring certain assets of Hitachi through various transactions. In connection with these transactions, Opnext acquired a number of patents and know-how from Hitachi, but also granted Hitachi and its wholly owned subsidiaries a perpetual right to continue to use those patents and know-how, as well as other patents and know-how that Opnext developed during a period which ended in July 2011 (or October 2012 in certain cases). This license back to Hitachi is broad and permits Hitachi to use this intellectual property for any products or services anywhere in the world, including licensing this intellectual property to our competitors.

Additionally, while significant intellectual property owned by Hitachi was assigned to Opnext when Opnext was formed, Hitachi retained and only licensed to Opnext the intellectual property rights to underlying technologies used in both Opnext products and the products of Hitachi. Under the agreement, Hitachi remains free to license these intellectual property rights to the underlying technologies to any party, including competitors. The intellectual property that has been retained by Hitachi and that can be licensed in this manner does not relate solely or primarily to one or more of Opnext’s products, or groups of products; rather, the intellectual property that is licensed to Opnext by Hitachi is generally used broadly across Opnext’s entire product portfolio. Competition by third parties using the underlying technologies retained by Hitachi could harm the Opnext business, financial condition and results of operations.

We may record additional impairment charges that will adversely impact our results of operations.

As of December 28, 2013, we had $9.2 million in other intangible assets on our condensed consolidated balance sheet. If we make changes in our business strategy or if market or other conditions adversely affect our business operations, we may be forced to record an impairment charge related to these assets, which would adversely impact our results of operations. If impairment has occurred, we will be required to record an impairment charge for the difference between the carrying value of the other intangible assets and the implied fair value of the other intangible assets in the period in which such determination is made. The testing of other intangible assets for impairment requires us to make significant estimates about the future performance and cash flows of our business, as well as other assumptions. These estimates can be affected by numerous factors, including changes in economic, industry, or market conditions, changes in underlying business operations, future reporting unit operating performance, changes in competition, or changes in technologies. Any changes in key assumptions, or actual performance compared with those assumptions, about our business and its future prospects or other assumptions could affect the fair value of one or more reporting units, and result in an impairment charge.

During the fourth quarter of fiscal year 2013 we completed our annual analysis for potential impairment of our goodwill, which included examining the impact of current general economic conditions on our future prospects and the current level of our market capitalization. Based on this analysis, we determined that the goodwill related to our Mintera reporting unit was fully impaired. This resulted in a $10.9 million impairment charge in our statement of operations for fiscal year 2013. In addition, during the first quarter of fiscal year 2013, we recorded $0.9 million in impairment charges related to the impairment of certain technology that is now considered redundant following the acquisition of Opnext. In the fourth quarter of fiscal year 2013, we recorded an additional $13.7 million impairment charge related to the impairment of intangible assets related to certain technologies and we recorded impairment charges of $1.7 million related to other long-lived assets.

Uncertainties associated with the sale of the Zurich and Amplifier Businesses may cause us to lose employees, customers and business partners.

Our current and prospective employees, customers and business partners may be uncertain about their future roles and relationships with us following the completion of the sale of the Zurich and Amplifier Businesses. This uncertainty may adversely affect our ability to attract and retain key management and employees, customers and business partners.

A lack of effective internal control over our financial reporting could result in an inability to report our financial results accurately, which could lead to a loss of investor confidence in our financial reports and have an adverse effect on our stock price.

In connection with establishing the fair values of certain assets and liabilities associated with our acquisition of Opnext, we identified a material weakness over controls related to our recording of the purchase under Accounting Standards Codification Topic 805, Business Combinations . In the fourth quarter of fiscal year 2013, we made adjustments to the fair value of certain items, including property and equipment, capital leases and intangible assets. As a result of these adjustments, management concluded that we did not maintain effective internal control over financial reporting as of June 29, 2013, because the potential impact of these adjustments could have been material to our financial position and results of operations. As of December 28, 2013, we continue to implement remediation efforts.

 

60


Table of Contents

In addition, in April 2012, in connection with the restatement of our previously issued consolidated financial statements as of and for the quarters ended March 31, 2012 and October 1, 2011, our management re-evaluated the effectiveness of our disclosure controls and procedures. As a result of that re-evaluation, our management determined that a material weakness existed in our internal controls over financial reporting such that our disclosure controls and procedures related to accounting for income taxes were not effective as of March 31, 2012 and October 1, 2011. During the three months ended March 31, 2012, we implemented enhancements to our internal controls over financial reporting, including adding additional monitoring controls over the preparation and filing of foreign income tax returns. Our remediation efforts, including the testing of these controls continued throughout our fiscal year 2012. The material weakness related to the preparation and filing of foreign income taxes was considered remediated in the fourth quarter of fiscal year 2012, once these controls were shown to be operational for a sufficient period of time to allow management to conclude that these controls were operating effectively.

We cannot assure you that similar material weaknesses will not recur. If additional material weaknesses or significant deficiencies in our internal control are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed. Our failure to implement and maintain effective internal control over financial reporting could result in a material misstatement of our financial statements or otherwise cause us to fail to meet our financial reporting obligations. This, in turn, could result in a loss of investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on our business, financial condition, operating results and our stock price, and we could be subject to stockholder litigation as a result. Even if we are able to implement and maintain effective internal control over financial reporting, the costs of doing business may increase and our management may be required to dedicate greater time and resources to that effort. In addition, we have in the past, and may in the future, acquire companies that have either experienced material weaknesses in their internal controls over financial reporting or have had no previous reporting obligations under Sarbanes-Oxley. Failure to integrate acquired businesses into our internal controls over financial reporting could cause those controls to fail.

Our business and operating results may be adversely affected by natural disasters or other catastrophic events beyond our control.

Our business and operating results are vulnerable to natural disasters, such as earthquakes, fires, tsunami, volcanic activity and floods, as well as other events beyond our control such as power loss, telecommunications failures and uncertainties arising out of terrorist attacks in the United States and armed conflicts overseas. For example, in the latter three quarters of fiscal year 2012, our results of operations were materially and adversely impacted by the flooding in Thailand. Additionally, our corporate headquarters and a portion of our research and development and manufacturing operations are located in Silicon Valley, California, and select manufacturing facilities are located in Japan. These regions in particular have been vulnerable to natural disasters, such as earthquakes and tsunamis. The occurrence of any of these events could pose physical risks to our property and personnel, which may adversely affect our ability to produce and deliver products to our customers. Although we presently maintain insurance against certain of these events, we cannot be certain that our insurance will be adequate to cover any damage sustained by us or by our customers.

 

61


Table of Contents

Our business involves the use of hazardous materials, and we are subject to environmental and import/export laws and regulations that may expose us to liability and increase our costs.

We handle hazardous materials as part of our manufacturing activities. Consequently, our operations are subject to environmental laws and regulations governing, among other things, the use and handling of hazardous substances and waste disposal. We may incur costs to comply with current or future environmental laws. As with other companies engaged in manufacturing activities that involve hazardous materials, a risk of environmental liability is inherent in our manufacturing activities, as is the risk that our facilities will be shut down in the event of a release of hazardous waste, or that we would be subject to extensive monetary liabilities. The costs associated with environmental compliance or remediation efforts or other environmental liabilities could adversely affect our business. Under applicable European Union regulations, we, along with other electronics component manufacturers, are prohibited from using lead and certain other hazardous materials in our products. We could lose business or face product returns if we fail to maintain these requirements properly.

In addition, the sale and manufacture of certain of our products require on-going compliance with governmental security and import/export regulations. We may, in the future, be subject to investigation which may result in fines for violations of security and import/export regulations. Furthermore, any disruptions of our product shipments in the future, including disruptions as a result of efforts to comply with governmental regulations, could adversely affect our revenues, gross margins and results of operations.

The new disclosure requirements related to the “conflict minerals” provision of the Dodd-Frank Act may limit our supply and increase our costs for certain metals used in our products and could affect our reputation with customers or shareholders.

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (Dodd-Frank Act), the Securities and Exchange Commission (SEC) adopted a new rule requiring public companies to disclose the use of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured. The new rule, which went into effect for calendar year 2013 and requires a disclosure report to be filed with the SEC by May 31, 2014, will require companies to perform due diligence, disclose and report whether or not such minerals originate from the Democratic Republic of Congo (DRC) or an adjoining country. The new rule could affect sourcing at competitive prices and availability in sufficient quantities of certain minerals used in the manufacturing of our products. The number of suppliers who provide conflict-free minerals may be limited. In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to the due diligence process of determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities. As our supply chain is complex and we use contract manufacturers for some of our products, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. If we cannot determine that our products exclude conflict minerals sourced from the DRC or adjoining countries, some of our customers may discontinue, or materially reduce, purchases of our products, which could negatively affect our results of operations.

We can issue shares of preferred stock that may adversely affect your rights as a stockholder of our common stock.

Our certificate of incorporation authorizes us to issue up to 1.0 million shares of preferred stock with designations, rights and preferences determined from time-to-time by our board of directors. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of holders of our common stock. For example, an issuance of shares of preferred stock could:

 

    adversely affect the voting power of the holders of our common stock;

 

    make it more difficult for a third-party to gain control of us;

 

    discourage bids for our common stock at a premium;

 

    limit or eliminate any payments that the holders of our common stock could expect to receive upon our liquidation; or

 

    otherwise adversely affect the market price of our common stock.

We may in the future issue shares of authorized preferred stock at any time.

 

62


Table of Contents

Delaware law and our charter documents contain provisions that could discourage or prevent a potential takeover, even if such a transaction would be beneficial to our stockholders.

Some provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, may discourage, delay or prevent a merger or acquisition that a stockholder may consider favorable. These include provisions:

 

    authorizing the board of directors to issue preferred stock;

 

    prohibiting cumulative voting in the election of directors;

 

    limiting the persons who may call special meetings of stockholders;

 

    prohibiting stockholder actions by written consent;

 

    creating a classified board of directors pursuant to which our directors are elected for staggered three-year terms;

 

    permitting the board of directors to increase the size of the board and to fill vacancies;

 

    requiring a super-majority vote of our stockholders to amend our bylaws and certain provisions of our certificate of incorporation; and

 

    establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.

We are subject to the provisions of Section 203 of the Delaware General Corporation Law which limit the right of a corporation to engage in a business combination with a holder of 15 percent or more of the corporation’s outstanding voting securities, or certain affiliated persons. We do not currently have a stockholder rights plan in place.

Although we believe that these charter and bylaw provisions, and provisions of Delaware law, provide an opportunity for the board to assure that our stockholders realize full value for their investment, they could have the effect of delaying or preventing a change of control, even under circumstances that some stockholders may consider beneficial.

ITEM 6. EXHIBITS

The exhibits filed as part of this Quarterly Report on Form 10-Q, or incorporated by reference, are listed on the Exhibit Index immediately preceding such exhibits, which Exhibit Index is incorporated herein by reference.

 

63


Table of Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

     

OCLARO, INC.

(Registrant)

Date: February 6, 2014       By:  

/s/ G REG D OUGHERTY

 
       

Greg Dougherty

Chief Executive Officer

(Principal Executive Officer)

 
Date: February 6, 2014       By:  

/s/ P ETE M ANGAN

 
       

Pete Mangan

Chief Financial Officer

(Principal Financial Officer)

 

 

64


Table of Contents

EXHIBIT INDEX

 

Exhibit
Number

 

Description of Exhibit

  2.1   Agreement and Plan of Merger dated March 26, 2012, among Oclaro, Inc., Tahoe Acquisition Sub, Inc. and Opnext, Inc. (previously filed as Exhibit 2.1 to Registrant’s Current Report on Form 8-K filed on March 26, 2012 and incorporated herein by reference.)
  2.2   Agreement of Merger among: Oclaro, Inc., a Delaware corporation; Nikko Acquisition Corp., a Delaware corporation; Mintera Corporation, a Delaware corporation; and Shareholder Representative Services LLC, as the Stockholders’ Agent. Dated as of July 20, 2010 (previously filed as Exhibit 2.1 to Registrant’s Current Report on Form 8-K filed on July 26, 2010 and incorporated herein by reference.)
  2.3   Agreement of Merger among: Oclaro, Inc., a Delaware corporation; Rio Acquisition corp., a Delaware corporation; Xtellus Inc., a Delaware corporation; and Alta Berkeley LLP, as the Stockholders’ Agent. Dated as of December 16, 2009 (previously filed as Exhibit 2.1 to Registrant’s Current Report on Form 8-K filed on December 22, 2009 and incorporated herein by reference.)
  3.1   Amended and Restated Bylaws of Oclaro, Inc., including Amendments No. 1 and No. 2 thereto (formerly Bookham, Inc.) (previously filed as Exhibit 3.1 to Registrant’s Registration Statement on Form S-8 dated May 5, 2009 and incorporated herein by reference.)
  3.2   Amendment No. 3 to Amended and Restated By-Laws of Oclaro, Inc. (previously filed as Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed on July 28, 2011 and incorporated herein by reference.)
  3.3   Restated Certificate of Incorporation of Oclaro, Inc. (previously filed as Exhibit 3.2 to Registrant’s Annual Report on Form 10-K filed on September 1, 2010 and incorporated herein by reference.)
  3.4   Certificate of Amendment to Restated Certificate of Incorporation of Oclaro, Inc. (previously filed as Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed on July 27, 2012 and incorporated herein by reference.)
  4.1   Indenture, dated December 14, 2012, entered into by Oclaro, Inc., Oclaro Luxembourg S.A., certain of Oclaro, Inc.’s domestic and foreign subsidiaries and Wells Fargo Bank, National Association (previously filed as Exhibit 4.1 to Registrant’s Quarterly Report on Form 10-Q/A filed on February 15, 2013 and incorporated herein by reference.)
  4.2   Form of Warrant Certificate dated May 6, 2013 (previously filed as Exhibit 4.2 to Registrant’s Annual Report on 10-K filed on September 27, 2013 and incorporated herein by reference.)
10.1(1)(2)   Confidential Separation Agreement and Release of Claims, dated November 7, 2013, between Oclaro, Inc. and Jerry Turin.
10.2(1)(2)   Confidential Separation Agreement and Release of Claims, dated January 9, 2014, between Oclaro, Inc. and Catherine Rundle.
10.3(2)   Oclaro, Inc. Fourth Amended and Restated 2001 Long-Term Stock Incentive Plan (previously filed as Annex A to our Proxy Statement for our 2013 Annual Meeting of Stockholders on November 26, 2013 and incorporated herein by reference.)
10.4(1)(2)   Offer Letter of Adrian Meldrum, Executive Vice President Worldwide Sales, dated October 16, 2013.
10.5(1)(2)   Contract of Employment, dated November 18, 2013, between Oclaro Technology Limited and Adrian Meldrum.
10.6(1)(2)   Executive Severance and Retention Agreement, dated November 18, 2013, between Oclaro Technology Limited and Adrian Meldrum.
10.7(1)(2)   Offer Letter of David L. Teichmann, Executive Vice President, General Counsel and Corporate Secretary, dated December 5, 2013.


Table of Contents
  10.8 (1)(2)   Executive Severance and Retention Agreement, dated January 1, 2014, between Oclaro, Inc. and David L. Teichmann.
  31.1(1)   Certification of Chief Executive Officer Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002
  31.2(1)   Certification of Chief Financial Officer Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002
  32.1(1)   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350
  32.2(1)   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

(1) Filed herewith.
(2) Management contract or compensatory plan or arrangement.

Exhibit 10.1

CONFIDENTIAL SEPARATION AGREEMENT

AND RELEASE OF CLAIMS

This Confidential Separation Agreement and Release of Claims (the “Agreement”) is entered into as of this 7th day of November, 2013 by and between Oclaro, Inc., a Delaware corporation (“Company”) and Jerry Turin (“Executive”). Company and Executive are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” This Agreement was originally provided to Executive for his review on October 17, 2013.

RECITALS

A. Executive currently serves as the Chief Financial Officer.

B. Company and Executive are parties to that certain Executive Severance and Retention Agreement dated January 1, 2012 (the “ESRA”). The ESRA provides severance under certain circumstances in the event Executive ceases to be an employee of Company. The execution of this Agreement is a condition to Executive’s receipt of the severance benefits under the ESRA.

C. Effective as of the Termination Date (defined below), the Parties hereto desire to terminate Executive’s employment with Company. This Agreement sets forth the terms and conditions in connection therewith.

NOW, THEREFORE, in consideration of the foregoing facts and the promises, covenants and releases, representations and warranties contained in this Agreement, the Parties hereto agree as follows:

1. Termination November 8, 2013 will be Executive’s last day of employment with the Company (the “Termination Date”). Effective as of the Termination Date, Executive shall no longer be employed by the Company or any of its subsidiaries. Whether or not Executive timely revokes this Agreement (as described in Section 20(6) below), on the last day of Executive’s employment, he will receive payment for all salary, draws and unused vacation pay owed to him through the Termination Date.

2. Benefits Executive’s group medical insurance benefits will end on the last day of the month in which his employment ended. Regardless of signing this Agreement, Executive may elect to continue receiving group medical insurance pursuant to the federal “COBRA” law, 29 U.S.C. § 1161 et seq . All premium costs shall be paid by Executive on a monthly basis for as long as, and to the extent that, Executive remains eligible for COBRA continuation coverage. Executive should consult the COBRA materials to be provided by the Company for details regarding COBRA continuation benefits. All other benefits will end on the Termination Date.

3. Stock Options Vesting of Executive’s stock options will end on the Termination Date pursuant to the Company’s 2004 Stock Plan (the “Plan”). Regardless of signing this Agreement, pursuant to the Plan, Executive will have up to ninety (90) days after the Termination Date to exercise any vested stock options Executive may have (as provided for by the Plan). If Executive does not timely exercise his vested options, and properly follow the required procedures, Executive’s vested options will expire and cannot be reinstated. Executive should consult his Stock Option Agreement regarding his obligations to exercise his vested options. All of the terms, conditions and limitations of the Stock Option Agreement will remain in full force and effect. All unvested stock rights will be cancelled on the Termination Date.


4. Severance Provided that Executive signs this Agreement within twenty-one (21) days after the Termination Date and does not revoke this Agreement, and in no event on a date earlier than the date seven (7) days after the date Executive signs and returns this Agreement, Company will provide Executive with the severance benefits described in Attachment “A” within 30 days following the Termination Date. If Executive does not sign this Agreement or signs and revokes this Agreement within such seven (7) day time period, this Agreement will become null and void. Executive acknowledges that Company’s payment of the severance benefits described in Attachment “A” shall satisfy all of Company’s severance payment obligations described in the ESRA and that this Agreement is intended to be an amendment of the ERSA as contemplated by Section 9.12 of the ERSA. In the event of any inconsistency between terms and provisions of the severance benefits in the ESRA and those of this Section 4, the terms and provisions of this Section 4 shall control. By signing and returning this Agreement, Executive will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in this Agreement, including without limitation, the release of claims set forth in Section 5 below.

5. Release and 1542 General Release In consideration for Company’s agreement to pay Executive the severance benefits pursuant to Section 4 above, Executive hereby fully, forever, irrevocably and unconditionally releases and discharges the Company, its officers, directors, stockholders, corporate affiliates, subsidiaries, parent companies, agents and employees (each in their individual and corporate capacities) (hereinafter the “Released Parties”) from any and all claims, charges, complaints, demands, causes of action, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that Executive ever had or now may have against the Released Parties, including, but not limited to, any arising out of his employment with and/or separation from the Company, including, but not limited to, all employment discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq ., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq ., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq ., the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq ., the California Fair Employment and Housing Act, Cal. Gov’t Code § 12900 et seq ., the California Family Rights Act, Cal. Gov’t Code § 12945.2 and § 19702.3, the California Equal Pay Law, Cal. Labor Code § 1197.5 et seq ., the California Unruh Civil Rights Act, Cal. Civil Code § 51 et seq . and the California Family and Medical Leave Law, Cal. Labor Code §§ 233, 7291.16 and 7291.2, all as amended, and all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq . and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq ., all as amended, and all common law claims including, but not limited to, actions in tort, defamation and breach of contract, all claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options, and any claim or damage arising out of his employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided , however , that nothing in this Agreement prevents him from filing, cooperating with, or participating in any proceeding before the EEOC or a state Fair Employment Practices Agency (except that Executive acknowledges that he may not be able to recover any monetary benefits in connection with any such claim, charge or proceeding).

 

2


Executive understands and agrees that the claims released in this Section 5 include not only claims presently known to him, but also include all unknown or unanticipated claims, rights, demands, actions, obligations, liabilities, and causes of action of every kind and character that would otherwise come within the scope of the released claims as described in this Section 5. Executive understands that he may hereafter discover facts different from what he now believes to be true, which if known, could have materially affected this Agreement, but he nevertheless waives any claims or rights based on different or additional facts. Executive knowingly and voluntarily waives any and all rights or benefits that he may now have, or in the future may have, under the terms of Section 1542 of the Civil Code of the State of California and under any similar statute of any other state. Section 1542 of the Civil Code of the State of California provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH A CREDITOR DOES NOT KNOW OF OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

Notwithstanding the foregoing, to the extent Executive is entitled to indemnification under that certain Indemnification Agreement dated August 1, 2008 by and between Company and Executive, the releases and waivers set forth in this Agreement do not excuse and shall not apply to Company’s obligations benefiting Executive to which Executive might otherwise be entitled to under such Indemnification Agreement.

6. Confidential Information

(a) Company Information . Executive acknowledges that during his employment with Company he received Confidential Information and Third Party Information as those terms are defined below. Executive represents that at all times during the term of his employment he held in strictest confidence, and did not use, except for the benefit of the Company as authorized by the Board of Directors of the Company, any Confidential Information of the Company. Executive agrees that he will continue to keep confidential and not to use for the benefit of any person or entity all non-public information about the Company or third parties that he acquired during the course of his employment with the Company, including without limitation any Confidential Information or Third Party Information. Executive acknowledges that “Confidential Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer lists and customers (including, but not limited to, customers of the Company on whom Executive called or with whom Executive became acquainted during the term of his employment), markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances or other business information disclosed to Executive by the Company either directly or indirectly in writing, orally or by drawings or observation of parts or equipment. Executive further acknowledges that Confidential Information does not include any of the foregoing items, which have become publicly known and made generally available through no wrongful act of Executive or of others who were under confidentiality obligations as to the item or items involved or improvements or new versions thereof.

 

3


(b) Third Party Information . Executive acknowledges that the Company has received from third parties their confidential or proprietary information subject to a duty on the part of the Company to maintain the confidentiality of such information (“Third Party Information”). Executive represents that he has held all such confidential or proprietary information in the strictest confidence and agrees not to disclose any Third Party Information to any person, firm or corporation or to use it.

(c) Obligation of Confidentiality . Nothing in this Agreement is intended to waive or release Executive from any and all obligations to Company under any confidentiality, proprietary information or non-disclosure agreement, or any obligation created by statutory or common law to protect any intellectual property or proprietary information of Company.

7. Intellectual Property

(a) Intellectual Property Retained and Licensed. Executive represents that prior to his employment with Company, he did not own and did not have an interest in any inventions, original works of authorship, developments, improvements, or trade secrets which relate to the business of the Company, products or research and development. Notwithstanding the foregoing, if during the course of his employment with the Company, he incorporated into a Company product, process or machine any invention, original work of authorship, development, improvement, or trade secret which were made by him prior to his employment with the Company (collectively referred to as “Prior Intellectual Property”) in which he owns or has an interest in, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Intellectual Property as part of or in connection with such product, process or machine.

(b) Assignment of Intellectual Property . Executive hereby assigns to the Company, or its designee, all his rights, title, and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, discoveries, ideas, trademarks or trade secrets, whether or not patentable or registrable under copyright or similar laws, which he may have solely or jointly conceived or developed or reduced to practice, or caused to be conceived or developed or reduced to practice, during the period of time he was employed by the Company (collectively referred to as “Intellectual Property”). Executive acknowledges that all original works of authorship which were made by him (solely or jointly with others) within the scope of and during the period of his employment with the company and which are protectable by copyright are “works made for hire”, as that term is defined in the United States Copyright Act. Executive understands and agrees that the decision whether or not to commercialize or market any invention developed by him (solely or jointly with others) is within the sole discretion of the Company and for the sole benefit of the Company and that no royalty will be due to him as a result of the efforts to commercialize or market any such invention by the Company.

 

4


(c) Exception to Assignments . Executive acknowledges that the provisions of this Agreement requiring assignment of Intellectual Property to the Company do not apply to any invention which qualifies fully under the provisions of California Labor Code Section 2870. Executive represents that he is not aware of any inventions that he believes meet the criteria in California Labor Code Section 2870.

8. Solicitation

(a) As a result of Executive’s access to and knowledge of Company’s Confidential Information, pursuant to Section 3.2 of the ESRA and as a condition to receipt of the severance benefits provided for in Section 4 above, Executive agrees that for a period of twelve (12) months immediately following the Termination Date, he will not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees to leave their employment, or take away such employees, or attempt to solicit, induce recruit, encourage or take away employees of the Company, for himself or for any other person or entity.

(b) As a result of Executive’s access to and knowledge of Company’s Confidential Information, pursuant to Section 3.2 of the ESRA and as a condition to receipt of the severance benefits provided for in Section 4 above (and Attachment “A”), Executive also agrees that for a period of six (6) months immediately following the Termination Date, he will not either directly or indirectly solicit or cause to be solicited any customers of Company for any purpose.

9. Return of Company Property Executive hereby confirms that he has returned to the Company in good working order all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones and pagers), access or credit cards, Company identification, Company vehicles and any other Company-owned property in his possession or control, has left intact all electronic Company documents, including, but not limited to, those that he developed or helped to develop during his employment, and has retained no copies (either paper or electronically stored or created) of any Confidential Information or Third Party Information in his possession, control or in a manner that would be retrievable by him following his separation from employment. Executive further confirms that he has cancelled all accounts for his benefit, if any, in the Company’s name, including, but not limited to, credit cards, telephone charge cards, cellular phone and/or pager accounts and computer accounts.

10. Business Expenses and Compensation Executive acknowledges that he has been reimbursed by the Company for all business expenses incurred in conjunction with the performance of his employment and that no other reimbursements are owed to him. Executive further acknowledge that he has received payment in full for all services rendered in conjunction with his employment by the Company and that no other compensation, including wages, draws, payment for accrued but unused vacation time or severance payments or benefits pursuant to any plan, policy or practice, is owed to him, with the exception of the severance benefits detailed in Attachment “A” hereto.

 

5


11. Tax Reporting; Disclaimer of Tax Advice Executive acknowledges and agrees that Company, and its respective agents, representatives, employees and attorneys, have made no representations to him regarding the tax consequences of any amounts received pursuant to this Agreement. Executive acknowledges and agrees that he is solely and individually responsible for his own tax reporting, payments and liabilities and if the tax characterization with regard to any amounts received pursuant to this Agreement is challenged by any governmental taxing authority, he shall indemnify, hold harmless and defend Company, and any attorney, agent or employee thereof, from any and all claim, tax liability, related interest or penalties, costs and expenses, including attorneys’ fees, caused by or which may be levied upon the Company as a result of the payment of any amounts paid by the Company under this Agreement. The Parties further agree that the terms of this Agreement are not contingent upon any particular tax characterization of the payment described in this Agreement. Executive agrees that neither the Company (or any agent, representative, employee or attorney thereof) has any duty to defend against any tax claim, levy or assessment, whether or not such tax claim, levy or assessment is based on existing tax law and regulations or as such laws or regulations may in the future be amended, or interpreted by the taxing authorities.

12. Non-Disparagement Executive understands and agrees that he shall not make any false, disparaging or derogatory statements to any media outlet, industry group, financial institution or current or former employee, consultant, client, customer of the Company or other person or entity regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company’s business affairs and financial condition.

13. Amendment This Agreement shall be binding upon the Parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the Parties hereto. This Agreement is binding upon and shall inure to the benefit of the Parties and their respective agents, assigns, heirs, executors, successors and administrators.

14. Waiver of Rights No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.

15. Validity Should any provision of this Agreement be declared or be determined to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this Agreement.

16. Confidentiality Executive understands and agrees that as a condition for payment to him of the severance benefits described in Section 4 above, the terms and contents of this Agreement, and the contents of the negotiations and discussions resulting in this Agreement, shall be maintained as confidential by Executive, his spouse, his attorney and his accountant, and shall not be disclosed except to the extent required by law or as otherwise agreed to in writing by the Company.

 

6


17. Nature of Agreement Executive understands and agrees that this Agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.

18. Voluntary Assent Executive affirms that no other promises or agreements of any kind have been made to or with Executive by any person or entity whatsoever to cause Executive to sign this Agreement, and that you fully understand the meaning and intent of this Agreement. Executive further states and represents that he has carefully read this Agreement, including Attachment “A”, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his own free act.

19. Cooperation The Parties hereto agree, without further consideration, to execute and perform such other documents and acts as are reasonably required in order to facilitate the terms of this Agreement, and the intent thereof, and to cooperate in good faith in order to effectuate the provisions of this Agreement, including without limitation, the protection or assignment of intellectual property rights described in Section 7 above.

20. Older Workers Benefits Protection Act Disclosure and Waiver Executive is over the age of forty (40) years, and in accordance with the Age Discrimination in Employment Act and Older Workers’ Benefit Protection Act (collectively, the “Act”), he acknowledges that:

(1) He has been advised in writing to consult with an attorney prior to executing this Agreement, and has had the opportunity to do so;

(2) He is aware of certain rights to make claims for age discrimination to which he may be entitled under the Act, and understands that by signing this Agreement he is giving up any rights to assert or sue for such claims;

(3) In exchange for executing this Agreement and the release it contains, he will receive continued employment payments and benefits to which he would otherwise not be entitled, in addition to the compensation and benefits that he earned as an employee of Company;

(4) By signing this Agreement, he will not waive rights or claims under the Act which may arise after the execution of this Agreement;

(5) He has been given a period of at least twenty-one (21) days to consider this Agreement, and understands that if he revokes this Agreement (as described below), he will not receive the severance benefits described in Section 4 above. If Executive is signing this Agreement after less than twenty-one (21) days review, he acknowledges that he is doing so voluntarily and expressly waiving his right to take twenty-one (21) days to review it; and

(6) Executive further acknowledges that he will have a period of seven (7) days from the date of execution in which to revoke this Agreement by written notice to Patrick Melone, Director Human Resources of Company. In the event Executive does not exercise his right to revoke this Agreement, the release and waivers given above shall become effective on the date immediately following the seven (7) day revocation period described above. If Executive exercises his right to revoke this Agreement, Company shall have no obligations under any portion of this Agreement.

 

7


21. Applicable Law This Agreement shall be interpreted and construed by the laws of the State of California, without regard to conflict of laws provisions.

22. Notification of New Employer . Executive hereby grants consent to notification by the Company to any new employer of Executive about his rights and obligations under this Agreement.

23. Attorneys Fees In the event of any dispute concerning this Agreement, the prevailing Party will be entitled to recover its attorneys’ fees and costs, in addition to any other relief to which such Party may be entitled.

24. Entire Agreement This Agreement, including Attachment “A”, and the ESRA contains and constitutes the entire understanding and agreement between the Parties hereto with respect to Executive’s severance benefits and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith. In the event of any inconsistency between the terms and provisions of the ESRA and those of this Agreement, the terms and provisions of this Agreement shall control.

IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the day and year first above written.

 

“COMPANY”       “EXECUTIVE”
Oclaro, Inc., a Delaware corporation      
By:  

/s/ GREG DOUGHERTY

 

 

 

 

 

/s/ JERRY TURIN

Greg Dougherty       Jerry Turin
Its: Chief Executive Officer      

 

8


ATTACHMENT “A”

DESCRIPTION OF SEVERANCE BENEFITS

In exchange for Executive’s execution of this Agreement, including, but not limited to, his waiver and release of claims described in Section 5, the Company hereby agrees to provide Executive with the following severance benefits:

(a) The Company shall pay Executive the “Accrued Obligations” (as defined in Section 3.1(a) of ESRA) less all applicable state and federal taxes and withholdings within thirty (30) days following the Termination Date (defined in Section 1 above).

(b) The Company shall pay the Executive the amount of [[$457,681.01 – (95,400) (Closing price per share of Company common stock on November 11, 2013)] less all applicable state and federal taxes and withholdings within thirty (30) days following the Termination Date (defined in Section 1 above).

(c) Accelerated Vesting – If Executive continues as an employee of the Company through the Termination Date, then effective as of the Termination Date, 80,400 shares of restricted stock and 15,000 shares of performance based restricted stock which were previously granted to Executive by the Company and which have not yet vested in accordance with their terms by the Termination Date shall as of the close of business on the Termination Date become fully vested.

(d) Outplacement – The Company agrees to provide Executive with outplacement assistance by the Lee Hecht Harrison company for two months under The Search Launch Program to be started by Executive no later than sixty (60) days from the Termination Date.

The foregoing payments are subject to the timing requirements set forth in the ERSA and in no event will they be made on a date earlier than the date seven (7) days after the date Executive signs and returns this Agreement following the Termination Date.

Exhibit 10.2

CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE OF CLAIMS

This Confidential Separation Agreement and Release of Claims (the “Agreement”) is entered into as of January 9, 2014 by and between Oclaro, Inc., a Delaware corporation (“Company”) and Catherine Hunt Rundle (“Executive”). Company and Executive are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

A. On December 4, 2013, Executive submitted her resignation, effective as of January 10, 2014, from her service with the Company as its Executive Vice President, General Counsel and Secretary of the Company.

B. The Company and Executive are parties to that certain Executive Severance and Retention Agreement dated January 1, 2012 (the “ESRA”). The ESRA provides severance under certain circumstances in the event Executive ceases to be an employee of the Company. The execution of this Agreement is a condition to Executive’s receipt of severance benefits under the ESRA.

C. The Company has determined that it is in the best interests of the Company and its stockholders to enter into this Separation Agreement and Release of Claims to ensure a smooth transition of Executive’s duties and on-going projects.

NOW, THEREFORE, in consideration of the foregoing facts and the promises, covenants and releases, representations and warranties contained in this Agreement, the Parties hereto agree as follows:

1. Termination . January 10, 2014 will be Executive’s last day of employment with the Company (the “Termination Date”). Executive has agreed to continue her at will employment from December 4, 2013 through the Termination Date, and during this time, she will use her best efforts to assist in transitioning her ongoing projects as directed by the Company’s Chief Executive Officer. Effective as of the Termination Date, Executive shall no longer be employed by the Company or any of its direct or indirect subsidiaries. Effective as of the Termination Date, Executive hereby resigns from all position she now holds or then holds with any direct or indirect subsidiary of the Company. Whether or not Executive timely revokes this Agreement (as described in Section 20(6) below), on the Termination Date, she will receive payment for all accrued but unpaid salary and accrued but unused vacation pay owed to her through the Termination Date.

2. Benefits . Executive’s regular coverage under the Company’s group medical insurance benefits will end on the last day of the month in which her employment ends. Regardless of signing this Agreement, Executive may elect to continue receiving group medical insurance coverage by timely electing continuation coverage under the federal “COBRA” law, 29 U.S.C. § 1161 et seq ., and any state law equivalent, including Cal-COBRA. All premium costs shall be paid by Executive on a monthly basis for as long as, and to the extent that, Executive remains eligible for this continuation coverage. Executive should consult the materials to be provided by the Company for details regarding electing continuation benefits. All other employee benefits will end on the Termination Date. Executive confirms that she has no rights to receive any payments under the Oclaro Variable Pay Program (the “VPP”) for performance after June 30, 2013.


3. Stock Options. Vesting of Executive’s stock options and all other compensatory equity awards (if any) will end on the Termination Date pursuant to the Company’s 2004 Stock Plan (the “Plan”). Regardless of signing this Agreement, pursuant to the Plan, Executive will have up to ninety (90) days after the Termination Date to exercise any vested stock options Executive may have (as provided for by the Plan). If Executive does not timely exercise her vested options, and properly follow the required procedures, Executive’s vested options will expire and cannot be reinstated. Executive should consult her Stock Option Agreement regarding her obligations to exercise her vested options. All of the terms, conditions and limitations of the Stock Option Agreement will remain in full force and effect. All unvested stock rights will be cancelled on the Termination Date.

4. Severance . Provided that Executive signs this Agreement by the Termination Date, and provided she does not revoke this release contained in this Agreement (as described in Section 20 below), the Company will provide Executive with the severance benefits described in Attachment “A,” with any cash severance payments beginning on the first regularly scheduled payroll paydate after the later of (i) the Termination Date or (ii) seven (7) days after Executive signs this Agreement (the “Payment Date”). If Executive does not sign this Agreement or signs and revokes this Agreement within such seven (7) day time period, she will have no right to receive any post-termination severance pay or benefits from the Company or any of its affiliates. By signing and returning this Agreement, Executive will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in this Agreement, including without limitation, the release of claims set forth in Section 5 below.

5. Release and 1542 General Release. In consideration for the Company’s agreement to pay Executive the severance benefits pursuant to Section 4 above, Executive hereby fully, forever, irrevocably and unconditionally releases and discharges the Company, its officers, directors, stockholders, corporate affiliates, subsidiaries, parent companies, agents and employees (each in their individual and corporate capacities) (hereinafter the “Released Parties”) from any and all claims, charges, complaints, demands, causes of action, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that Executive ever had or now may have against the Released Parties, including, but not limited to, any arising out of her employment with and/or separation from the Company, including, but not limited to, all employment discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq ., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq ., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq ., the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq ., the California Fair Employment and Housing Act, Cal. Gov’t Code § 12900 et seq ., the California Family Rights Act, Cal. Gov’t Code § 12945.2 and § 19702.3, the California Equal Pay Law, Cal. Labor Code § 1197.5 et seq ., the California Unruh Civil Rights Act, Cal. Civil Code § 51 et seq . and the California Family and Medical Leave Law, Cal. Labor Code §§ 233, 7291.16 and 7291.2, all as amended, and all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq . and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq ., all as amended, and all common law claims including, but not limited to, actions in tort, defamation and breach of contract, all claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options, and any claim or damage arising out of her employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided , however , that nothing in this Agreement prevents her from filing, cooperating with, or participating in any proceeding before the EEOC or a state Fair Employment Practices Agency (except that Executive acknowledges that she may not be able to recover any monetary benefits in connection with any such claim, charge or proceeding).

 

2


Executive understands and agrees that the claims released in this Section 5 include not only claims presently known to her, but also include all unknown or unanticipated claims, rights, demands, actions, obligations, liabilities, and causes of action of every kind and character that would otherwise come within the scope of the released claims as described in this Section 5. Executive understands that she may hereafter discover facts different from what she now believes to be true, which if known, could have materially affected this Agreement, but she nevertheless waives any claims or rights based on different or additional facts. Executive knowingly and voluntarily waives any and all rights or benefits that she may now have, or in the future may have, under the terms of Section 1542 of the Civil Code of the State of California and under any similar statute of any other state. Section 1542 of the Civil Code of the State of California provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH A CREDITOR DOES NOT KNOW OF OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

Notwithstanding the foregoing, to the extent Executive is entitled to indemnification under that certain Indemnification Agreement dated January 25, 2008 by and between Company and Executive, the releases and waivers set forth in this Agreement do not excuse and shall not apply to Company’s obligations benefiting Executive to which Executive might otherwise be entitled to under such Indemnification Agreement.

6. Confidential Information .

(a) Company Information. Executive acknowledges that during her employment with Company she received Confidential Information and Third Party Information as those terms are defined below. Executive represents that at all times during the term of her employment she held in strictest confidence, and did not use, except for the benefit of the Company as authorized by the Board of Directors of the Company, any Confidential Information of the Company. Executive agrees that she will continue to keep confidential and not to use for the benefit of any person or entity all non-public information about the Company or third parties that she acquired during the course of her employment with the Company, including without limitation any Confidential Information or Third Party Information. Executive acknowledges that “Confidential Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer lists and customers (including, but not limited to, customers of the Company on whom Executive called or with whom Executive became acquainted during the term of her employment), markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances or other business information disclosed to Executive by the Company either directly or indirectly in writing, orally or by drawings or observation of parts or equipment. Executive further acknowledges that Confidential Information does not include any of the foregoing items, which have become publicly known and made generally available through no wrongful act of Executive or of others who were under confidentiality obligations as to the item or items involved or improvements or new versions thereof.

 

3


(b) Third Party Information . Executive acknowledges that the Company has received from third parties their confidential or proprietary information subject to a duty on the part of the Company to maintain the confidentiality of such information (“Third Party Information”). Executive represents that she has held all such confidential or proprietary information in the strictest confidence and agrees not to disclose any Third Party Information to any person, firm or corporation or to use it.

(c) Obligation of Confidentiality . Nothing in this Agreement is intended to waive or release Executive from any and all obligations to Company under any confidentiality, proprietary information or non-disclosure agreement, or any obligation created by statutory or common law to protect any intellectual property or proprietary information of Company.

7. Intellectual Property .

(a) Intellectual Property Retained and Licensed . Executive represents that prior to her employment with Company, she did not own and did not have an interest in any inventions, original works of authorship, developments, improvements, or trade secrets which relate to the business of the Company, products or research and development. Notwithstanding the foregoing, if during the course of her employment with the Company, she incorporated into a Company product, process or machine any invention, original work of authorship, development, improvement, or trade secret which were made by her prior to her employment with the Company (collectively referred to as “Prior Intellectual Property”) in which she owns or has an interest in, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Intellectual Property as part of or in connection with such product, process or machine.

(b) Assignment of Intellectual Property . Executive hereby assigns to the Company, or its designee, all her rights, title, and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, discoveries, ideas, trademarks or trade secrets, whether or not patentable or registrable under copyright or similar laws, which she may have solely or jointly conceived or developed or reduced to practice, or caused to be conceived or developed or reduced to practice, during the period of time she was employed by the Company (collectively referred to as “Intellectual Property”). Executive acknowledges that all original works of authorship which were made by her (solely or jointly with others) within the scope of and during the period of her employment with the Company and which are protectable by copyright are “works made for hire”, as that term is defined in the United States Copyright Act. Executive understands and agrees that the decision whether or not to commercialize or market any invention developed by her (solely or jointly with others) is within the sole discretion of the Company and for the sole benefit of the Company and that no royalty will be due to her as a result of the efforts to commercialize or market any such invention by the Company.

 

4


(c) Exception to Assignments . Executive acknowledges that the provisions of this Agreement requiring assignment of Intellectual Property to the Company do not apply to any invention which qualifies fully under the provisions of California Labor Code Section 2870. Executive represents that she is not aware of any inventions that she believes meet the criteria in California Labor Code Section 2870.

8. Solicitation .

(a) As a result of Executive’s access to and knowledge of Company’s Confidential Information, pursuant to Section 3.2 of the ESRA and as a condition to receipt of the severance benefits provided for in Section 4 above, Executive agrees that for a period of twelve (12) months immediately following the Termination Date, she will not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees to leave their employment, or take away such employees, or attempt to solicit, induce recruit, encourage or take away employees of the Company, for herself or for any other person or entity.

(b) As a result of Executive’s access to and knowledge of Company’s Confidential Information, pursuant to Section 3.2 of the ESRA and as a condition to receipt of the severance benefits provided for in Section 4 above, Executive also agrees that for a period of six (6) months immediately following the Termination Date, she will not either directly or indirectly solicit or cause to be solicited any customers of Company for any purpose to the extent permitted by law.

9. Return of Company Property . Executive hereby confirms that she has returned to the Company in good working order all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones and pagers), access or credit cards, Company identification, Company vehicles and any other Company-owned property in her possession or control, has left intact all electronic Company documents, including, but not limited to, those that she developed or helped to develop during her employment, and has retained no copies (either paper or electronically stored or created) of any Confidential Information or Third Party Information in her possession, control or in a manner that would be retrievable by her following her separation from employment. Executive further confirms that she has cancelled all accounts for her benefit, if any, in the Company’s name, including, but not limited to, credit cards, telephone charge cards, cellular phone and/or pager accounts and computer accounts.

10. Business Expenses and Compensation . Executive acknowledges that she has been reimbursed by the Company for all business expenses incurred in conjunction with the performance of her employment and that no other reimbursements are owed to her. Executive further acknowledges that she has received payment in full for all services rendered in conjunction with her employment by the Company through the date of this Agreement, except for any accrued but unpaid salary and accrued but unused vacation owed to her on her Termination Date. Executive agrees that except for such accrued but unpaid amounts, and except for the severance benefits to be provided under Section 4, she has been paid all earned and accrued wages and compensation.

 

5


11. Tax Reporting; Disclaimer of Tax Advice . Executive acknowledges and agrees that Company, and its respective agents, representatives, employees and attorneys, have made no representations to her regarding the tax consequences of any amounts received pursuant to this Agreement. Executive acknowledges and agrees that she is solely and individually responsible for her own tax reporting, payments and liabilities and if the tax characterization with regard to any amounts received pursuant to this Agreement is challenged by any governmental taxing authority, she shall indemnify, hold harmless and defend Company, and any attorney, agent or employee thereof, from any and all claim, tax liability, related interest or penalties, costs and expenses, including attorneys’ fees, caused by or which may be levied upon the Company as a result of the payment of any amounts paid by the Company under this Agreement. The Parties further agree that the terms of this Agreement are not contingent upon any particular tax characterization of the payment described in this Agreement. Executive agrees that neither the Company (or any agent, representative, employee or attorney thereof) has any duty to defend against any tax claim, levy or assessment, whether or not such tax claim, levy or assessment is based on existing tax law and regulations or as such laws or regulations may in the future be amended, or interpreted by the taxing authorities.

12. Non-Disparagement . Executive understands and agrees that she shall not make any false, disparaging or derogatory statements to any media outlet, industry group, financial institution or current or former employee, consultant, client, customer of the Company or other person or entity regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company’s business affairs and financial condition.

13. Amendment . This Agreement shall be binding upon the Parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the Parties hereto. This Agreement is binding upon and shall inure to the benefit of the Parties and their respective agents, assigns, heirs, executors, successors and administrators.

14. Waiver of Rights . No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.

15. Validity . Should any provision of this Agreement be declared or be determined to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this Agreement.

16. Confidentiality . Executive understands and agrees that as a condition for payment to her of the severance benefits described in Section 4 above, the terms and contents of this Agreement, and the contents of the negotiations and discussions resulting in this Agreement, shall be maintained as confidential by Executive, her spouse, her attorney and her accountant, and shall not be disclosed except to the extent required by law or as otherwise agreed to in writing by the Company.

 

6


17. Nature of Agreement . Executive understands and agrees that this Agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.

18. Voluntary Assent . Executive affirms that no other promises or agreements of any kind have been made to or with Executive by any person or entity whatsoever to cause Executive to sign this Agreement, and that you fully understand the meaning and intent of this Agreement. Executive further states and represents that she has carefully read this Agreement, including Attachment “A”, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs her name of her own free act.

19. Cooperation . The Parties hereto agree, without further consideration, to execute and perform such other documents and acts as are reasonably required in order to facilitate the terms of this Agreement, and the intent thereof, and to cooperate in good faith in order to effectuate the provisions of this Agreement, including without limitation, the protection or assignment of intellectual property rights described in Section 7 above.

20. Older Workers Benefits Protection Act Disclosure and Waiver . Executive is over the age of forty (40) years, and in accordance with the Age Discrimination in Employment Act and Older Workers’ Benefit Protection Act (collectively, the “Act”), she acknowledges that:

(1) She has been advised in writing to consult with an attorney prior to executing this Agreement, and has had the opportunity to do so;

(2) She is aware of certain rights to make claims for age discrimination to which she may be entitled under the Act, and understands that by signing this Agreement she is giving up any rights to assert or sue for such claims;

(3) In exchange for executing this Agreement and the release it contains, she will receive the severance benefits described in Section 4 to which she would otherwise not be entitled;

(4) By signing this Agreement, she will not waive rights or claims under the Act which may arise after the execution of this Agreement;

(5) She has been given a period of at least twenty-one (21) days to consider this Agreement, and understands that if she revokes this Agreement (as described below), she will not receive the severance benefits described in Section 4 above. If Executive is signing this Agreement after less than twenty-one (21) days review, she acknowledges that she is doing so voluntarily and expressly waiving her right to take twenty-one (21) days to review it; and

(6) Executive further acknowledges that she will have a period of seven (7) days from the date of execution in which to revoke this Agreement by written notice to Patrick Melone, Director Human Resources of Company. In the event Executive does not exercise her right to revoke this Agreement, the release and waivers given above shall become effective on the date immediately following the seven (7) day revocation period described above. If Executive exercises her right to revoke this Agreement, Company shall have no obligations to pay the severance benefits described in Section 4 of this Agreement.

 

7


21. Applicable Law . This Agreement shall be interpreted and construed by the laws of the State of California, without regard to conflict of laws provisions.

22. Notification of New Employer . Executive hereby grants consent to notification by the Company to any new employer of Executive about her rights and obligations under this Agreement.

23. Attorneys Fees . In the event of any dispute concerning this Agreement, the prevailing Party will be entitled to recover its attorneys’ fees and costs, in addition to any other relief to which such Party may be entitled.

24. Entire Agreement . This Agreement, including Attachment “A”, contains and constitutes the entire understanding and agreement between the Parties hereto with respect to Executive’s severance benefits and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith.

IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the day and year first above written.

 

“COMPANY”       “EXECUTIVE”
Oclaro, Inc., a Delaware corporation      
By:  

/s/ GREG DOUGHERTY

 

 

 

 

 

/s/ CATHERINE HUNT RUNDLE

Greg Dougherty       Catherine Hunt Rundle
Its: Chief Executive Officer      

 

8


ATTACHMENT “A”

DESCRIPTION OF SEVERANCE BENEFITS

In exchange for Executive’s execution of this Agreement, including, but not limited to, her waiver and release of claims described in Section 5, the Company hereby agrees to provide Executive with the following severance benefits:

(a) The Company shall pay the Executive the amount of $ 410,300.00 less all applicable state and federal taxes and withholdings, on the Payment Date (as defined in Section 4 of this Agreement).

(b) Outplacement – The Company agrees to provide Executive with outplacement assistance by the Lee Hecht Harrison company for two months under The Search Launch Program to be started by Executive not earlier than January 1, 2014 and to be completed not later than March 15, 2014.

Exhibit 10. 4

 

LOGO

16 th  October 2013

Adrian Meldrum

71 Bishops Drive

Wokingham

Berks

RG40 1WA

Dear Adrian,

Offer of Employment

We are delighted to offer you the position of Executive Vice President Worldwide Sales reporting to Greg Dougherty, to start on a date to be agreed. Your employment will be based at Caswell. Your salary will be £170,000 per annum.

Your compensation package also includes eligibility to join the Oclaro variable pay scheme, which is a discretionary arrangement that is based on company performance on specific objectives. Your target participation level will be 60% of your base salary , with a maximum of 150%, as determined by the board of directors. Subject to any contrary provisions in the Executive Severance and Retention Agreement between you and Oclaro, if any, if you are not actively employed with the Company as of the payment date, you will not be eligible to receive any variable pay, and no right to such variable pay will have accrued. Details of the scheme will be provided to you on joining . Please note that this plan is subject to amendment , modification and withdrawal by the company at any time.

Subject to formal approval by the Board of Directors (the “Board”), the position being offered to you includes a stock option to own 60,000 shares and 60,000 restricted shares of the Company under the terms of the Company’s Employee Option Share Plan and any other policies, laws or rulings that may govern the stock options and their issuance.

The exercise price will be the market price at the time of formal Board approval. These stock options will vest over a four year period, with twenty-five (25%) percent vesting after the first year and the balance vesting monthly over the following three years, however, all vesting will cease upon termination of employment.

As an Executive, you will also be entitled to our Executive Severance and Retention Agreement. Further details will be shared with you at the start of your employment.

You will also be entitled to membership of the company’s money purchase pension scheme, private medical expenses insurance (currently supplied by BUPA), permanent health insurance and life assurance.

The Company has a fixed benefits scheme for all UK employees, details of which will be provided to you when you join the company.

You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.


LOGO

 

This offer is conditional upon you signing that you have read, understood and accept the following policies:

 

    Code of Conduct and Ethics

 

    Acceptable Computer Use

 

    Disciplinary

 

    Grievance

In addition to the above the principal terms of this offer are detailed in the enclosed Contract of Employment. To accept this offer, please sign and return one copy of the Contract together with your written acceptance of this offer and signed policies. Please return your signed documents to Elaine Barnden, Senior HR Director, EMEA, Caswell, Towcester, Northamptonshire, NN12 SEQ.

Yours sincerely

Greg Dougherty

Chief Executive Officer

Enc:

Contract of Employment

Code of Conduct and Ethics

Acceptable Computer Use

Disciplinary

Grievance

Acceptance

1. I accept the appointment referred to in the terms and conditions set out in this offer letter.

2. In accordance with the 1998 Data Protection Act it is agreed that Oclaro Technology may hold and use personal information about me for personnel reasons and to enable Oclaro Technology Limited to keep in touch with me. This information can be sorted in both manual or computer form, including the data in Section 2 of the Data Protection Act 1998.

 

Signed  /s/ ADRIAN MELDRUM                         Date 19 th October 2013

            Adrian Meldrum

I confirm that I

will be available to start work on      /           /             

or

þ will advise you as soon as possible on my earliest preferred date e.g. once this has been agreed by my current employer . (You need not delay acceptance of this offer if this is likely to take some time).

Exhibit 10.5

 

LOGO

OCLARO TECHNOLOGY LIMITED

(the “Company”)

Caswell, Towcester, Northamptonshire, NN12 SEQ

SUMMARY OF TERMS OF EMPLOYMENT

This summary of the terms and conditions of employment is provided for ease of reference only and has no legal effect. The terms and conditions applicable to your employment are set out in the attached contract of employment. In the event that this summary contradicts or differs from the attached contract of employment, the terms and conditions set out in the contract shall prevail and take precedence over this summary.

 

EMPLOY EE’S NAME:

  

ADRIAN MELDRUM

ADDRESS:

  

71 Bishops Drive

Wokingham

Berks

RG40 lWA

Summarv of terms and conditions

Commencement date:

   TBA2013 18/11/13

NOTICE PERIOD:

   Three months or statutory minimum whichever is greater, following completion of the probationary period.
JOB TITLE:    EXECUTIVE VICE PRESIDENT WORLDWIDE SALES
REPORTING TO:    CHIEF EXECUTIVE OFFICER
PLACE OF WORK:    Caswell, but please note that the contract includes a mobility clause.
HOURS OF WORK:    VARI-TIME, 37.5 HOURS PER WEEK
SALARY:    £170,000 per annum

BONUS

   60% at target with a maximum of 150%. All bonuses are discretionary and subject to Company targets.

HOLIDAYS:

   25 days per calendar year

SICK PAY:

   This is limited to Statutory Sick Pay only for first three months of employment (see note). You will subsequently be eligible for Company sick pay, which includes SSP and varies between 4 weeks to 26 weeks depending on length of service (with part time staff receiving a pro rata entitlement.)

PENSION:

   The Company will match your contribution plus pay 3% up to a maximum of 9%.

MEDICAL INSURANCE:

   The Company will provide Family cover for you. Cover that includes children will provide insurance for children up to age 24 regardless of whether they are in full time education or not.

 

Oclaro CoE Page 1 of 18


MEDICAL CASHPLAN :

   The Company will provide Cashplan Level 1 cover for you.

INCOME PROTECTION:

   40% of your salary will be paid as Company sick pay for 5 years (less Single Person’s Incapacity Benefit) following 52 weeks continuous sick absence. This is dependent on acceptance of your application by the scheme provider.

LIFE ASSURANCE

   This scheme provides benefits on death in service of 4 times your basic annual salary, which is paid in accordance with the rules of the scheme in force.

AMOUNT OF STOCK

   60,000 subject to the conditions stated in this contract.

OPTION/RSU/RSA:

   60,000 subject to the conditions stated in this contract.

N.B. THERE ARE

 

RESTRICTIONS

 

RELATING TO:

  

a) Your use of Confidential Information.

 

b) Your undertaking other employment, engagements and/or having other business interests during your employment with the Company.

 

c) You being employed, engaged or interested in a competing business for 6 months following the termination of your employment.

 

d) You soliciting or dealing with clients of the Company in competition with the Company’s business for 6 months following the termination of your employment.

 

e) You enticing away or employing any employee of the Company for 6 months following the termination of your employment.

 

f) You enticing away any supplier of the Company or endeavouring to interfere with the terms of business between the Company and its suppliers for 6 months following the termination of your employment.

 

g) Your dealing in the shares of the Company.

 

Oclaro CoE Page 2 of 18


CONTRACT OF EMPLOYMENT

This Agreement is dated the * 2013.

BETWEEN:

 

(1) OCLARO TECHNOLOGY LIMITED, a company registered in England and Wales under company number 02298887 and with its registered office at Caswell, Towcester, Northamptonshire, NN12 8EQ (the “Company”); and

 

(2) Add name and address of employee*.

 

1. JOB TITLE AND DUTIES

 

1.1. You will be employed as Executive Vice President Worldwide Sales, reporting to the Chief Executive Officer, or such other person as the Company may from time to time determine (“your Manager”).

 

1.2. You may however be required to carry out such alternative or additional duties as the Company may require from time to time and you agree that you may be seconded to work for one or more Group Companies at any time.

 

1.3. You agree to faithfully and diligently perform your duties to the best of your ability and use your best endeavours to promote the interests of the Company and any Group Companies for whom you are required to work.

 

2. OUTSIDE INTERESTS

 

2.1. For the purposes of avoiding a conflict of interests with your duties under this agreement, you agree that during your employment you will not be employed, engaged, interested or concerned in any trade, business, firm, company or organisation without the prior written consent of your Manager. You may, however, hold (directly or through nominees including your spouse, partner or minor children) by way of bona fide personal investment up to 3% of the issued shares, debentures or other securities of any company whose shares are listed on a recognised investment exchange or dealt in the Alternative Investment Market.

 

2.2. During your employment you will, and will procure that your spouse/partner and minor children will comply with all applicable rules of law, any recognised investment exchange regulations or any Company policy, code or regulations in relation to dealings in shares, debentures or other securities of the Company and any Group Company or relating to any unpublished price sensitive information affecting the securities of the Company, any Group Company or any other company.

 

3. FREEDOM TO TAKE UP EMPLOYMENT WITH THE COMPANY

 

     You warrant that any notice period you are required to give or to serve with a previous employer has expired and that, by entering into this contract or performing any of your duties for the Company, you will not be in breach of any other contract, agreement or obligation binding on you.

 

4. PERIOD OF CONTINUOUS EMPLOYMENT

 

     Your employment will commence on (date). No employment with a previous employer counts as part of your period of continuous employment with the Company

 

Oclaro CoE Page 3 of 18


5. CONDITIONS OF EMPLOYMENT

 

5.1. Your employment with the Company is conditional on:

 

  (a) Receipt by the Company of at least two references in relation to you which the Company considers satisfactory, one of which must be from your last employer; and

 

  (b) You producing such documentation as the Company may reasonably require to establish your right to work lawfully in the United Kingdom.

 

5.2. Should you fail to comply with either of these conditions, any offer of employment by the Company may be withdrawn without notice and if already accepted, the Company may terminate your employment (notwithstanding any other term of this Agreement) without notice or a payment in lieu of notice during the first month of employment or thereafter by giving you the minimum period of notice required by statute.

 

6. PROBATIONARY PERIOD

 

6.1. The first six months of your employment will be probationary and your performance, conduct and suitability for continued employment will be reviewed throughout this probationary period.

 

6.2. Your employment may be terminated by the Company giving to you not less than one month’s notice at any time during or at the end of the probationary period and you agree that any disciplinary or poor performance procedures the Company may have in force shall not apply to you during your probationary period.

 

7. TERM

 

     Subject to the remainder of this clause 7, following completion of your probationary period your employment may be terminated by the Company giving to you not less than three months’ written notice.

 

7.1. You may terminate your employment at any time by giving to the Company not less than three months’ notice in writing.

 

7.2. Notwithstanding any other term of this Agreement, the Company may terminate your employment without notice and without any payment in lieu of notice in the event that you are guilty of gross misconduct, gross negligence or breach a fundamental term of this Agreement.

 

7.3. As an alternative to giving you notice in accordance with clause 7.1, the Company may in its absolute discretion choose to terminate your employment immediately at any time provided that the Company will make you a payment in lieu of notice equivalent to your basic salary over any unexpired period of notice due under clause 7 of this Agreement, subject to deductions for income tax, employee’s national insurance contributions and other deductions required by law.

 

7.4. You hereby acknowledge and agree that you shall not be entitled to any enhanced redundancy payment(s) in the event that the Company terminates your employment by reason of redundancy at any time, and your entitlement shall be limited to a statutory redundancy payment calculated in accordance with Section 162 Employment Rights Act 1996 in this event.

 

Oclaro CoE Page 4 of 18


8. PLACE OF WORK

 

     Your normal place of work will initially be Caswell, Towcester, Northants NN12 8EQ. You agree that the Company may change your normal place of work, temporarily or permanently, to anywhere within the United Kingdom, even if this requires you to relocate your home. The Company will give you at least one months’ prior notice of any permanent change of location.

 

8.1. If you are required to move your home, the Company will provide you with reasonable relocation assistance.

 

8.2. You may be required to travel and undertake your duties anywhere in the world, provided that you shall not be required to work outside the United Kingdom for periods in excess of one month at a time.

 

9. SALARY

 

9.1. You will be paid a basic salary at a rate of £170,000 (One Hundred and Seventy Thousand pounds} per annum, subject to deductions for income tax, employee’s national insurance contributions and any other deductions required or permitted by law. Your salary will accrue on a day-to-day basis and is paid on or about 24 th day of each month for that complete month. Your salary is paid in respect of your duties both for the Company and any other Group Company for whom you are required to work.

 

10. EXPENSES

 

     You will be reimbursed for all expenses reasonably and properly incurred by you on the business of the Company or the Group provided you comply with any expenses policy of the Company in force from time to time and you produce to the Company such receipts, voucher or other evidence of actual payment of the expenses concerned as the Company may reasonably require from time to time.

 

11. PENSION AND OTHER BENEFITS

 

     P en sion. You are eligible to join the Company’s Group Personal Pension Plan {GPPP}. The Company will contribute to the GPPP, by means of equal monthly installments, during such periods as you are an active member of the GPPP at a rate per complete year of membership equivalent to three percent of your base salary more than the personal pension cont ribution you choose to make to the GPPP (with contributions for part of a year being reduced on a pro rata basis), subject at all times to: (a) a maximum employer contribution per year of nine percent of base salary being payable by the Company; (b) any contribution limitations prescribed by HM Revenue and Customs from time to time; and (c) the rules of the GPPP (which you acknowledge may vary from time to time) . Contribution levels are outlined in the table below.

 

Employee contribution rate

   Employer’s
contribution rate
  Combined contribution rate

1%

   4%   5%

2%

   5%   7%

3%

   6%   9%

4%

   7%   11%

5%

   8%   13%

6%

   9%   15%

7% and above

   Remains at 9%   16% and above dependent on employee

contribution

 

Oclaro CoE Page 5 of 18


     The Company reserves the right to withdraw this benefit at any time or to vary the rules applicable to the scheme or the level of Company contributions to the scheme.

 

11.1. Private Medical Insurance.

 

     The Company will provide Family cover for you. Cover that includes children will provide insurance for children up to the age of 24 regardless of whether they are in full time education or not. The scheme is provided by such a reputable medical expenses insurance provider as the Company shall determine from time to time, subject to the Company being able to secure such cover at rates which it determines reasonable. The Company reserves the right to withdraw this benefit at any time or to vary the terms or level of cover at any time. This is a benefit on which you will be liable to pay income tax.

 

11.2. Medical Cashplan.

 

     The Company will provide Cash plan Level 1 cover for you. This cover includes children to age 18 regardless of whether they are in full time education or not. The scheme is provided by such a reputable Medical Cashplan expenses insurance provider as the Company shall determine from time to time, subject to the Company being able to secure such cover at rates which it determines to be reasonable. The Company reserves the right to withdraw this benefit at any time or to vary the terms or level of cover at any time.

 

11.3. Income Protection Insurance.

 

     The Company shall bear the cost of cover for you at rates which are reasonably acceptable to the Company. The Company will provide cover for you under its Income Protection Insurance subject to and in accordance with the rules and terms of such insurance scheme as may be in force from time to time. If you remain sick for a continuous period of 52 weeks regardless of your length of service you may be entitled to Income Protection Insurance. On acceptance of your application, 40% your salary will be paid for up to a maximum of 5 years (less Single Person’s Incapacity Benefit). The Company reserves the right to withdraw this benefit at any time or to vary the terms or level of benefits provided by this cover at any time.

 

11.4. Life Assurance

 

     The Company shall bear the cost of membership of a HMRC approved life assurance scheme for you, subject to and in accordance with the rules and terms of such life assurance scheme as may be in force from time to time. This scheme provides benefits on death in service of 4 times your basic annual salary, which is paid in accordance with the rules of the scheme in force. The Company reserves the right to withdraw this benefit at any time or to vary the terms or level of cover at any time.

 

11.5. Stock Options.

 

     Subject to the formal approval of the Board of Directors of Oclaro, Inc. {the “Parent”) and to the terms and conditions stated in the 2004 Amended and Restated Oclaro Stock Incentive Plan and the option agreement or other documentation governing any grant made to you (together the “Option Documentation”), the Company shall recommend to the Parent that it grants you an option over 60,000 shares of common stock of the Parent at an option price of not less than the fair market price per share of such common stock on the date of grant {the “Options”). Any Options granted (if any) shall be granted at such time as the Parent shall determine in its absolute discretion and all Options shall be exercisable and lapse in accordance with the rules of the Option Documentation.

 

Oclaro CoE Page 6 of 18


     In no circumstances shall you be entitled upon the termination of your employment with the Company to any compensation for any loss of any right or benefit or prospective right or benefit under the Option Documentation or in respect of any Options, which right or benefit you might have enjoyed if it were not for the termination of your employment (including, without limitation, the lapse of the Options (or part thereof held by you) by reason of the termination of this agreement or your employment (whether or not such termination is lawful) or your ceasing to be employed by the Company or any Group Company), and regardless whether such compensation is claimed by way of damages for breach of contract or otherwise. You hereby waive all and any rights you have or may have in the future to any compensation or damages in consequence of the termination of your employment under this agreement or otherwise for any reason whatsoever (including, without prejudice to the generality of the foregoing, any termination of this agreement by the Company in breach of contract) insofar as those rights arise, or may arise, from your ceasing to have rights under, or be entitled to exercise any Options (or part thereof) under, the Option Documentation as a result of such termination of your employment or of this agreement or from the loss or diminution in value of such rights or entitlements.

 

11.6. Restricted Stock Unit (RSU/RSA Subject to the formal approval of the Board of Directors of Oclaro, Inc. (the “Parent”) and to the terms and conditions stated in the 2004 Amended and Restated Oclaro Stock Incentive Plan and the option agreement or other documentation governing any grant made to you (together the “Restricted Stock Documentation”) the Company shall recommend to the Parent that it makes an award of restricted stock to you with regard to 60,000 [shares of common stock of the Parent] [restricted stock units] (the “Award”). Any Award made (if any) shall be granted at such time as the Parent shall determine in its absolute discretion and the Award shall vest and be forfeited in accordance with the rules of the Restricted Stock Documentation.

 

     In no circumstances shall you be entitled upon the termination of your employment with the Company to any compensation for any loss of any right or benefit or prospective right or benefit under the Restricted Stock Documentation or in respect of the Award, which right or benefit you might have enjoyed if it were not for the termination of your employment (including, without limitation, the forfeit of the Award (or part thereof held by you) by reason of the termination of this agreement or your employment (whether or not such termination is lawful) or your ceasing to be employed by the Company or any Group Company) and regardless whether such compensation is claimed by way of damages for breach of contract or otherwise. You hereby waive all and any rights you have or may have in the future to any compensation or damages in consequence of the termination of your employment under this agreement or otherwise for any reason whatsoever {including, without prejudice to the generality of the foregoing, any termination of this agreement by the Company in breach of contract) insofar as those rights arise, or may arise, from your ceasing to have rights under, or be entitled to further vesting of any Award (or part thereof) under, the Restricted Stock Documentation as a result of such termination of your employment or of this agreement or from the loss or diminution in value of such rights or entitlements.

 

12. HOURS OF WORK

 

12.1. Your normal working hours are 37.5 hours per week. You must work between the hours of 9.30 a .m. to 4.00 p.m. Monday to Friday inclusive provided that you shall be entitled to take between 30 minutes and 2 hours for lunch each day. You may vary your start time between 7.30 a.m. and 9.30 a.m. and your finish time between 4.00 p.m. and 6.00 p.m. each working day provided that you must work 37.5 hours each week. You may finish early (3.00 p.m.) on a Friday provided you have worked for 2 hours after lunch and have completed 37.5 hours during the week. You are required to obtain approval from your manager to agree your working hours with your manager.

 

Oclaro CoE Page 7 of 18


12.2. You may be required to work overtime as required to meet the needs of the business. Your full co-operation is expected at these times . You agree that the limit on average weekly working time set out in Regulation 4(1) of the Working Time Regulations 1998 will not apply to you, although you may withdraw your consent on giving the Company three months’ prior written notice.

 

13. HOLIDAYS

 

13.1. The Company’s holiday year runs from 1January to 31 December.

 

13.2. You are entitled to 25 days paid holiday entitlement in addition to English public holidays or the equivalent pro rata in each holiday year if you are contracted to work part-time. The holiday entitlement for a part-time employee will be shown in hours. You are required to save up to four days holiday each year, or the equivalent in hours if you are a part-time employee, each year which shall be taken by you on such days that the Company determines a shutdown period. Adequate notice will be given by the Site Leader prior to any shutdown, unless you are notified otherwise by the Board in any year. The Company reserves the right to make changes to the amount of days required for a shutdown period provided that the Company gives you not less than three months’ notice of such changes.

 

13.3. All holiday must be taken at times authorised by your Manager. You should submit requests for leave giving twice as much notice as the period of leave for which you are applying (e.g. if you are applying for one week of leave, you should apply at least two weeks before the start of the holiday period). For the avoidance of doubt Regulations 15(1) to 15(4) of the Working Time Regulations 1998 will apply to your employment.

 

13.4. You may not, save with the prior express permission of your Manager in writing, carry forward any unused part of your holiday entitlement for a given holiday year into the subsequent holiday year. When permission is granted, the maximum permitted number of days’ holiday entitlement you may carry forward from any holiday year is limited to five days. This amount will be pro rata and expressed in hours for part-time employees dependent on their contractual hours. This holiday must be taken by the last day in April of the following year.

 

13.5. For the holiday year during which your employment commences or terminates, your holiday entitlement will be calculated on a pro rata basis according to the number of weeks of completed service in such year.

 

13.6. On the termination of your employment with the Company, the Company may at its discretion:

 

   Require you to take, during your notice period, any or all holiday entitlement which will have accrued to you by the date on which your employment terminates; or

 

  (a) Pay you in lieu of your accrued but unused holiday entitlement, save that, if you are dismissed summarily for gross misconduct, the Company shall be under no obligation to pay you in respect of accrued but untaken holiday entitlement in excess of any minimum holiday entitlement required by law. All pay in lieu of holiday entitlement will be subject to deductions for income tax, employee’s national insurance contributions and other deductions required by law; or

 

  (b) Deduct an amount equal to salary paid to you in respect of holiday taken by you but not accrued by the date on which your employment terminates from any salary or payment in lieu of notice due to you or, in the event that this is insufficient, require you to repay such an amount to the Company.

 

Oclaro CoE Page 8 of 18


14. DEDUCTIONS FROM WAGES

 

     Without prejudice to any other rights open to the Company, you agree that the Company may deduct from any wages due to you, (including Company sick pay and any payment in lieu of notice or holiday entitlement) sums representing the value of any Company property negligently or deliberately lost by you; the cost of repairing any Company property damaged negligently or deliberately by you; any other sums owing from you to the Company; where you have been unable to perform your duties under this Agreement due to an accident caused by a third party, an amount equal to the amount of any damages you recover from a third party in respect of that accident capped at an amount equal to the salary and benefits you have received from the Company in respect of any period of absence to which the damages relate; any overpayment of salary or expenses or payment made to you by mistake or through misrepresentation; and any other sums authorised to be deducted by Section 13 of the Employment Rights Act 1996.

 

15. DATA PROTECTION

 

     In order to keep and maintain any records relating to your employment under this Agreement, it will be necessary for the Company to record, keep and process personal data relating to you on computer and in hard copy form. (Examples of personal data include details of your disciplinary record, any grievances raised by you and the contents of your personnel file, together with any sensitive personal data held by the Company such as your religious beliefs, your ethnic or racial origin and information relating to any physical disability or pregnancy). Further in order to pay your salary and offer you the other benefits to which you may be entitled, the Company may also need to obtain from you details of your bank account and other financial information. To the extent that it is reasonably necessary in connection with your employment and the Company’s responsibilities as an employer, this data may be disclosed to others, including other employees of the Company or any Group Company, the Company’s professional advisers, the Her Majesty’s Revenue and Customs or other taxation authority, the police and other regulatory authorities. You hereby consent to the recording, processing, use and disclosure by the Company of personal data relating to you as set out above, including the recording, processing, use and disclosure of your sensitive personal data to the extent required by reason of your employment or by law and the transmission of such data within or outside the European Union.

 

16. SICKNESS OR INJURY

 

16.1. Your sick absence entitlement includes any right to Statutory Sick Pay for any period of sick absence in line with the prevailing rules of the Statutory Sick Pay scheme and consists of (see note):

 

Year

   Length of service    Maximum entitlement in
weeks
   Level of sick pay
1    0 > 3 months    0    SSP only
1    3>12 months    4    Full pay (including SSP)
2    12 > 24 months    8    Full pay (including SSP)
3    24 > 36 months    16    Full pay (including SSP)
4    36 > 48 months    20    Full pay (including SSP)
5& above    48 months & above    26    Full pay (including SSP)

 

     Your entitlement to Company paid sick absence will be based on a rolling twelve month period. This will not affect your right to Statutory Sick Pay for any period of sick absence in line with the prevailing rules of the Statutory Sick Pay scheme. If you remain sick for a continuous period of 52 weeks regardless of your length of service-you may be entitled to receive benefits under the Company’s Income Protection Insurance. On acceptance of your application,40% your salary will be paid for 5 years (less Single Person’s Incapacity Benefit) unless during that period you became fit to return to work, subject to the insurer accepting liability for your claim.

 

Oclaro CoE Page 9 of 18


16.2. If you are absent from work due to sickness, injury or accident you must notify your line manager (or their deputy) as soon as possible and in any event within 30 minutes of your normal start time on the first working day of absence. You will contact your manager (or their deputy) in person unless you are unable to use the phone. You should not text unless this is a supplementary message.

 

16.3. If you are absent from work for less than 7 days you must complete a Back to Work Form setting out the nature of your illness or incapacity and the date the sickness ended on your return to work. If your absence continues for more than 7 days you will, on the eighth day of such absence, submit a Fitness To Work Statement from your doctor to your line manager (or their deputy) and continue to submit promptly any additional Statements from your doctor covering any further period of absence.

 

16.4. Failure to comply with the certification requirements set out above may result in you forfeiting your entitlement to be paid during periods of absence and you may also subject to disciplinary action. Provided you comply with the notification and certification procedure set out above, during such absence the Company will pay your normal basic salary for the number of weeks specified in 16.1 of this contract, dependent on your length of service at the time of your sick absence. Thereafter, any Company sick pay is entirely at the discretion of the Company, provided that you shall be entitled to Statutory Sick Pay in accordance with the rules of the Statutory Sick Pay scheme, subject to the Company’s right to terminate your employment under this Agreement.

 

16.5. Any Company sick pay shall include any Statutory Sick Pay payable to you under the prevailing rules of the Statutory Sick Pay scheme. The Company may deduct from Company sick pay an amount or amounts equal to any state benefit to which you are entitled.

 

16.6. The Company reserves the right to require you to undergo a medical examination by the Company’s doctor or an independent medical practitioner at any time during a period of absence. You agree that the doctor or independent medical practitioner may disclose to the Company the results of the examination and discuss with the Company and its professional advisers any matters arising from the examination as might impair you from properly discharging your duties. The Company may also require you to also authorise your own doctor to provide the Company’s doctor and/or independent medical practitioner with any relevant extracts from your medical notes subject to your rights under the Access to Medical Reports Act 1988.

 

17. CONFIDENTIALITY

 

17.1 During the course of your employment you will have access to and become aware of information which is confidential to the Company. You undertake that you will not, save in the proper performance of your duties for the Company, disclose to any person, firm, company or organisation or use (whether for your own benefit or for the benefit of any person, firm, company or organisation) any of the trade secrets or other confidential information of or relating to (a) the Company; (b) any Group Company; (c) any client or customer of the Company; (d) any person, firm, company or organisation with whom or which the Company is involved in any kind of business venture or partnership; or (e) any other third party to which the Company or any Group Company owes a duty or confidentiality. Further, you agree to use your best endeavours to prevent the unauthorised publication or disclosure of any such trade secrets or confidential information.

 

Oclaro CoE Page 10 of 18


     The restriction stated in clause 17.1 above shall apply during, and after the termination of, your employment, but shall cease to apply to information which:

 

  (a) must be disclosed by law or pursuant to an order of any court or tribunal of competent jurisdiction:

 

  (b) any information that you can demonstrate to the reasonable satisfaction of the Company came into your knowledge via a third party unrelated to the Company or any Group Company who did not owe any duty of confidentiality to the Company or relevant Group Company with regard to the applicable information;

 

  (c) becomes available to the public generally (other than by reason of your breaching this clause).

 

  (d) Nothing in this clause will prevent you making a “protected disclosure” within the meaning of Sections 43A-L of the Employment Rights Act 1996, provided that you have first followed and exhausted any reasonable Company procedure in relation to the reporting of any alleged wrongdoing or wrongful conduct on the part of the Company or any Group Company or any of its/their officers, directors, employees or advisers.

 

17.2. For the purposes of this Agreement confidential information shall include, but shall not be limited to:-

 

  (a) Corporate and marketing strategy and plans and business development plans;

 

  (b) Budgets, management accounts, bank account details and other confidential financial data;

 

  (c) Business sales and marketing methods;

 

  (d) Details, designs, know-how, technical data, techniques, processes and specifications of or relating to any products and services being sold, provided, manufactured, distributed, researched or developed, including all research and development reports and data and details of intellectual property solutions or rights relating to products or services;

 

  (e) Methods, procedures and information relating to the operation of its business, including details of salaries, bonuses, commissions and other employment terms applicable;

 

  (f) The names, addresses and contact details of any Customers or Prospective Customers, including customer lists in whatever medium this information is stored and details in relation to the requirements of those Customers or the potential requirements of Prospective Customers for any products or services, without prejudice to the generality of the foregoing, information provided by visitors to and users of any of its web sites,

 

  (g) The terms of business with its advertisers, customers and suppliers, including any pricing policy adopted and the terms of any partnership, joint venture or other form of commercial co-operation or agreement entered into with any third party;

 

  (h) Software and technical information necessary for the development, maintenance or operation of any of any website and the source and object code of each website; and

 

  (i) Any other information in respect of which it is bound by an obligation of confidence owed to a third party.

 

17.3. Your undertaking to the Company in clause 18.1 is given to the Company for itself and as trustee for each Group Company.

 

18. DELIVERY/RETURN OF THE COMPANY’S PROPERTY

 

18.1. You may not save in the proper performance of your duties or with the Company’s permission, remove any property belonging to the Company or any Group Company, or relating to the affairs of the Company or any Group Company, from the Company’s or any Group Company’s premises, or make any copies of documents or records relating to the Company’s or any Group Company’s affairs.

 

Oclaro CoE Page 11 of 18


18.2. Upon the Company’s request at any time, and in any event on the termination of your employment, you will immediately deliver up to the Company or its authorised representative, any plans, keys, mobile telephone, security passes, credit cards, customer lists, price lists, equipment, documents, records, papers, computer disks, tapes or other computer hardware or software (together with all copies of the same), and all property of whatever nature in your possession or control which belongs to the Company or any Group Company or relates to its or their business affairs. You will at the Company’s request furnish the Company with a written statement confirming that you have complied with this obligation.

 

18.3. If, on the termination of your employment, you have any information relating to the Company or any Group Company or work you have carried out for the Company or any Group Company which is stored on a device (which for the purpose of this agreement includes any personal computer, laptop computer, web-server, personal digital assistant, mobile telephone, memory, disk or any other storage medium) which device does not belong to the Company, you agree to disclose this fact to the Company prior to or immediately upon the termination of your employment and you agree to provide the Company with immediate access to the relevant device so that the Company may download the information and/or supervise its deletion from the device concerned.

 

19. COPYRIGHT AND DESIGN RIGHTS

 

19.1. You acknowledge and agree that the provisions of this clause 19 apply in respect of any designs, databases, improvements, data, modifications, documents, software, processes, techniques or other things or works (“Works”) in which any Intellectual Property may subsist that you have made or originated either by yourself or jointly with other people during your employment with the Company or any Group Company including prior to the date of this agreement (but only to the extent that any such Intellectual Property has not already vested in any Group Company), as well as any such works which you may so make or originate after the date of this agreement (all such Works being “Relevant Works”).

 

19.2. You will promptly disclose to your line manager all Relevant Works.

 

19.3. Any Work which has been or may be created by you in the normal course of your employment in the course of carrying out duties specifically assigned to you or which is capable of being used or exploited by the Company or any Group Company in its business operations, shall be the property of the Company whether or not the Work was made at the direction of the Company, or was intended for the Company and the Intellectual Property in and in relation to it shall belong absolutely to the Company throughout all jurisdictions and in all parts of the world, together with all rights of registration, extensions and renewal (where relevant).

 

19.4. To the extent that such Intellectual Property is not otherwise vested in the Company, you hereby assign, and agree to assign, the same to the Company, together with all past and future rights of action relating thereto.

 

19.5. In relation to any Work that may be created by you in the future (but while you remain employed by the Company), whether in the normal course of your employment, in the course of carrying out duties specifically assigned to you or which is capable of being used or exploited by the Company or any Group Company in its business operations, you hereby assign, by way of present assignment of future rights to the extent permissible by law, the Intellectual Property in the same to the Company, with the intention that such Intellectual Property should immediately (upon arising vest in the Company.

 

Oclaro CoE Page 12 of 18


19.6. You recognise and accept that the Company may edit, copy, add to, take from, adapt, alter and translate any Works in exercising the rights assigned under this clause 19.

 

19.7. To the fullest extent permitted by law, you irrevocably and unconditionally waive any provision of law known as “moral rights” including any moral rights you may otherwise have under sections 77 to 85 inclusive of the Copyright Designs and Patents Act 1988 in relation to all Relevant Works. You give this waiver in favour of the Company and each Group Company, and all successors in title to and licensees of any Intellectual Property in such works (whether existing or future).

 

19.8. You agree that you will at the Company’s request and expense, execute such further documents or deeds and do all things necessary or reasonably requested to vest Intellectual Property in the Company pursuant to, and/or to confirm and substantiate the rights of the Company under and/or allow Company to enjoy the benefit of, this clause 19 and/or clause 20 both before and after the termination of this agreement for any reason.

 

19.9. You agree that you will not at any time make use of, disclose or exploit any property, trademarks, service marks, documents, materials or information in which the Company or any Group Company owns (wholly or partially) any Intellectual Property for any purpose which has not been authorised by the Company.

 

19.10. This clause 19 is subject to clause 20 with respect to Inventions and Intellectual Property in inventions.

 

20. INVENTIONS

 

20.1. You acknowledge and agree that the provisions of this clause 20 apply in respect of any invent ion made or discovered or to be made or discovered by you (whether alone or jointly with others) from time to time during the course of your employment with the Company and any Group Company whether before or after the date of this agreement.

 

20.2 It has been and it shall be part of your normal duties at all times to consider in what manner and by what new methods or devices, products, services, processes, equipment or systems of the Company and each Group Company might be improved and to further the intellectual property interests of the Company. You and the Company agree that, because of the nature of your duties and the particular responsibilities arising from your duties, you have had and continue to have a special ob ligation to further the interests of the Company.

 

20.3. You hereby acknowledge and agree that the sole ownership of any invention made or discovered or to be made or discovered by you (whether alone or jointly with others) from time to time in the course of undertaking your normal duties for the Company or any Group Company under this agreement or in the course of carrying out duties assigned to you by the Company or any Group Company under this agreement, whether in each case before or after the date of this agreement (“Company Inventions”), and all patents and other Intellectual Property there in shall (subject to any contrary provisions of the Patents Act 1977 the Copyright Designs and Patents Act 1988 or any other applicable laws and to any rights of a joint inventor thereof) belong free of charge and exclusively to the Company or as it may direct.

 

20.4. You shall promptly give to your line manager full details of all inventions made or discovered by you from time to time during your employment with the Company or any Group Company, whether before or after the date of this agreement.

 

Oclaro CoE Page 13 of 18


20.5. All Intellectual Property in all Company Inventions shall be and remain the property of the Company and the provisions of clause 19 above shall apply in relation to the same.

 

20.6. You agree that you shall, at any time during your employment or thereafter, at the Company’s expense, do all such acts and things and execute such documents (including without limitation making application for letters patent) as the Company may reasonably request in order to vest effectually all Company Inventions, to the extent that the same is the property of the Company or any other Group Company, and any protection as to ownership or use (in any part of the world) of the same, in the Company or any Group Company, or as the Company may direct, and you hereby irrevocably appoint the Company for these purposes to be your attorney in your name and on your behalf to execute and do such acts and things and execute any such documents as set out above.

 

20.7. You agree that you will not knowingly do or omit to do anything which will or may have the result of imperiling any such protection aforesaid or any application for such protection.

 

20.8. You agree that you will not at any time make use of, disclose or exploit any Company Invention belonging wholly or partially to the Company or any Group Company for any purpose which has not been authorised by the Company.

 

20.9. Each of the provisions in this clause 20 is distinct and severable from the others and if at any time one or more of such provisions is or becomes invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions of the clause will not in any way be affected or impaired.

 

21. GARDEN LEAVE

 

21.I. The Company shall be under no obligation to provide you with work during any period of notice to terminate your employment (or any part thereof), whether given by the Company or by you. During such period the Company may require you: (a) to carry out different duties from your normal duties, whether or not this occasions a loss of status;(b) to cease carrying out your duties altogether;(c) not to attend work and may exclude you from any premises of the Company or any Group Company; and/or (d) not to have any business dealings or contact with the Company’s employees, suppliers , advertisers, customers, Prospective Customers and agents. You will continue to receive your salary and all contractual benefits save: (i) where any term of this agreement or any other contract, agreement or plan to which you are a party, or in which you participate, states otherwise; (ii) that any bonus otherwise due to you shall be reduced on a pro-rata basis to take into account any part of the notice period during which you are on placed on garden leave and suspended from undertaking any duties for the Company; and (iii) that the Company shall have no obligation to compensate you for any commissions you fail to earn as a result of not actively pursuing your duties for the Company during any part of the notice period during which you are on garden leave and suspended from undertaking any duties for the Company. During such period of notice, you may not be engaged or employed by or take up any office in any other company, firm, business or organisation or trade on your own account or enter into any partnership without the prior written permission of the Board.

 

22. SUSPENSION

 

     The Company may at any time suspend you on full pay pending the outcome of a disciplinary investigation or for health reasons. Whilst you are suspended, the Company may impose the same conditions as apply to garden leave under clause 21 above.

 

Oclaro CoE Page 14 of 18


23. RESTRICTIONS AFTER TERMINATION OF EMPLOYMENT

 

23.1. You agree that you will not, without the prior written permission of the Board during the period of 6 months immediately following the termination of your employment ({less any period you spend on garden leave pursuant to clause 21), whether on your own behalf or on behalf of any individual, company, firm, business or other organisation, directly or indirectly:

 

  (a) in connection with the carrying on of any business which competes with any business of the Company or any Group Company with which business you were involved in the period of 12 months prior to the termination of your employment, solicit or entice away from the Company or any Group Company the business or custom of any customer or Prospective Customer with whom you had business dealings on behalf of the Company or any Group Company in the course of the period of 12 months prior to the termination of your employment or about which customer or Prospective Customer you are privy to confidential information at the date your employment terminates; or

 

  (b) in connection with the carrying on of any business which competes with any business of the Company or any Group Company with which business you were involved in the period of 12 months prior to the termination of your employment, have business dealings or contract with any Customer or Prospective Customer of the Company or any Group Company with which Customer or Prospective Customer you had business dealings on behalf of the Company or any Group Company in the course of the period of 12 months prior to the termination of your employment or about which Customer or Prospective Customer you are privy to confidential information at the date your employment terminates; or.

 

  (c) seek to entice away from the Company or any Group Company any person employed or engaged by the Company or any Group Company as or carrying out the functions of a director, vice president, manager or any other person acting in a sales, research and development or technical capacity at the date your employment terminates with whom you had material contact in the period of 12 months prior to the termination of your employment with the Company provided that this restriction shall apply regardless of whether the solicitation involves a breach of contract on the part of the director or employee concerned; or

 

  (d) employ or engage or offer to employ or engage any person employed or engaged by the Company any Group Company as or carrying out the functions of a Director, Vice President, Manager or any other person acting in a sales, research and development or technical capacity at the date your employment terminates with whom you had dealings in the last 12 months of your employment with the Company provided that this restriction shall apply regardless of whether the employment involves a breach of contract on the part of the Director or employee concerned; or

 

  (e) endeavour to entice away from the Company or in any way seek to affect the terms of business on which the Company deals with any person, firm, company or organisation whom or which supplied goods or services to the Company during the period of 12 months prior to the termination of your employment.

 

23.2. You agree that you will not, without the prior written permission of the Board, for a period of 6 months following the termination of your employment with the Company (less any period you spend on garden leave pursuant to clause 21), be engaged or employed in the Restricted Area by or otherwise involved or interested in any company, firm, organisation or business which competes in the Restricted Area with any business of the Company or any Group Company with which business you are involved in the last 12 months of your employment under this Agreement.

 

23.3. Each of the sub-clauses contained in clause 23 constitutes an entirely separate and independent covenant. If any restriction is held to be invalid or unenforceable by a court of competent jurisdiction, it is intended and understood by the parties that such invalidity or unenforceability will not affect the remaining restrictions or the validity of the rest of the Agreement and that if any such restriction would be valid if some part thereof were deleted, such restrictions shall apply with such modification as may be necessary to make them effective.

 

Oclaro CoE Page 15 of 18


23.4. You agree that if you receive an offer of employment, consultancy, directorship or other office or partnership during the continuance in force of any of the above, you will prior to acceptance of an offer, provide the party making the offer with copies of this clause and details of your notice period, the restrictions on your use and disclosure of confidential information and the clauses dealing with copyright and inventions. Further, within 48 hours of receiving the aforementioned offer you will notify the Company of the identity of the party making the offer and the terms of the offer.

 

23.5. You acknowledge that:-

 

  (a) Each of the restrictions in clause 23 goes no further than is necessary to protect the legitimate business interests of the Company and any Group Company; and

 

  (b) The Company is entering into this Agreement not only for itself but as trustee for each Group Company and with the intention that the Company and/or any Group Company will be entitled to seek the protection of and enforce each of its restrictions directly against you. If requested to do so by the Company however, you will at any time enter into like restrictions as those contained in this clause 24 (mutatis mutandis) with any other Group Company.

 

23.6. Nothing in this clause 23 shall prohibit you from holding the investments and interests set out in clause 2.1 above.

 

23.7. Following the date your employment terminates, you will not:

 

  (a) represent yourself as being in any way connected with the business of the Company or any Group Company (except to the extent agreed by such Company):

 

  (b) represent, promote or advertise or refer to your previous connection with the Company or any Group Company in such a way as to utilise any of their goodwill

 

  (c) carry on, cause or permit to be carried on any business under or using any name, trade mark, service mark, style, logo, get-up or image which is or has been used by the Company or any Group Company, or which in the reasonable opinion of the Board, is calculated to cause confusion with such a name, trade mark, service mark, style, logo, get-up or image or infer a connection with the Company or any Group Company.

 

24. DISCIPLINARY AND GRIEVANCE PROCEDURES

 

     A copy of the Company’s disciplinary and grievance procedures are available from Human Resources. These policies do not form part of your contract of employment and may be varied by the Company at any time.

 

25. COLLECTIVE AGREEMENTS

 

     There are no Collective Agreements which directly affect your terms and conditions of employment.

 

26. SECURITY

 

26.1. All communications, whether by telephone, email, fax, or any other means, which are transmitted, undertaken or received using Company property or on Company premises will be treated by the Company as work related and are subject to interception, recording and monitoring without further notice. You should not regard any such communications as private.

 

26.2. Interception, recording and monitoring of communications is intended to protect the Company’s business interests, for example, but without limitation, for the purposes of quality control, security of communication and IT systems, record-keeping and evidential requirements, detection and prevention of criminal activity or misconduct and to assist the Company to comply with relevant legal requirements. Such interception, recording and monitoring will not be undertaken for prurient interest.

 

Oclaro CoE Page 16 of 18


26.3. Intercepted communications may be used as evidence in disciplinary or legal proceedings, including in any such action against you.

 

26.4. By transmitting, undertaking or receiving communication using Company property or on Company premises you consent to the above terms.

 

27. ENTIRE AGREEMENT

 

27.1. This Agreement sets out the entire agreement between the Company and you at the date of this Agreement in relation to your terms and conditions of employment and is in substitution for and supersedes any previous contract of employment between the Company and you, which shall be deemed to have been terminated by mutual consent and without giving rise to claims against the Company. You represent and warrant that you are not entering into this Agreement in reliance on any representation not expressly set out herein.

 

27.2. The termination of this Agreement howsoever arising shall not affect any of the provisions of this Agreement which are expressed to operate or have effect or are capable of operation or effect after such termination.

 

28. NOTICES

 

     Any notice you are required to give under this Agreement should be given by you to your Manager. Any notice the Company is required to give you should be handed to you or delivered or posted by special delivery post to your last notified address. These notices will be deemed to have been given on receipt if handed to you or your Manager, when delivered if delivered or posted to your last notified address.

 

29. THIRD PARTIES

 

     This Agreement constitutes an agreement solely between the Company and you and, save where otherwise provided, nothing in this contract confers or purports to confer on a third party any benefit or any right to enforce a term of this contract for the purposes of the Contracts (Rights of Third Parties) Act 1999.

 

30. INTERPRETATION

 

     Any reference in this Agreement to:-

 

30.1. Any Act or delegated legislation includes any statutory modification or re-enactment of it or the provision referred to;

 

30.2. “Board” shall mean the Board of Directors of the Company from time to time or any person or any committee of the Board duly appointed by it;

 

30.3. “Group Company” means a company which from time to time is a subsidiary or a holding company of the Company or a subsidiary of such holding company (where the terms “subsidiary” and “holding company” have the meanings attributed to them by section 1159 of the Companies Act 2006);

 

30.4. “include” and “including” and “in particular” shall be construed as being by way of illustration only and shall not limit the generality of the preceding words;

 

30.5. “Intellectual Property” means rights in designs, copyrights and related rights, patents, rights in confidential information (including know-how), trade mark rights and database rights, in each case whether or not registered or registrable and including applications (and rights to apply) for registration, and all rights and forms of protection of a similar nature or having equivalent effect subsisting from time to time in any jurisdiction worldwide;

 

Oclaro CoE Page 17 of 18


30.6. “Prospective Customer” means any person with whom the Company (or any Group Company) is in negotiations or is tendering for the supply of its goods and services; and

 

30.7. “Restricted Area” means England and such other countries within which, on the date your employment terminates, the Company or any Group Company operates the business within which you were employed by the Company during the last 12 months of your employment with the Company and in relation to which country, during the last 12 months of your employment, you:

 

  (a) undertook material duties for the Company or any Group Company in relation to any part of the Business being operated in that country; or

 

  (b) had a material degree of management responsibility for a material part of the Business being operated in that country; or

 

  (c) were privy to confidential information relating to the Business .

 

31. GOVERNING LAW

 

     Your terms of employment with the Company are governed by English law and the parties submit to the exclusive jurisdiction of the English Courts. The Company may however enforce the Agreement in any other courts of competent jurisdiction.

IN WITNESS WHEREOF this agreement has been executed by an authorised employee of the Company, and executed and delivered as a deed by you, on the date stated on the first page of this agreement.

 

EXECUTED by Oclaro Technology Limited:    /s/ ELAINE BARNDEN
   Elaine Barnden, Senior HR Director EMEA
EXECUTED and DELIVERED as a DEED   
By Adrian Meldrum:    /s/ ADRIAN MELDRUM

 

in the presence of:-

  
Signature of witness    /s/ STEPHEN SHAW
Name of witness    Stephen Shaw
Address of witness   

79 Bishops Drive

Wokingham

RG40 lWA

Occupation of witness    IT Consultant

 

Oclaro CoE Page 18 of 18

Exhibit 10.6

OCLARO, INC.

EXECUTIVE SEVERANCE AND RETENTION AGREEMENT

THIS EXECUTIVE SEVERANCE AND RETENTION AGREEMENT by and between Oclaro, Inc., a Delaware corporation (the “Company”), Oclaro Technology Limited, a company registered in England under registered number 02298887 (the “Subsidiary”) and Adrian Meldrum (the “Executive”) is made as of 18 th November 2013 (the “Effective Date”).

WHEREAS, the Company, the Subsidiary and Executive wish to provide for agreed­ upon severance arrangements in the event that the Executive ceases to be an employee of the Subsidiary under certain circumstances prior to any change in control of the Company,

WHEREAS, the Company also recognizes that, as is the case with many publicly-held corporations, the possibility of a change in control of the Company exists and that such possibility, and the uncertainty and questions which it may raise among key personnel, may result in the departure or distraction of key personnel to the detriment of the Company, the Subsidiary and the Company's stockholders, and

WHEREAS, the Compensation Committee of the Board of Directors of the Company (the “Board”) has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication of the key personnel of the Company and the Subsidiary without distraction from the possibility of termination under certain circumstances or a change in control of the Company and related events and circumstances.

NOW, THEREFORE, as an inducement for and in consideration of the Executive remaining in the employ of the Subsidiary, the Company and the Subsidiary agree that the Executive shall receive the severance benefits set forth in this Agreement under the terms and subject to the provisions, provided below.

1. Key Definitions.

As used herein, the following terms shall have the following respective meanings:

1.1 “ Cause” means:

(a) the Executive’s willful and continued failure to substantially perform Executive’s reasonable assigned duties as an employee of the Company and/or the Subsidiary (other than any such failure resulting from incapacity due to physical or mental illness or any failure after the Executive gives notice of termination for Good Reason), which failure is not cured within 30 days after a written demand for substantial performance is received by the Executive from the Board that specifically identifies the manner in which the Board believes the Executive has not substantially performed the Executive’s duties; provided that, for purposes of Section 3.1, for all Executives other than the Chief Executive Officer of the Company (“CEO”), substantial performance shall be determined by the CEO and such written demand for substantial performance shall be provided by the CEO; or


(b) the Executive’s willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company and/or the Subsidiary.

For purposes of this Section 1.1, no act or failure to act by the Executive shall be considered “willful” unless it is done, or omitted to be done, in bad faith and without reasonable belief that the Executive’s action or omission was in the best interests of the Company or the Subsidiary.

1.2 “Change in Control” means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 50% or more of either (x) the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition directly from the Company (excluding an acquisition pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the Person exercising, converting or exchanging such security acquired such security directly from the Company or an underwriter or agent of the Company), (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.2; or

(b) such time as the Continuing Directors (as defined below) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term “Continuing Director” means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Agreement or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

 

-2-


(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a “Business Combination”), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 30% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination); or

(d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

1.3 “Change in Control Date” means the first date during the Term (as defined in Section 2) on which a Change in Control occurs. Anything in this Agreement to the contrary notwithstanding, if (a) a Change in Control occurs, (b) the Executive’s employment with the Subsidiary is terminated prior to the date on which the Change in Control occurs, and (c) it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change in Control or (ii) otherwise arose in connection with or in anticipation of a Change in Control, then for all purposes of this Agreement the “Change in Control Date” shall mean the date immediately prior to the date of such termination of employment.

1.4 “Disability” means the Executive’s incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or the insurers of the Company or the Subsidiary and acceptable to the Executive or the Executive’s legal representative. Notwithstanding anything to the contrary herein, for purposes of this Agreement, each reference to the Subsidiary’s termination of the Executive’s employment without Cause shall be deemed to exclude the Subsidiary’s termination of the Executive’s employment by reason of his or her Disability.

 

-3-


1.5 “Good Reason ” means the occurrence, without the Executive’s written consent, of any of the events or circumstances set forth in clauses (a) through (d) below.

(a) a material diminution in the Executive’s authority, duties or responsibilities as in effect immediately prior to the earliest to occur of (i) the Change in Control Date, (ii) the date of the execution by the Company of the definitive

written agreement or instrument providing for the Change in Control or (iii) the date of the adoption by the Board of a resolution providing for a Change in Control (with the earliest to occur of such dates referred to herein as the “Measurement Date”);

(b) a material diminution in the Executive’s base compensation as in effect on the Measurement Date or as the same may be increased from time to time thereafter;

(c) a change by the Subsidiary in the location at which the Executive performs Executive’s principal duties for the Subsidiary to a new location that is both (i) outside a radius of 35 miles from the Executive’s principal residence immediately prior to the Measurement Date and (ii) more than 20 miles from the location at which the Executive performed Executive’s principal duties for the Subsidiary immediately prior to the Measurement Date; or

(d) any other action or inaction that constitutes a material breach by the Company of this Agreement.

2. Term of Agreement. This Agreement, and all rights and obligations of the pcu1ies hereunder, shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) if a Change in Control has not occurred during the Term, (b) the termination of the Executive’s employment with the Subsidiary prior to the expiration of the Term, other than by reason of a termination by the Subsidiary without Cause or a termination of the Executive’s employment by reason of a Disability prior to the occurrence of a Change in Control, (c) the fulfillment by the Company and the Subsidiary of all of its respective obligations under Section 3 if the Executive’s employment with the Subsidiary is terminated without Cause prior to a Change in Control, (d) the date 12 months after the Change in Control Date, if the Executive is still employed by the Subsidiary as of such later date, or (e) the fulfillment by the Company and the Subsidiary of all of its obligations under Section 4 if the Executive’s employment with the Subsidiary terminates within 12 months following the Change in Control Date. “Term” shall mean the period commencing as of the Effective Date and continuing in effect through December 31, 2014.

3. Benefits Prior to a Change in Control.

3.1 Termination of Employment Without Cause or Upon Death. Subject to the terms and conditions set forth in Section 5, in the event that the Executive’s employment is terminated because of the death of the Executive or by the Subsidiary without Cause at any time prior to a Change in Control (such date of termination or death, the “Section 3 Date of Termination”), the Executive (or Executive’s heirs) shall be entitled to the following aggregate benefits:

 

-4-


(a) The sum of (i) an amount equal to the average of the Executive’s bonuses earned during the last 3 full fiscal years (or such lesser number of years in which the Executive earned a bonus), (“Average Bonus”) divided by 2, with the resulting amount multiplied by a fraction, the numerator of which is the number of days preceding the Section 3 Date of Termination in the current bonus period and the denominator of which is the total number of days in the current bonus period (the “Pro-Rata Bonus”), (ii) any prior period bonus approved by the Board or the Compensation Committee of the Board but not paid, (iii) the amount of any accrued base salary and/or vacation pay to the Section 3 Date of Termination, in each case to the extent not previously paid (the sum of the amounts described in clauses (ii) and (iii) shall be herein referred to as “Accrued Obligations”), payable in a lump sum in cash within 55 days following the Section 3 Date of Termination; and

(b) An amount, capped at 1.5 times the Executive’s base salary then in effect, equal to (i) Executive’s annual base salary then in effect multiplied by 0.67, plus (ii) one (1) month of the Executive’s monthly base salary then in effect for each whole year of the Executive’s employment by the Subsidiary, as measured from the Section 3 Date of Termination (the “Section 3 Termination Payment Period”), which amount shall be paid as a lump sum cash payment within 55 days following the Section 3 Date of Termination (subject to Section 3.2 below). Existing option, restricted stock and other equity awards will continue to be governed by the terms of their respective grants and plan provisions.

For the avoidance of doubt, the bonus shall be determined by (a) including bonuses earned for the prior three fiscal years, regardless of whether such bonus amounts were paid during such fiscal year or in the following fiscal year and (b) excluding any bonus amount paid during any of such three fiscal years that was earned for any fiscal year prior to such three fiscal years.

3.2 Release. The payment to the Executive (or Executive’s heirs) of the amounts and benefits payable under Sections 3.l(a)(i) and 3.l(b) shall be contingent upon both (i) the execution by the Executive (or Executive’s heirs) of a compromise agreement and release in a form reasonably acceptable to the Company and substantially as set forth in Exhibit A to this Agreement (the “Executive Release”) and upon the Executive Release becoming effective and irrevocable in accordance with its terms within 55 days following the Section 3 Date of Termination, and upon the Executive’s independent legal adviser providing a signed solicitor’s certificate in the form reasonably acceptable to the Company; and (ii) agreement by the Executive to standard confidentiality obligations, a non­ solicitation of the customers of the Company and/or the Subsidiary for six-months following the Section 3 Date of Termination and a non-solicitation of the employees of the Company or of the Subsidiary for twelve-months following the Section 3 Date of Termination, provided that the Executive signs such agreement by the 55th day following his or her Section 3 Date of Termination. Executive will be given a 21 day period to review and consider the Executive Release (such period may be extended to 45 days if required under applicable law) and the Executive may revoke the release for a period of 7 days, during which time the release shall not become effective or enforceable until the revocation period has expired.

 

-5-


3.3 Sole Remedy. The payments under this Section 3 constitute the sole remedy of the Executive as a result of the circumstances set forth in this Section 3.

4. Benefits after a Change in Control.

4.1 Termination of Employment.

(a) If the Change in Control Date occurs during the Term, any termination of the Executive’s employment by the Subsidiary or by the Executive within 12 months following the Change in Control Date or termination due to the Executive’s death within 12 months following the Change in Control Date, shall be communicated by a written notice to the other party hereto (the “Notice of Termination”), given in accordance with Section 8. Any Notice of Termination shall: (i) indicate the specific termination provision (if any) of this Agreement relied upon by the party giving such notice, (ii) to the extent applicable, set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated and (iii) specify the Date of Termination (as defined below). The effective date of an employment termination (the “Date of Termination”) shall be (I) the close of business on the date specified in the Notice of Termination (which date may not be more than 45 days after the date of delivery of such Notice of Termination or such longer period as may be required by applicable law) or (IO the date of the Executive’s death.

(b) The failure by the Executive, the Subsidiary or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive, the Subsidiary or the Company, respectively, hereunder or preclude the Executive, the Subsidiary or the Company, respectively, from asserting any such fact or circumstance in enforcing the Executive’s, the Subsidiary’s or the Company’s rights hereunder.

(c) Any Notice of Termination for Cause given by the Company or the Subsidiary must be given within 90 days of the occurrence of the event(s) or circumstance(s) which constitute(s) Cause. Prior to any Notice of Termination for Cause being given (and prior to any termination for Cause being effective), the Executive shall be entitled to a hearing before the Board at which the Executive may, at the Executive’s election, be represented by legal counsel and at which Executive shall have a reasonable opportunity to be heard. Such hearing shall be held on not less than 15 days prior written notice to the Executive stating the Board’s intention to terminate the employment of the Executive for Cause and stating in detail the particular event(s) or circumstance(s) which the Board believes constitutes Cause for termination.

 

-6-


(d) Any Notice of Termination for Good Reason given by the Executive must be given within 90 days of the occurrence of the event(s) or circumstance(s) that constitute(s) Good Reason. Notwithstanding the foregoing, such occurrence shall not be deemed to constitute Good Reason unless (i) within 30 days of the receipt by the Company or the Subsidiary of the Notice of Termination , such event or circumstance has not been fully corrected and the Executive has not been reasonably compensated for any losses or damages resulting there from and (ii) the Executive’s Date of Termination occurs within two years following the Company’s receipt of the Notice of Termination.

4.2 Benefits to Executive.

4.2.1. Stoc k Acceleration. For each equity award (including options and other awards) granted to the Executive prior to the Effective Date, if the Change in Control Date occurs during the Term, then, effective upon the Change in Control Date, (a) each outstanding option to purchase shares of Common Stock of the Company held by the Executive (or Executive’s heirs) shall become immediately exercisable in full, (b) each outstanding restricted stock award (“RS”) or restricted stock unit (“RSU”) shall be deemed to be fully vested and, for RSUs, the shares of Company Stock will be delivered upon vesting and (c) notwithstanding any provision in any applicable option agreement to the contrary, each such option shall continue to be exercisable by the Executive (to the extent such option was exercisable on the Date of Termination) until the earlier of (i) a period of six months following the Date of Termination and (ii) the original expiration date of such option.

For each equity award (including options and other awards) granted to the Executive after the Effective Date and prior to the Change in Control Date, if the Change in Control Date occurs during the Term and the Date of Termination occurs within 12 months following the Change in Control Date due to death, a termination without Cause or a termination for Good Reason, then, effective upon the Date of Termination, (a) each outstanding option to purchase shares of Common Stock of the Company held by the Executive (or Executive’s heirs) shall become immediately exercisable in full, (b) each outstanding restricted stock award or RSU shall be deemed to be fully vested and, for RSUs, the shares of Company Stock will be delivered upon vesting and (c) notwithstanding any provision in any applicable option agreement to the contrary, each such option shall continue to be exercisable by the Executive (to the extent such option was exercisable on the Date of Termination) until the earlier of (i) a period of twelve months following the Date of Termination and (ii) the original expiration date of such option.

4.2.2 Compensation . If the Change in Control Date occurs during the Term and the Executive’s employment with the Subsidiary terminates within 12 months following the Change in Control Date, the Executive shall be entitled to the following additional benefits:

 

-7-


(a) Termination Upon Death, Without Cause or for Good Reaso n. Subject to the terms and conditions set forth in Sections 4.4 and 5, if the Executive’s employment with the Subsidiary is terminated (i) because of the death of the Executive or (ii) by the Subsidiary (other than for Cause or by reason of the Executive’s Disability) or by the Executive for Good Reason in each case within 12 months following the Change in Control Date, then the Executive shall be entitled to a lump sum payment in cash, payable within 55 days following the Date of Termination, of the aggregate of the following amounts:

(1) the Accrued Obligations;

(2) an amount equal to 1.5 times the Executive’s annual base salary then in effect;

(3) Average Bonus; and

(4) a taxable lump-sum cash payment equal to the Executive’s aggregate premiums to continue his or her existing group health coverage (medical, dental, and vision) in effect as of the Date of Termination for a period of 12 months (which payment shall be made if the Executive elects such continuation coverage within 55 days following the Date of Termination .).

(b) Termination upon Disability. Subject to the terms and conditions set forth in Sections 4.4 and 5, if the Executive’s employment with the Subsidiary is terminated by reason of the Executive’s Disability, then the Company shall pay the Executive in a lump sum in cash within 55 days following the Date of Termination, the Accrued Obligations and the Pro-Rata Bonus; provided, however, that the Pro Rata Bonus shall be paid to the Executive no later than March 15th of the calendar year immediately following the calendar year in which the Executive suffers such Disability or the Executive shall thereafter no longer be eligible to receive such a bonus.

4.3 T axe s. Notwithstanding any provision of this Agreement to the contrary, if any payment or benefit to be paid or provided hereunder would be an “Excess Parachute Payment,” within the meaning of Section 280G of the Code, or any successor provision thereto, but for the application of this sentence, then the payments and benefits to be paid or provided hereunder shall be reduced to the minimum extent necessary (but in no event to less than zero) so that no portion of any such payment or benefit, as so reduced , constitutes an Excess Parachute Payment; provided, however, that the foregoing reduction shall be made only if and to the extent that such reduction would result in an increase in the aggregate payments and benefits to be provided (i.e. a “best results provision”) determined on an after-tax basis (taking into account the excise tax imposed pursuant to Section 4999 of the Internal Revenue Code of the United States of America, or any successor provision thereto, any tax imposed by any comparable provision of state law, and any applicable federal, state and local income taxes). The determination of whether any reduction in such payments or benefits to be provided hereunder is required pursuant to the preceding sentence shall be made by the Company’s independent accountants at the expense of the Company. The fact that Executive’s right to payments or benefits may be reduced by reason of the limitations contained in this Section shall not of itself limit or otherwise affect any other rights of Executive under this Agreement. In the event that any payment or benefit intended to be provided hereunder is required to be reduced pursuant to this Section then the payments shall be reduced or eliminated in the following order: (W) any cash payments, (X) any taxable benefits, (Y) any nontaxable benefits, and (Z) any vesting of equity awards, in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that triggers the applicability of the excise tax.

 

-8-


4.4 Release. The payment to the Executive (or the Executive’s heirs) of the amounts and benefits payable under Section 4.2.2 shall be contingent on both (i) the execution by the Executive (or the Executive’s heirs) of the Executive Release and upon the Executive Release becoming effective in accordance with its terms within 55 days following the Date of Termination, and upon the Executive’s independent legal adviser providing a signed solicitor’s certificate in the form reasonably acceptable to the Company and (ii) agreement by the Executive to standard confidentiality, a non-solicitation of the customers of the Company and/or the Subsidiary for six-months following the Change in Control and a non-solicitation of any employees of the Company or the Subsidiary for twelve months following the Change in Control, provided that the Executive signs such agreement by the 55th day following his or her Date of Termination. Executive will be given a 21 day period to review and consider the release (such period may be extended to 45 days if required under applicable law) and the Executive may revoke the release for a period of 7 days, during which time the release shall not become effective or enforceable until the revocation period has expired.

4.5 Sole Remedy. The payments under this Section 4 constitute the sole remedy of the Executive in the circumstances set forth in this Section 4.

5. Payments Subject to Section 409A. Subject to the provisions in this Section 5, any severance payments or benefits under this Agreement shall begin only upon the date of the Executive’s "separation from service" (determined as set forth below) which occurs on or after the Section 3 Date of Termination or the Date of Termination, as applicable. The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Executive under this Agreement.

5.1 If, as of the date of the Executive’s “separation from service” from the Subsidiary, the Executive is not a “specified employee” (within the meaning of Section 409A), then severance payments and benefits shall be made on the dates and terms set forth in this Agreement.

5.2 If, as of the date of the Executive’s “separation from service” from the Subsidiary, the Executive is a “specified employee” (within the meaning of Section 409A), then:

5.2.1. Each severance payment and benefit due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-l(b)(4) to the maximum extent permissible under Section 409A; and

 

-9-


5.2.2. Each severance payment and benefit due under this Agreement that is not described in Section 5.2.1 above and that would, absent this subsection, be paid within the six-month period following the Executive’s “separation from service” from the Subsidiary shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive’s death), with any such payments and benefits that are required to be delayed being accumulated during the six-month period and paid in a lump swn on the date that is six months and one day following the Executive’s separation from service; provided, however, that the preceding provisions of this sentence shall not apply to any severance payments and benefits if and to the maximum extent that any such payment or benefit is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-l(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).

5.3 The determination of whether and when the Executive’s separation from service from the Subsidiary has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h).

5.4 All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.

5.5 Notwithstanding anything herein to the contrary, the Company shall have no liability to the Executive or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.

6. Disputes.

6.1 Settlement of Disputes. All claims by the Executive for benefits under Sections 3 and 4 of this Agreement shall be directed to and determined by the Board and shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon. The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim.

 

-10-


6.2 Expenses. The Company agrees to pay as incurred, to the full extent permitted by law, all legal , accounting and other fees and expenses which the Executive may reasonably incur as a result of any claim or contest by the Company, the Subsidiary, the Executive or others regarding the validity or enforceability of, or liability under, Sections 3 and 4 of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive regarding the amount of any payment or benefits pursuant to this Agreement); provided that Executive prevails in the outcome of such claim or contest.

6.3 Compensation During a Dispute. Subject to any limitations under Section 409A, if the Change in Control Date occurs during the Term and the Executive’s employment with the Subsidiary terminates within 12 months following the Change in Control Date, and the right of the Executive to receive benefits under Section 4 (or the amount or nature of the benefits to which Executive is entitled to receive) are the subject of a dispute between the Company and/or the Subsidiary and the Executive, the Subsidiary shall continue (a) to pay Executive, the Executive’s base salary in effect as of the Measurement Date and (b) to provide benefits to the Executive and the Executive’s family at least equal to those which would have been provided to them, if the Executive’s employment had not been terminated, in accordance with the applicable Benefit Plans in effect on the Measurement Date, until such dispute is resolved either by mutual written agreement of the parties or by final adjudication. Following the resolution of such dispute, the sum of the payments made to the Executive under clause (a) of this Section 6.3 shall be deducted from any cash payment which the Executive is entitled to receive pursuant to Section 4, if any; and if such sum exceeds the amount of the cash payment which the Executive is entitled to receive pursuant to Section 4, if any, the excess of such sum over the amount of such payment shall be repaid (without interest) by the Executive to the Company within 60 days of the resolution of such dispute.

7. Successors.

7.1 Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place, provided that: (i) nothing in this Agreement shall oblige any successor to pay any further sums to the Executive in the event that the Company and the Subsidiary have fulfilled their respective obligations to make payments to the Executive and/or the Agreement expires due to any other term set forth in Section 2 above; and (ii) the successor shall not be entitled to ignore the occurrence of a Change in Control in order to avoid any obligations under this Agreement. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a breach of this Agreement and shall constitute Good Reason if the Executive elects to terminate employment As used in this Agreement, “Company” shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

 

-11-


7.2 Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or Executive’s family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive’s estate.

8. Notice . All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company or the Subsidiary, both at 2584 Junction Avenue, San Jose, CA 95134, Attn: General Counsel, and to the Executive at the Executive’s address indicated on the signature page of this Agreement (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered .five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.

9. Miscellaneous.

9.1 Employment by Subsidiary. For purposes of this Agreement, the Executive’s employment with the Subsidiary shall not be deemed to have terminated solely as a result of the Executive continuing to be employed by the Company itself or another wholly-owned subsidiary of the Company.

9.2 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect

9.3 Injunctive Relief. The Company and the Executive agree that any breach of this Agreement by the Company or the Subsidiary is likely to cause the Executive substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Executive shall have the right to specific performance and injunctive relief.

9.4 Exclusive Severance Benefits. The making of the payments and the provision of the benefits by the Subsidiary and/or the Company to the Executive under this Agreement shall constitute the entire obligation of the Subsidiary and the Company respectively to the Executive as a result of the termination of Executive’s employment, and the Executive shall not be entitled to additional payments or benefits as a result of such termination of employment under any other plan, program, policy, practice, contract or agreement of the Company, the Subsidiary or their respective subsidiaries. In particular, the payments made by the Company and/or the Subsidiary to the Executive under this Agreement shall be deemed by the parties to include any redundancy payments (whether statutory or otherwise), and any payment in lieu of notice or damages for wrongful dismissal that may otherwise have been due. Hence, no additional redundancy payment, payment in lieu of notice or damages for wrongful dismissal shall be owed to the Executive in these circumstances.

 

-12-


9.5 Mitigation. The Executive shall not be required to mitigate the amount of any payment or benefits provided for in Sections 3.1 and 4.2.2 by seeking other employment or otherwise. Further, the amount of any payment or benefits provided for in this Agreement shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or the Subsidiary or otherwise.

9.6 Not an Employment Contract. The Executive acknowledges that this Agreement does not constitute a contract of employment or impose on the Company or the Subsidiary any obligation to retain the Executive as an employee and that this Agreement does not prevent the Executive from terminating employment at any time. If the Executive’s employment with the Subsidiary terminates for any reason and subsequently a Change in Control shall occur, the Executive shall not be entitled to any benefits hereunder except as otherwise provided pursuant to Section 3 or 4.

9.7 Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of the State of Delaware, without regard to conflicts of law principles.

9.8 Waivers. No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by the Company or the Subsidiary shall be deemed a waiver of that or any other provision at any subsequent time.

9.9 Co unte rparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

9.10 Tax Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

9.11 Entire Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein; and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled.

9.12 Amendments . This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.

 

-13-


9.13 Executive’s Acknowledgements. The Executive acknowledges that Executive: (a) has read this Agreement; (b) has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of the Executive’s own choice or has voluntarily declined to seek such counsel; and (c) understands the terms and consequences of this Agreement; and (d) understands that by executing this Agreement, the Employee forever waives and forfeits all rights under any prior agreements relating to the subject matter herein.

 

-14-


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

 

OCLARO, INC.

By:

 

/s/ GREG DOUGHERTY

  Greg Dougherty
Title:   CEO

OCLARO TECHNOLOGY LIMITED

 

By:   /s/ ELAINE BARNDEN
  Elaine Barnden

Title:

  Senior Director HR, EMEA
 

The Executive

 

/s/ ADRIAN MELDRUM
Adrian Meldrum

Address:

 

71 Bishops Drive,

Wokingham,

Berks

RG40 lWA

 

-15-

Exhibit 10.7

 

LOGO

PRIVATE AND CONFIDENTIAL

December 5, 2013

David L. Teichmann

1621 Oakdell Drive

Menlo Park, CA 94025

 

RE: Offer of Employment

Dear David:

We are pleased to offer you the position of Executive Vice President, General Counsel and Corporate Secretary, reporting directly to me. We believe that you will bring great value to Oclaro, and we are excited about you joining our team.

Your base compensation for the regular, full-time, exempt position will be at the annualized rate of $300,000.00. Such rate may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. Applicable payroll deductions as required by state and federal law will be withheld from your paycheck, along with any mandatory or voluntary deductions that you authorize. The Company issues payroll on a bi-weekly basis. Your compensation package also includes:

1. Eligibility to participate in the Company’s Variable Pay Scheme, which is a discretionary arrangement that is based on Company performance of specific objectives. Your target participation level will be 60 % of your base compensation. If you are not actively employed with the Company as of the payment date, you will not be eligible to receive any variable pay, and no right to such variable pay will have accrued. Details of the Variable Pay Scheme will be provided to you by Human Resources. The Company reserves all rights to terminate, amend, suspend, withdraw or modify the Variable Pay Scheme at any time.

2. Participation in the Company’s Benefits Program is effective on your first day of employment. A Benefits Summary is enclosed. Further details will be provided to you by Human Resources at the New Hire Orientation.

3. Subject to formal approval by the Board of Directors (the “Board”), the position being offered to you includes 60,000 Restricted Stock (Unit) (RSU or RSA) of the Company under the terms of the 2004 Amended and Restated Oclaro Stock Incentive Plan and any other policies, laws or rulings that may govern the (RSU/RSA) and its issuance. The grant date of the (RSU/RSA) will be on the 10th day of the month following the month of your first date of employment. The first 25% of the (RSU/RSA) will vest on or before the first anniversary of the grant date. Specifically, the 25% vesting will occur on the February 10th, May 10th, August 10th or November 10th which occurs on or immediately preceding the one year anniversary of the date of grant. Thereafter, 6.25% of the (RSU/RSA) will vest each February 10th, May 10th, August 10th and November 10th over the following three years of continuous service to the Company. All vesting will cease upon termination of employment.

4. Additionally, subject to formal approval by the Board of Directors (the “Board”), the position being offered to you includes a stock option to own 60,000 shares under the terms of the Company’s plan and any other policies, laws or rulings that may govern the stock options and their issuance. The exercise price of the options will be the market price at the time of formal Board approval. The stock options will vest over a four year period, with twenty-five (25%) percent vesting after the first year and the balance vesting monthly over the following three years, however, all vesting will cease upon termination of employment at will.


LOGO

 

Pursuant to the Immigration Reform and Control Act of 1986, the Company is required to verify the identity and employment eligibility of all new hires. In order to comply with this legal obligation, we can only hire those individuals who are eligible to work in the United States. As a condition of employment, you will be required to provide documents verifying your identity and your eligibility to work in the United States; and to complete an Employment Eligibility Verification form I-9 within three (3) business days from your hire date. To verify your identity, we have enclosed a list of acceptable documents for the I-9 which you will complete at the New Hire Orientation. Please note that you will need to bring either (i) one document from List A or (ii) one document from List B and one document from List C. If you anticipate having difficulty producing the required documents, please contact the Human Resources Department at (408) 919-2793.

You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.

To accept this offer, subject to the foregoing conditions and the other conditions set forth herein, please sign in the space provided below, and return the signed letter to me by close of business on Friday, December 6, 2013. I have enclosed a copy of the Offer Letter for your records.

This employment opportunity is contingent upon the completion of an application for employment, satisfactory references and background checks and upon your signature of the Oclaro, Inc. Employment Agreement that will be distributed and reviewed in the New Hire Orientation.

Any future employment at the Company is subject to the terms and conditions of the Company and is terminable at will by either the employee or the Company. Further details will be provided to you by Human Resources. This letter supersedes all prior understandings, whether written or oral, relating to the terms of your employment.

Except as otherwise specifically provided for in the Executive Severance and Retention Agreement to be entered into between you and Oclaro effective on your first date of employment by Oclaro (the form of which is attached hereto as Annex 1 ) the offer outlined in this Offer Letter contains the entire agreement between you and the Company and constitutes the complete, final and exclusive embodiment of the subject matter herein. This Offer Letter is executed without reliance upon any promise, warranty, or representation by the Company or any representatives of the Company not expressly contained herein. This Offer Letter may not be modified unless in writing signed by the Company’s Chief Executive Officer, except that the policies of the company may be modified from time to time with reasonable advance notice.

We look forward to your joining Oclaro and hope that you find your employment with the Company enjoyable and professionally rewarding.

 

Yours Sincerely,
/s/ GREG DOUGHERTY

Greg Dougherty

CEO, Oclaro


LOGO

 

I HAVE READ AND UNDERSTAND THE PROVISIONS OF THIS AGREEMENT. I FULLY INTEND TO COMPLY WITH, AND BE BOUND BY, THE PROVISIONS SET FORTH HEREIN.

I accept this offer of employment with Oclaro, Inc. and will begin work no later than January 6, 2014. I AM NOT RELYING ON ANY REPRESENTATIONS OTHER THAN AS SET FORTH ABOVE.

 

Date:

 

December 6, 2013

Signed:

 

/s/ DAVID L. TEICHMANN

 

David L. Teichmann


LOGO

 

ANNEX 1

TO

DAVID L. TEICHMANN

EMPLOYMENT OFFER LETTER

 

Exhibit 10.8

OCLARO, INC.

E XECUTIVE S EVERANCE AND R ETENTION A GREEMENT

THIS EXECUTIVE SEVERANCE AND RETENTION AGREEMENT (the “Agreement”) by and between Oclaro, Inc., a Delaware corporation (the “Company”), and David Teichmann (the “Executive”) is made as January 1, 2014, (the “Effective Date”).

WHEREAS, the Company and Executive wish to provide for agreed-upon severance arrangements in the event that the Executive ceases to be an employee of the Company under certain circumstances prior to any change in control of the Company,

WHEREAS, the Company also recognizes that, as is the case with many publicly-held corporations, the possibility of a change in control of the Company exists and that such possibility, and the uncertainty and questions which it may raise among key personnel, may result in the departure or distraction of key personnel to the detriment of the Company and its stockholders, and

WHEREAS, the Compensation Committee of the Board of Directors of the Company (the “Board”) has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication of the Company’s key personnel without distraction from the possibility of termination under certain circumstances or a change in control of the Company and related events and circumstances.

NOW, THEREFORE, as an inducement for and in consideration of the Executive remaining in its employ, the Company agrees that the Executive shall receive the severance benefits set forth in this Agreement under the terms and subject to the provisions, provided below.

1. Key Definitions .

As used herein, the following terms shall have the following respective meanings:

1.1 “ Cause ” means:

(a) the Executive’s willful and continued failure to substantially perform Executive’s reasonable assigned duties as an employee of the Company (other than any such failure resulting from incapacity due to physical or mental illness or any failure after the Executive gives notice of termination for Good Reason), which failure is not cured within 30 days after a written demand for substantial performance is received by the Executive from the Board that specifically identifies the manner in which the Board believes the Executive has not substantially performed the Executive’s duties; provided that , for purposes of Section 3.1, for all Executives other than the Chief Executive Officer (“CEO”), substantial performance shall be determined by the CEO and such written demand for substantial performance shall be provided by the CEO; or


(b) the Executive’s willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.

For purposes of this Section 1.1, no act or failure to act by the Executive shall be considered “willful” unless it is done, or omitted to be done, in bad faith and without reasonable belief that the Executive’s action or omission was in the best interests of the Company.

1.2 “ Change in Control ” means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 50% or more of either (x) the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however , that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition directly from the Company (excluding an acquisition pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the Person exercising, converting or exchanging such security acquired such security directly from the Company or an underwriter or agent of the Company), (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.2; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term “Continuing Director” means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Agreement or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however , that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

 

- 2 -


(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a “Business Combination”), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 30% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination); or

(d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

1.3 “ Change in Control Date ” means the first date during the Term (as defined in Section 2) on which a Change in Control occurs. Anything in this Agreement to the contrary notwithstanding, if (a) a Change in Control occurs, (b) the Executive’s employment with the Company is terminated prior to the date on which the Change in Control occurs, and (c) it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change in Control or (ii) otherwise arose in connection with or in anticipation of a Change in Control, then for all purposes of this Agreement the “Change in Control Date” shall mean the date immediately prior to the date of such termination of employment.

1.4 “ Disability ” means the Executive’s incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive’s legal representative. Notwithstanding anything to the contrary herein, for purposes of this Agreement, each reference to the Company’s termination of the Executive’s employment without Cause shall be deemed to exclude the Company’s termination of the Executive’s employment by reason of his or her Disability.

 

- 3 -


1.5 “ Good Reason ” means the occurrence, without the Executive’s written consent, of any of the events or circumstances set forth in clauses (a) through (d) below.

(a) a material diminution in the Executive’s authority, duties or responsibilities as in effect immediately prior to the earliest to occur of (i) the Change in Control Date, (ii) the date of the execution by the Company of the definitive written agreement or instrument providing for the Change in Control or (iii) the date of the adoption by the Board of a resolution providing for a Change in Control (with the earliest to occur of such dates referred to herein as the “Measurement Date”);

(b) a material diminution in the Executive’s base compensation as in effect on the Measurement Date or as the same may be increased from time to time thereafter;

(c) a change by the Company in the location at which the Executive performs Executive’s principal duties for the Company to a new location that is both (i) outside a radius of 35 miles from the Executive’s principal residence immediately prior to the Measurement Date and (ii) more than 20 miles from the location at which the Executive performed Executive’s principal duties for the Company immediately prior to the Measurement Date; or

(d) any other action or inaction that constitutes a material breach by the Company of this Agreement.

2. Term of Agreement . This Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) if a Change in Control has not occurred during the Term, (b) the termination of the Executive’s employment with the Company prior to the expiration of the Term, other than by reason of a termination by the Company without Cause or a termination of the Executive’s employment by reason of a Disability prior to the occurrence of a Change in Control, (c) the fulfillment by the Company of all of its obligations under Section 3 if the Executive’s employment with the Company is terminated without Cause prior to a Change in Control, (d) the date 12 months after the Change in Control Date, if the Executive is still employed by the Company as of such later date, or (e) the fulfillment by the Company of all of its obligations under Section 4 if the Executive’s employment with the Company terminates within 12 months following the Change in Control Date. “Term” shall mean the period commencing as of the Effective Date and continuing in effect through December 31, 2016.

3. Benefits Prior to a Change in Control .

3.1 Termination of Employment Without Cause or Upon Death . Subject to the terms and conditions set forth in Section 5, in the event that the Executive’s employment is terminated because of the death of the Executive or by the Company without Cause at any time prior to a Change in Control (such date of termination or death, the “Section 3 Date of Termination”), the Executive (or Executive’s heirs) shall be entitled to the following aggregate benefits:

 

- 4 -


(a) The sum of (i) an amount equal to the average of the Executive’s bonuses earned during the last 3 full fiscal years (or such lesser number of years in which the Executive earned a bonus), (“Average Bonus”) divided by 2, with the resulting amount multiplied by a fraction, the numerator of which is the number of days preceding the Section 3 Date of Termination in the current bonus period and the denominator of which is the total number of days in the current bonus period (the “Pro-Rata Bonus”), (ii) any prior period bonus approved by the Board or the Compensation Committee of the Board but not paid, (iii) the amount of any accrued base salary and/or vacation pay to the Section 3 Date of Termination, in each case to the extent not previously paid (the sum of the amounts described in clauses (ii) and (iii) shall be herein referred to as “Accrued Obligations”), payable in a lump sum in cash within 55 days following the Section 3 Date of Termination; and

(b) An amount, capped at 1.5 times the Executive’s base salary then in effect, equal to (i) Executive’s annual base salary then in effect multiplied by 0.67, plus (ii) one (1) month of the Executive’s monthly base salary then in effect for each whole year of the Executive’s employment by the Company, as measured from the Section 3 Date of Termination (the “Section 3 Termination Payment Period”), which amount shall be paid as a lump sum cash payment within 55 days following the Section 3 Date of Termination (subject to Section 3.2 below). Existing option, restricted stock and other equity awards will continue to be governed by the terms of their respective grants and plan provisions.

For the avoidance of doubt, the bonus shall be determined by (a) including bonuses earned for the prior three fiscal years, regardless of whether such bonus amounts were paid during such fiscal year or in the following fiscal year and (b) excluding any bonus amount paid during any of such three fiscal years that was earned for any fiscal year prior to such three fiscal years.

3.2 Release . The payment to the Executive (or Executive’s heirs) of the amounts and benefits payable under Sections 3.1(a)(i) and 3.1(b) shall be contingent upon both (i) the execution by the Executive (or Executive’s heirs) of a separation agreement and release in a form reasonably acceptable to the Company and substantially as set forth in Exhibit A to this Agreement (the “Executive Release”) and upon the Executive Release becoming effective and irrevocable in accordance with its terms within 55 days following the Section 3 Date of Termination and (ii) agreement by the Executive to standard confidentiality obligations, a non-solicitation of Company customers for six-months following the Section 3 Date of Termination and a non-solicitation of Company employees for twelve-months following the Section 3 Date of Termination, provided that the Executive signs such agreement by the 55 th day following his or her Section 3 Date of Termination. Executive will be given a 21 day period to review and consider the release (such period may be extended to 45 days if required under applicable law) and the Executive may revoke the release for a period of 7 days, during which time the release shall not become effective or enforceable until the revocation period has expired.

3.3 Sole Remedy . The payments under this Section 3 constitute the sole remedy of the Executive as a result of the circumstances set forth in this Section 3.

 

- 5 -


4. Benefits after a Change in Control .

4.1 Termination of Employment .

(a) If the Change in Control Date occurs during the Term, any termination of the Executive’s employment by the Company or by the Executive within 12 months following the Change in Control Date or termination due to the Executive’s death within 12 months following the Change in Control Date, shall be communicated by a written notice to the other party hereto (the “Notice of Termination”), given in accordance with Section 8. Any Notice of Termination shall: (i) indicate the specific termination provision (if any) of this Agreement relied upon by the party giving such notice, (ii) to the extent applicable, set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated and (iii) specify the Date of Termination (as defined below). The effective date of an employment termination (the “Date of Termination”) shall be (I) the close of business on the date specified in the Notice of Termination (which date may not be more than 45 days after the date of delivery of such Notice of Termination) or (II) the date of the Executive’s death.

(b) The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting any such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder.

(c) Any Notice of Termination for Cause given by the Company must be given within 90 days of the occurrence of the event(s) or circumstance(s) which constitute(s) Cause. Prior to any Notice of Termination for Cause being given (and prior to any termination for Cause being effective), the Executive shall be entitled to a hearing before the Board at which the Executive may, at the Executive’s election, be represented by counsel and at which Executive shall have a reasonable opportunity to be heard. Such hearing shall be held on not less than 15 days prior written notice to the Executive stating the Board’s intention to terminate the Executive for Cause and stating in detail the particular event(s) or circumstance(s) which the Board believes constitutes Cause for termination.

(d) Any Notice of Termination for Good Reason given by the Executive must be given within 90 days of the occurrence of the event(s) or circumstance(s) that constitute(s) Good Reason. Notwithstanding the foregoing, such occurrence shall not be deemed to constitute Good Reason unless (i) within 30 days of the Company’s receipt of the Notice of Termination, such event or circumstance has not been fully corrected and the Executive has not been reasonably compensated for any losses or damages resulting therefrom and (ii) the Executive’s Date of Termination occurs within two years following the Company’s receipt of the Notice of Termination.

 

- 6 -


4.2 Benefits to Executive .

4.2.1. Stock Acceleration . For each equity award (including options and other awards) granted to the Executive prior to the Effective Date, if the Change in Control Date occurs during the Term, then, effective upon the Change in Control Date, (a) each outstanding option to purchase shares of Common Stock of the Company held by the Executive (or Executive’s heirs) shall become immediately exercisable in full, (b) each outstanding restricted stock award (“RS”) or restricted stock unit (“RSU”) shall be deemed to be fully vested and, for RSUs, the shares of Company Stock will be delivered upon vesting and (c) notwithstanding any provision in any applicable option agreement to the contrary, each such option shall continue to be exercisable by the Executive (to the extent such option was exercisable on the Date of Termination) until the earlier of (i) a period of six months following the Date of Termination and (ii) the original expiration date of such option.

For each equity award (including options and other awards) granted to the Executive after the Effective Date and prior to the Change in Control Date, if the Change in Control Date occurs during the Term and the Date of Termination occurs within 12 months following the Change in Control Date due to death, a termination without Cause or a termination for Good Reason, then, effective upon the Date of Termination, (a) each outstanding option to purchase shares of Common Stock of the Company held by the Executive (or Executive’s heirs) shall become immediately exercisable in full, (b) each outstanding restricted stock award or RSU shall be deemed to be fully vested and, for RSUs, the shares of Company Stock will be delivered upon vesting and (c) notwithstanding any provision in any applicable option agreement to the contrary, each such option shall continue to be exercisable by the Executive (to the extent such option was exercisable on the Date of Termination) until the earlier of (i) a period of twelve months following the Date of Termination and (ii) the original expiration date of such option.

4.2.2 Compensation . If the Change in Control Date occurs during the Term and the Executive’s employment with the Company terminates within 12 months following the Change in Control Date, the Executive shall be entitled to the following additional benefits:

(a) Termination Upon Death, Without Cause or for Good Reason . Subject to the terms and conditions set forth in Sections 4.4 and 5, if the Executive’s employment with the Company is terminated (i) because of the death of the Executive or (ii) by the Company (other than for Cause or by reason of the Executive’s Disability) or by the Executive for Good Reason in each case within 12 months following the Change in Control Date, then the Executive shall be entitled to a lump sum payment in cash, payable within 55 days following the Date of Termination, of the aggregate of the following amounts:

(1) the Accrued Obligations;

 

- 7 -


(2) an amount equal to 1.5 times the Executive’s annual base salary then in effect;

(3) Average Bonus; and

(4) a taxable lump-sum cash payment equal to the Executive’s aggregate premiums to continue his or her existing group health coverage (medical, dental, and vision) in effect as of the Date of Termination pursuant to 29 U.S.C. §§ 1161-1169 (“COBRA”) for a period of 12 months (which payment shall be made if the Executive elects COBRA continuation coverage within 55 days following the Date of Termination.).

(b) Termination upon Disability . Subject to the terms and conditions set forth in Sections 4.4 and 5, if the Executive’s employment with the Company is terminated by reason of the Executive’s Disability, then the Company shall pay the Executive in a lump sum in cash within 55 days following the Date of Termination, the Accrued Obligations and the Pro-Rata Bonus; provided, however, that the Pro Rata Bonus shall be paid to the Executive no later than March 15 th of the calendar year immediately following the calendar year in which the Executive suffers such Disability or the Executive shall thereafter no longer be eligible to receive such a bonus.

4.3 Taxes . Notwithstanding any provision of this Agreement to the contrary, if any payment or benefit to be paid or provided hereunder would be an “Excess Parachute Payment,” within the meaning of Section 280G of the Code, or any successor provision thereto, but for the application of this sentence, then the payments and benefits to be paid or provided hereunder shall be reduced to the minimum extent necessary (but in no event to less than zero) so that no portion of any such payment or benefit, as so reduced, constitutes an Excess Parachute Payment; provided, however, that the foregoing reduction shall be made only if and to the extent that such reduction would result in an increase in the aggregate payments and benefits to be provided (i.e. a “best results provision”) determined on an after-tax basis (taking into account the excise tax imposed pursuant to Section 4999 of the Internal Revenue Code, or any successor provision thereto, any tax imposed by any comparable provision of state law, and any applicable federal, state and local income taxes). The determination of whether any reduction in such payments or benefits to be provided hereunder is required pursuant to the preceding sentence shall be made by the Company’s independent accountants at the expense of the Company. The fact that Executive’s right to payments or benefits may be reduced by reason of the limitations contained in this Section shall not of itself limit or otherwise affect any other rights of Executive under this Agreement. In the event that any payment or benefit intended to be provided hereunder is required to be reduced pursuant to this Section then the payments shall be reduced or eliminated in the following order: (W) any cash payments, (X) any taxable benefits, (Y) any nontaxable benefits, and (Z) any vesting of equity awards, in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that triggers the applicability of the excise tax.

 

- 8 -


4.4 Release . The payment to the Executive (or the Executive’s heirs) of the amounts and benefits payable under Section 4.2.2 shall be contingent on both (i) the execution by the Executive (or the Executive’s heirs) of the Executive Release and upon the Executive Release becoming effective in accordance with its terms within 55 days following the Date of Termination and (ii) agreement by the Executive to standard confidentiality, a non-solicitation of Company customers for six-months following the Change in Control and a non-solicitation of Company employees for twelve months following the Change in Control, provided that the Executive signs such agreement by the 55 th day following his or her Date of Termination. Executive will be given a 21 day period to review and consider the release (such period may be extended to 45 days if required under applicable law) and the Executive may revoke the release for a period of 7 days, during which time the release shall not become effective or enforceable until the revocation period has expired.

4.5 Sole Remedy . The payments under this Section 4 constitute the sole remedy of the Executive in the circumstances set forth in this Section 4.

5. Payments Subject to Section 409A . Subject to the provisions in this Section 5, any severance payments or benefits under this Agreement shall begin only upon the date of the Executive’s “separation from service” (determined as set forth below) which occurs on or after the Section 3 Date of Termination or the Date of Termination, as applicable. The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Executive under this Agreement.

5.1 If, as of the date of the Executive’s “separation from service” from the Company, the Executive is not a “specified employee” (within the meaning of Section 409A), then severance payments and benefits shall be made on the dates and terms set forth in this Agreement.

5.2 If, as of the date of the Executive’s “separation from service” from the Company, the Executive is a “specified employee” (within the meaning of Section 409A), then:

5.2.1. Each severance payment and benefit due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A; and

5.2.2. Each severance payment and benefit due under this Agreement that is not described in Section 5.2.1 above and that would, absent this subsection, be paid within the six-month period following the Executive’s “separation from service” from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive’s death), with any such payments and benefits that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive’s separation from service; provided , however , that the preceding provisions of this sentence shall not apply to any severance payments and benefits if and to the maximum extent that any such payment or benefit is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).

 

- 9 -


5.3 The determination of whether and when the Executive’s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h).

5.4 All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.

5.5 Notwithstanding anything herein to the contrary, the Company shall have no liability to the Executive or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.

6. Disputes .

6.1 Settlement of Disputes . All claims by the Executive for benefits under Sections 3 and 4 of this Agreement shall be directed to and determined by the Board and shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon. The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim.

6.2 Expenses . The Company agrees to pay as incurred, to the full extent permitted by law, all legal, accounting and other fees and expenses which the Executive may reasonably incur as a result of any claim or contest by the Company, the Executive or others regarding the validity or enforceability of, or liability under, Sections 3 and 4 of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive regarding the amount of any payment or benefits pursuant to this Agreement); provided that Executive prevails in the outcome of such claim or contest.

 

- 10 -


6.3 Compensation During a Dispute . Subject to any limitations under Section 409A, if the Change in Control Date occurs during the Term and the Executive’s employment with the Company terminates within 12 months following the Change in Control Date, and the right of the Executive to receive benefits under Section 4 (or the amount or nature of the benefits to which Executive is entitled to receive) are the subject of a dispute between the Company and the Executive, the Company shall continue (a) to pay Executive, the Executive’s base salary in effect as of the Measurement Date and (b) to provide benefits to the Executive and the Executive’s family at least equal to those which would have been provided to them, if the Executive’s employment had not been terminated, in accordance with the applicable Benefit Plans in effect on the Measurement Date, until such dispute is resolved either by mutual written agreement of the parties or by final adjudication. Following the resolution of such dispute, the sum of the payments made to the Executive under clause (a) of this Section 6.3 shall be deducted from any cash payment which the Executive is entitled to receive pursuant to Section 4, if any; and if such sum exceeds the amount of the cash payment which the Executive is entitled to receive pursuant to Section 4, if any, the excess of such sum over the amount of such payment shall be repaid (without interest) by the Executive to the Company within 60 days of the resolution of such dispute.

7. Successors .

7.1 Successor to Company . The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place, provided that : (i) nothing in this Agreement shall oblige any successor to pay any further sums to the Executive in the event that the Company has fulfilled its obligations to make payments to the Executive and/or the Agreement expires due to any other term set forth in Section 2 above; and (ii) the successor shall not be entitled to ignore the occurrence of a Change in Control in order to avoid any obligations under this Agreement. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a breach of this Agreement and shall constitute Good Reason if the Executive elects to terminate employment. As used in this Agreement, “Company” shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

7.2 Successor to Executive . This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or Executive’s family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive’s estate.

8. Notice . All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company, at 2560 Junction Avenue, San Jose, CA 95134, Attn: General Counsel, and to the Executive at the Executive’s address indicated on the signature page of this Agreement (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.

 

- 11 -


9. Miscellaneous .

9.1 Employment by Subsidiary . For purposes of this Agreement, the Executive’s employment with the Company shall not be deemed to have terminated solely as a result of the Executive continuing to be employed by a wholly-owned subsidiary of the Company.

9.2 Severability . The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

9.3 Injunctive Relief . The Company and the Executive agree that any breach of this Agreement by the Company is likely to cause the Executive substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Executive shall have the right to specific performance and injunctive relief.

9.4 Exclusive Severance Benefits . The making of the payments and the provision of the benefits by the Company to the Executive under this Agreement shall constitute the entire obligation of the Company to the Executive as a result of the termination of Executive’s employment, and the Executive shall not be entitled to additional payments or benefits as a result of such termination of employment under any other plan, program, policy, practice, contract or agreement of the Company or its subsidiaries.

9.5 Mitigation . The Executive shall not be required to mitigate the amount of any payment or benefits provided for in Sections 3.1 and 4.2.2 by seeking other employment or otherwise. Further, the amount of any payment or benefits provided for in this Agreement shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or otherwise.

9.6 Not an Employment Contract . The Executive acknowledges that this Agreement does not constitute a contract of employment or impose on the Company any obligation to retain the Executive as an employee and that this Agreement does not prevent the Executive from terminating employment at any time. If the Executive’s employment with the Company terminates for any reason and subsequently a Change in Control shall occur, the Executive shall not be entitled to any benefits hereunder except as otherwise provided pursuant to Section 3 or 4.

 

- 12 -


9.7 Governing Law . The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of the State of Delaware, without regard to conflicts of law principles.

9.8 Waivers . No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time.

9.9 Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

9.10 Tax Withholding . Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

9.11 Entire Agreement . This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein; and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled.

9.12 Amendments . This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.

9.13 Executive’s Acknowledgements . The Executive acknowledges that Executive: (a) has read this Agreement; (b) has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of the Executive’s own choice or has voluntarily declined to seek such counsel; and (c) understands the terms and consequences of this Agreement; and (d) understands that by executing this Agreement, the Employee forever waives and forfeits all rights under any prior agreements relating to the subject matter herein.

Termination of Change In Control Agreement . The Agreement is terminated effective immediately.

 

- 13 -


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

 

O CLARO , I NC .
By:   /s/ GREG DOUGHERTY
  Greg Dougherty
CEO, Oclaro
Executive
By:   /s/ DAVID TEICHMANN
  David Teichmann
Address:
1621 Oakdell Drive
Menlo Park, CA 94025

 

- 14 -


Exhibit A

F ORM OF E XECUTIVE R ELEASE A GREEMENT

This Release Agreement (the “Agreement”) is between Oclaro, Inc. (“Company”) and                     (“Executive”).

R ECITAL

The Company and Executive have entered into an Executive Severance and Retention Agreement dated                     , 20     (“ESRA”), providing for the execution of this release as a condition to receipt of benefits under the ESRA.

1. Consideration .

a. The Recital set forth above is incorporated herein by reference as if fully set forth. All capitalized terms used in this Agreement have the same meaning as those contained in the ERSA, except where expressly defined otherwise.

b. Executive expressly acknowledges and agrees that as of the date this Agreement is signed and except as otherwise provided in subparagraph 1(b) above, Executive has received all compensation Executive has earned while employed by the Company, save and except for base salary which has accrued since Executive’s last paycheck from the Company. Executive further acknowledges and agrees that as of the date this Agreement is signed, Executive has submitted for reimbursement all claims which he has for reimbursement of expenses Executive has incurred in connection with the performance of Executive’s duties for the Company, and that Executive has no dispute with the Company pertaining to any expense reports and reimbursements submitted to or received from the Company.

2. Release . As of the date Executive signs this Agreement, Executive waives all claims Executive might have against the Company (or any person or entity that could be made liable through the Company, including such persons as officers, directors, partners, members, managers, employees, representatives, agents, assigns, investors, stockholders, insurers, purchasers, successors, assigns, and others) arising out of or relating in any manner to Executive’s prior or current relationship, or change of relationship, with the Company, whether or not Executive’s claims have matured and whether or not Executive is aware of such claims. As used throughout this Agreement, “claims” means and includes all claims for breach of contract, fraud, discrimination on any prohibited basis (including, but not limited to, race, color, ancestry, national origin, religion, disability, age, sex, sexual orientation, gender identity, medical condition, marital status, or veteran status), breach of the covenant of good faith and fair dealing, violation of any statute, defamation, breach of any benefit plan provision, breach of any California Labor Code provision, breach of any Business & Professions Code provision, breach of any securities laws or regulations, breach of any Corporations Code provision, interference with contract, interference with economic advantage, violation of ERISA, violation of any wage and hour laws (including any applicable wage orders and regulations) and any other claim arising out of or relating in any manner to the parties’ former or current relationship, or change of that relationship. Executive specifically waives the provisions of Civil Code section 1542 which provides:


A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.

The Company and Executive agree that this release does not apply to claims which cannot be waived as a matter of law or public policy (including, by way of example, claims for unemployment insurance benefits, or claims arising under the Workers Compensation Act). In addition to the foregoing, Executive expressly represents and warrants that Executive has not and will not assign any claim released in this Agreement to any other person or entity. Executive will indemnify and defend the Company for all liabilities (including costs, attorneys fees, damages, settlements, compromises, judgments, penalties, interest, and any other sums) it incurs arising in whole or part from Executive’s untrue representation and warranty.

[Remainder of Page Intentionally Blank]

 

- 2 -


3. Miscellaneous . This Agreement is the complete agreement between the Company and Executive concerning the subject matters discussed herein, and supersedes all previous discussions, understandings, and agreements between them concerning said matters, except as otherwise expressly stated in this Agreement. This Agreement is governed by California law (except to the extent its conflict of laws principles would apply the law of a different jurisdiction), is entered into and performed entirely in Santa Clara County, San Jose, California. If any provision of this is found invalid by any court having jurisdiction, the remainder of this Agreement shall be fully valid and enforceable. Executive and the Company understand this is a binding, legal agreement. This Agreement is binding on the parties’ respective heirs, successors, assigns, and representatives

 

   

“Executive”

DATED:                                     

 

   

Signature

   

 

   

Print Name

 

   
    “Company”
    O CLARO , I NC .
DATED:                                      By:  

 

   

Signature

   

 

   

Print Name, Title

 

- 3 -

Exhibit 31.1

SECTION 302(a) CERTIFICATION

I, Greg Dougherty, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Oclaro, Inc. for the period ended December 28, 2013;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 6, 2014

  By:   /s/ GREG DOUGHERTY
    Greg Dougherty
    Chief Executive Officer
    (Principal Executive Officer)

Exhibit 31.2

SECTION 302(a) CERTIFICATION

I, Pete Mangan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Oclaro, Inc. for the period ended December 28, 2013;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 6, 2014

  By:   /s/ P ETE M ANGAN
    Pete Mangan
    Chief Financial Officer
    (Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Oclaro, Inc. (the “Company”) for the period ended December 28, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Greg Dougherty, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: February 6, 2014

  By:   /s/ G REG D OUGHERTY
    Greg Dougherty
    Chief Executive Officer
    (Principal Executive Officer)

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Oclaro, Inc. (the “Company”) for the period ended December 28, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Pete Mangan, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: February 6, 2014

  By:   /s/ P ETE M ANGAN
    Pete Mangan
    Chief Financial Officer
    (Principal Financial Officer)